[go: up one dir, main page]

US20030153596A1 - Novel thiourea derivatives and the pharmaceutical compositions containing the same - Google Patents

Novel thiourea derivatives and the pharmaceutical compositions containing the same Download PDF

Info

Publication number
US20030153596A1
US20030153596A1 US10/169,805 US16980502A US2003153596A1 US 20030153596 A1 US20030153596 A1 US 20030153596A1 US 16980502 A US16980502 A US 16980502A US 2003153596 A1 US2003153596 A1 US 2003153596A1
Authority
US
United States
Prior art keywords
thiourea
compound
butylbenzyl
nmr
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/169,805
Inventor
Young Suh
Uh Oh
Hee Kim
Jee Lee
Hyeung Park
Ok Park
Yong Lee
Young Park
Yung Joo
Jin Choi
Kyung Lim
Sun Kim
Jin Kim
Hyun Koh
Joo Moh
Yeon Jeong
Jung Yi
Young Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacific Corp
Original Assignee
Pacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Corp filed Critical Pacific Corp
Assigned to PACIFIC CORPORATION reassignment PACIFIC CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, JIN KYU, JEONG, YEON SU, JOO, YUNG HYUP, KIM JIN KWAN, KIM, SUNG YOUNG, KOH, HYUN JU, LEE, JEE WOO, LEE, YOUNG SIL, LIM, KYUNG MIN, MOH, JOO HYUN, OH, UH TAEK, OH, YOUNG IM, PARK, HYEUNG GEUN, PARK, OK HUI, PARK, YOUNG HO, SUH, YOUNG GER, YI, JUN BUM
Publication of US20030153596A1 publication Critical patent/US20030153596A1/en
Priority to US11/727,413 priority Critical patent/US8071650B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/175—Ink supply systems ; Circuit parts therefor
    • B41J2/17503—Ink cartridges
    • B41J2/17506—Refilling of the cartridge
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/18—Esters of dithiocarbamic acids
    • C07C333/20—Esters of dithiocarbamic acids having nitrogen atoms of dithiocarbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/14—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/24—Derivatives of thiourea containing any of the groups, X being a hetero atom, Y being any atom
    • C07C335/26—Y being a hydrogen or a carbon atom, e.g. benzoylthioureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/175—Ink supply systems ; Circuit parts therefor
    • B41J2/17503—Ink cartridges
    • B41J2/17513—Inner structure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/175—Ink supply systems ; Circuit parts therefor
    • B41J2/17503—Ink cartridges
    • B41J2/1752—Mounting within the printer
    • B41J2/17523—Ink connection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/175—Ink supply systems ; Circuit parts therefor
    • B41J2/17563—Ink filters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/18—Ink recirculation systems
    • B41J2/185—Ink-collectors; Ink-catchers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to novel thiourea derivatives and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions thereof.
  • the modulator means the thing that can be bonded to the receptor to act as an antagonist or an agonist.
  • Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a main pungent component in hot peppers. Hot peppers have been used, for a long time, not only as a spice but also as traditional medicine in the treatment of gastric disorders and when applied locally, for the relief of pain and inflammation (Szallasi and Blumberg, 1999, Pharm, Rev. 51, ppl59-211). Capsaicin has a wide spectrum of biological actions, and not only exhibits effects on the cardiovascular and respiratory systems but also induces pain and irritancy on local application. Capsaicin, however, after such induction of pain, induces desensitization, both to capsaicin itself and also to other noxious stimuli to make the pain stopped.
  • capsaicin and its analogues such as olvanil, nuvanil, DA-5018, SDZ-249482, resiniferatoxin are either used as analgesic agent, therapeutic agent for incontinentia urinae or skin disorder, or under development (riggleworth and Walpole, 1998, Drugs of the Future 23, pp 531-538).
  • Vanilloid receptor (VR-1) has been recently cloned and its existence becomes clear(Caterina et al., 1997, Nature 389, pp816-824). It was clarified that this receptor transmits not only stimuli by capsaicin anlogues(vanilloid) but also various noxious stimuli such as proton and thermal stimuli (Tominaga et al., 1998, Neuron 21, pp531-543). Based on this, it is considered that vanilloid receptor finctions as a integrative modulator against various noxious stimuli and carries out critical role in transmissions of pain and noxious stimuli.
  • leucotriene metabolite represented by 12-hydroperoxyeicosatetraenoic acid (12-BPETE) (Hwang et al., 2000, PNAS 11, pp61 5 5-6160) and arachidonic aicd derivatives such as anandamide (Zygmunt et al., 2000, Trends Phannocol. Sci. 21, pp 4 3-44) act as the most likely endogenous ligand for the receptor and proton acts as a cofactor with receptor-stimulating activity, rather than as a direct ligand.
  • 12-BPETE 12-hydroperoxyeicosatetraenoic acid
  • anandamide Zaygmunt et al., 2000, Trends Phannocol. Sci. 21, pp 4 3-44
  • a capsaicin-sensitive sensory nerve cell and a vanilloid receptor existing in the cell are distributed over the entire body and play basic function in transmission of noxious stimuli and pain, further act as crucial factor in expression of neurogenic inflammation, thereby to have close relation with the cause of neuropathies, nerve injury, stroke, asthma, chronic obstructive pulmonary diseases, urinary bladder hypersensitiveness, irritable bowel syndrome, inflammatory bowel disease, fervescence, skin disorder and inflammatory disease. Lately, their correlation even with neuropathic disease is suggested (WO 99/00125).
  • afferent sensory nerve responding to capsaicin in gastrointestinal injury
  • the afferent nerve might have a dual character that it exhibits protective action against gastric damage by improving gastric microcirculation through releasing peripheral neuropeptide such as CGRP (calcitonin gene-related peptide), while inducing gastric injury by stimulating sympathetic nervous system (Ren et al., 2000, Dig. Dis. Sci. 45, pp830-836).
  • CGRP calcium calcium receptor
  • vanilloid receptor modulator has very high potential to be used for prevention or treatment of the said various diseases by modulating the activity of the vanilloid receptor conducting such varied functions.
  • vainiloid receptor agonist As described above, there has been widely studied for clinical application of vainiloid receptor agonist, and it is understood that there is a possibility that the agonist derived from the present studies will be developed for clinical application. Though it may be, theoretically, anticipated that antagonist for this receptor would exhibit substantial degree of inhibitory action against pain and neurogenic inflammation, it was found out that the competitive antagonist for this receptor, capsazepine, almost the only one known until now, failed to exhibit significant analgesic and anti-inflammatory effects (Perkins and Campbell, 1992, Br. J. Pharmacol. 107, pp329-333). Therefore, not much progress was made on this field.
  • vanilloid receptor antagonist or agonist derived from the present studies will mainly act based on the antagonistic or agonistic activity of itself, even a possibility that it could exhibit the pharmacological activity through transformation into agonist or antagonist via metabolism after absorption into body is not to be excluded.
  • the present invention is to provide novel compounds which are acted as a modulator for vanilloid receptor and exhibit excellent analgesic, anti-inflammatory and anti-ulcer effects, and pharmaceutical compositions containing the same.
  • X represents S, O or —NCN;
  • Y represents single bond, NRW, O or S;
  • R 1 represents
  • R 2 represents R 8 —(CH 2 ) n —
  • n 0, 1, 2, 3 or 4;
  • R 8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzimidazolyl, chromonyl or benzothiazolyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or
  • R 9 is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, lower alkoxy having 1 to 5 carbon atoms, hydroxy, nitro, cyano, —NHSO 2 R 2 , —S(O) p R 12 , NR 13 R 14, carboxyl;
  • R 10 is hydrogen, nitro, NHSO 2 R 2 , S(O) p R 12 or NR 13 R 14 ;
  • R 11 is hydrogen or cyano;
  • R 12 is lower alkyl having 1 to 5 carbon atoms, methylphenyl, NR 13 R 14 , tifluoromethyl or alkenyl;
  • R 13 and R 14 are independently hydrogen or lower alkyl having 1 to 5 carbon atoms; and p is 0 or 2.); or or or or
  • Z is 0, S, NH or —NCH 3 ;
  • R 15 is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, nitro, cyano, —NHSO 2 R 12 , —S(O) p R 12 , N,N-dimethylaminomethyl or alkoxycarbonylamino; and p and R 12 have the same meanings as defined in R 9 );
  • W is O, S, NH, NR 16 , —N(SO 2 CH 3 )— or —CH 2 —; and R 16 is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, methancsulfonylamino or halogen; or benzyl or phenethyl substituted or unsubstitued with lower alkyl having 1 to 5 carbon atoms, alkoxy, hydroxy, nitro, methanesulfonylamnino or halogen);
  • R 17 , R 18 , R 19 , R 20 and R 21 are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, amninoalkoxy, alkoxycarbonylamino, —NHCH 2 CO 2 H, alkoxyalkylcarbonylammo, alkoxycarbonylalkylarnino, nitro, formyl, acetyl, formylamino, acetoxyamino, cyano, —OSO 2 CH 3 , —NHSO 2 R 12 , —N(SO 2 R 12 )CH 3 , —N(SO 2 R 12 ) 2 , —S(O) p R 12 , —NR 13 R 14 , thiocarbamoyl, —C( ⁇ O)NHNH 2
  • R 3 represents hydrogen, alkyl or cycloalkyl having 1 to 8 carbon atoms, lower alkylphenyl having 1 to 5 carbon atoms, pyridinylethyl, bisphenylmethyl; or phenylallcyl substituted with lower allcyl having 1 to 5 carbon atoms, halogen or methanesulfonylamino.
  • X represents S, O or —NCN;
  • Y represents NR 3 or 0;
  • R 1 represents
  • m is 0, 1 or 2; and R 4 and R 5 are independently hydrogen, lower alkyl having 1 to 4 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);
  • R 2 represents R 8 —(CH 2 ) n —
  • R 9 is hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, nitro, cyano, —NHSO 2 R 12 , —NR 13 R 14 or carboxyl; Rk° is hydrogen, nitro, NHSO 2 R 12 or —NR 13 R 14 ; R 11 is hydrogen or cyano; R 12 is lower alkyl having 1 to 4 carbon atoms, methylphenyl, —NR 13 R 14 or trifluoromethyl; R 13 and R 14 are independently hydrogen or lower alkyl having 1 to 4 carbon atoms; and p is 0 or 2);
  • Z is O, S, NH or —NCH 3 ;
  • R 15 is hydrogen, lower alkyl having 1 to 4 carbon atoms, nitro, cyano or NHSO 2 R 12 ; and
  • R 12 has the same meanings as defined in R 9 ); or
  • W is O, S, NH, NR 16 or —CH 2 —; and R 16 is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, nitro or methanesulfonylamino; or benzyl or phenethyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, alkoxy, hydroxy or methanesulfonylamino);
  • R 17 , R 18 , R 19 , R 20 and R 21 are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonyl amino, —NHCH 2 CO 2 H, alkoxyalkylcarbonylaminno, alkoxycarbonylalkylamino, nitro, fonnyl, acetyl, fonnylamino, acetoxyamnino, cyano, —OSO 2 CH 3 , —NHSO 2 R 12 , —N(SO 2 R 12 )CH 3 , —N(SO 2 R 12 ) 2 , —S(O) p R 2 , NR 13 R 14 , thiocarbamoyl, —C( ⁇ O)NHNH 2 , —C( ⁇ O)NHNH 2 ,
  • R 3 represents hydrogen, alkyl having 1 to 4 carbon atoms, lower alkcylphenyl having 1 to 3 carbon atoms, pyridinylethyl or bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 4 carbon atoms, halogen or methanesulfonylamino.
  • X represents S, O or —NCN;
  • Y represents NR 3 or O
  • R 1 represents
  • m is 1 or 2; and R 4 and R 5 are independently hydrogen, t-butyl, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxymethoxy, methoxyethoxy, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);
  • R 2 represents R 8 —(CH 2 ) n — ⁇ wherein, n is 1, 2 or 3; R 8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl or benzimidazolyl substituted or unsubstituted with methyl, nitro or halogen;
  • R 9 is hydrogen, halogen, methyl, nitro or methanesulfonylamino; R 10 is hydrogen or nitro; and R 11 is hydrogen or cyano);
  • Z is O, S, NH or —NCH 3 ; and R 15 is hydrogen, methyl, nitro, cyano or methanesulfonylamino);
  • W is O, S, NH, NR 16 or —CH 2 —; and R 16 is pyridinyl, pyrimnidinyl; or benzyl or phenethyl substituted or unsubstituted with methyl, methoxy or hydroxy);
  • R 17 , R 18 , R 19 , R 20 and R 21 are independently hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, methoxy, methylenedioxy, methanesulfonylaminomethyl, methoxycarbonyli hydroxy, sulfamoyl, alkoxycarbonylamino, —NHCH2CO 2 H, methoxymethylcarbonylamino, alkoxycarbonylalkylamino, nitro, acetyl, fonnylamino, acetoxyamino, cyano, —OSO 2 CH 3 , —NHSO 2 R 12 , —N(SOR 12 )CH 3 , —N(SO 2 R 12 ) 2 , —S(O) p R 12 , NR 13 R 14 , thiocarbamoyl, —C( ⁇ O)NHNH 2 , —C( ⁇ O)NHOH, —C(C( ⁇ O)NHOH
  • R 3 represents hydrogen, methyl, isopropyl, isobutyl, cyclohexyl, benzyl, phenethyl or bisphenylmethyl; or phienylalkyl substituted with t-butyl, halogen or methanesulfonylamino.
  • amine compound 5-1 is mesylated and the obtained compound 5-2 is hydrogenated to afford amine compound 5-3, and then 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 5-4 ⁇ 5-9.
  • hydroxy group of 2-hydroxy-4-nitrobenzaldehyde is protected with TBDPS, and then oxime 10-1 is prepared therefrom.
  • the compound 10-1 is reduced with hydrogen in the presence of palladium catalyst and protected with Boc group to afford compounds 10-2 and 10-3.
  • the compond 10-2 is reacted with t-butylbenzylisothiocyanate, and then TBDPS is removed therefrom to synthesize compound 10-4.
  • Two protecting groups of compound 10-3 are removed using trifluoroacetic acid and the deprotected compound is protected with Boc group in the presence of triethylamine to synthesize compound 10-5.
  • TBDPS and Boc group are removed from the compound 10-5 and t-butylbenizylisothiocyanate is reacted therewith in the presence of triethylamine to give compound 10-6.
  • respective compounds 14-1 and 14-4 are obtained from 4-(methylthio)benzylalcohol and 4-methylthiazol-5-ethanol, respectively, under Mitsunobu condition, or obtained by introducing mesyl group into 4-(methylthio)benzylalcohol and 4-methylthiazol-5-ethanol, respectively, followed by reacting potassium phthalimide therewith. Phthalimide group is removed from compounds 14-1 and 14-4 with hydrazine to give amine compounds 14-2 and 14-5, respectively. The obtained amine compounds 14-2 and 14-5 are separately reacted with one equivalent of 4-t-butylbenzylisothiocyanate to the objective thiourea compounds 14-3 and 14-6, respectively. 2-Chloro-5-chloromethylpyridine is reacted with potassium phtlialimide to yield compound 14-7, and then compound 14-9 is synthesized according to the same procedure as the synthetic method of the compounds 14-3 and 14-6.
  • 2-aminopicoline is reacted with pivaloyl chloride to yield compound 21-1.
  • the compound 21-1 is brominated with NBS to prepare compound 21-2 and potassium phthalimide is reacted therewith to obtain compound 21-3 protected with phthaloyl group.
  • Pivaloyl group is removed from compound 21-3 in the presence of concentrated sulfuiric acid, and methanesulfonylchloride is reacted therewith to prepare compound 21-5.
  • the prepared compound 21-5 is treated with hydrazine and reacted with 4-t-butylbenzylisothiocyanate to yield compound 21-7.
  • Nitro group is selectivlely introduced into pyrrolecarboxaldehyde under nitric acid/acetic anhydride condition and the compound 22-1 was reduced with borane to prepare alcohol 22-2.
  • the prepared compound 22-2 is reacted with 4-t-butylbenzylisothiocyanate in the presence of sodium hydride to yield compound 22-3.
  • pyrrolecarboxaldehyde is reacted with hydroxylamine hydrochloride in the presence of 1-methyl-2-pyrrolidinone (NMP) as a solvent to produce nitrile compound 22-4 and nitro goup is introduced thereinto under the similar condition as above.
  • the nitro goup is reduced and mesylated to give compound 22-7.
  • the nitrite group of the compound 22-7 is reduced in the presence of palladium/carbon and 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 22-9.
  • amine compound D is reacted with isothiocyanate compound B in suitiable solvent to yield thiourea compound E (Example 136 ⁇ 141).
  • cyanoguanidine compounds are synthesized by two methods. As one method, 4-t-butylbenzylamine is reacted with dimethyl N-cyanodithioiminocarbonate or diphenyl cyanocarbonimidate, and then amine is reacted therewith to yield final compounds 31-1 ⁇ 31-6 (Example 173 ⁇ 178). And thiourea compound is reacted with lead cyanamide to give compounds 31-7 ⁇ 31- 9 (Example 179 ⁇ 181).
  • tetralone is converted to oxime and the oxime is reduced with nickel catalyst and sodium borohydride to prepare amine compounds 32-1, 32-3 and 32-5. These compounds are reacted with various benzylisothiocyanates to give compounds 32-2, 32-4 and 32-6 ⁇ 32-10. And methoxy group of compounds 32-3 and 32-5 are treated with hydrobromic acid to form hydroxy group and the resulting compound are reacted with various benzylisothiocyanates in the presence of triethylamine to yield compounds 32-11 and 32-12.
  • N-t-butyloxycarbonyl-p-aminobenzylamine 8-1 is reacted with sulfamoyl chloride in basic condition to prepare compound 35-1.
  • the prepared compound 35-1 is deprotected with trifluoroacetic acid to afford amine, and 4-t-butylbenzylisothiocyanate is subjected to condensation reaction therewith to yield thiourea compounds 35-2a, 35-2b and 35-2c.
  • 3-Nitro-4-aminobenzonitrile is mesylated to give compound 35-4, and then nitrile group of the compound 35-4 is reduced with borane to afford amine.
  • 4-t-Butylbenzylisothiocyanate is subjected to condensation reaction therewith to synthesize thiourea compound 35-5.
  • oxime 36-2 prepared from 4-aminoacetophenone as a starting material, is reduced to yield compound 36-3. Isothiocyanates are reacted therewith to give compounds 36-4 and 36-5. And compound 36-1 is reduced with methylamine to afford benzylamine derivatives, and 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 36-6.
  • the compound of formula (I) according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants, or diluents.
  • the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the compounds of the present invention can be formulated in the form of ointment or cream.
  • the pharmaceutical composition containing the compound of the present invention as an active ingredient can be used for preventing or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as astluna or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases.
  • pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as astluna or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal
  • the compound according to the present invention may also be used in the forms of pharmaceutically acceptable salts thereof, for example, alkali metals salts such as sodium salts, potassium salts and the like; alkali earth metals salts such as calcium salts, magnesium salts and the like; amines such as triethanolamine or ammonium salts, and may be used either alone or in combination or in admixture with other pharmaceutically active compounds.
  • alkali metals salts such as sodium salts, potassium salts and the like
  • alkali earth metals salts such as calcium salts, magnesium salts and the like
  • amines such as triethanolamine or ammonium salts
  • the compounds of the present invention may be formulated into injections by dissolving, suspending or emulsifying in water-soluble solvent such as saline and 5% dextrose, or in water-insoluble solvents such as vegetable oils, synthetic fatty acid glyceride, higher fatty acid esters and propylene glycol.
  • the formulations of the invention may include any of conventional additives such as dissolving agents, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives.
  • the preferable dose level of the compounds according to the present invention depends upon a variety of factors including the condition and body weight of the patient, severity of the particular disease, dosage form, and route and period of administration, but may appropriately be chosen by those skilled in the art.
  • the compounds of the present invention are preferably administered in an amount ranging from 0.001 to 100 mg/kg of body weight per day, and more preferably from 0.01 to 30 mg/kg of body weight per day. Doses may be administered once a day, or several times a day with each divided portions.
  • the compounds of the present invention are used in a pharmaceutical composition in an amount of 0.0001 ⁇ 10% by weight, and preferably 0.001 ⁇ 1% by weight, based on the total amount of the composition.
  • the pharmaceutical composition of the present invention can be administered to a mammalian subject such as rat, mouse, domestic animals, human being and the like via various routes.
  • the methods of administration which may easily be expected include oral and rectal administration; intravenous, intramuscular, subcutaneous, intrauterine, duramatral and intracerebroventricular injections.
  • Step 2 synthesis of 1-(1H-indol-5-yhmethyl)-3-phenethylthiourea (1-5)
  • Step 1 synthesis of 4-t-butylbenzylisotbiocyanate
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7)
  • Lithium aluminum hydride (0.38 g) was dissolved in anhydrous ether (20 ml). The solution was cooled to 0° C. and 4-(methylsulfonyl)benzonitrile (1.81 g) was slowly added dropwise thereto. The mixture was stirred for 3 hours while allowed to slowly warm up to room temperature and the reaction was quenched with 20% aqueous sodium hydroxide solution and water. The water layer was washed with ether, and then the ether layer was mixed with the organic layer. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column-chromatography (acetone) to yield a liquid (0.3 g).
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrro1-2-yl)ethyl]thiourea (1-9)
  • Step 2 Sythesis of 1-(4-amino-2,5-difluorobenzyl)-3-(4-t-butylbenzyl)thiourea (1-13)
  • Pipsylchloride (100 mg) was dissolved in 28% ammonia solution (4 ml) and the solution was stirred at room temperature for 1 hours. The resulting mixture was extracted with ethyl acetate (20 ml), washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was chromatographed on column eluting with ethyl acetate/hexane (1/2) to yield the compound 2-2 (89 mg, 100%/0).
  • Step 4 Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)thiourea (2-5)
  • Step 1 Synthesis of 2-fluoro-4-iodo-1-methanesulfonylaminobenzene (3-2)
  • Step 3 Sythesis of 3-fluoro-4-methanesulfonaminobenzylamine hydrochloride (3-4)
  • Step 4 Synthesis of 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)tbiourea (3-5)
  • Compound 3-7 (8.3 mg, 24%) was synthesized according to the same procedure as desribed in Step 4 of Example 13 except that compound 3-4 (20 mg) and phenethylisothiocyanate (27 ⁇ l) were used as reactants.
  • Compond 3-10 (1.08 g) prepared according to the procedure as described in Example 13 was dissolved in acetone (20 ml) and to the solution was added 2.5 M aqueous lithium hydroxide solution (15 ml). The mixture was stirred at room temperature for 5 hours and the solvent was removed therefrom. The residue was dissolved in ethyl acetate and then extracted to yield the compound 4-1 (980 mg, 94%/).
  • Step 1 Synthesis of 4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene
  • Step 2 Synthesis of 2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiourea (5-4)
  • Step 1 Synthesis of 2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene
  • Step 2 Sythesis of 2,5-difluoro-4-methanesulfonaminobenzyl hydrochloride
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonaminebenzyl)thiourea (5-5)
  • Step 1 Synthesis of 3-methanesulfonylamino-6-cyanopyridine
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-[(5-methanesulfonylaminopyridin-2-yl)methyl]thiourea (5-6)
  • the obtained compound was dissolved in methanol (10 ml), and then the solution was stirred for 15 hours in the presence of a small amount of concentrated hydrochloric acid and 5% palladium/carbon catalyst to hydrogenate the compound.
  • the reaction solution was filtered through celite and concentrated.
  • the concentrate was dissolved in dichloromethane (5 ml) and to the solution were added 4-t-butylbenzylisothiocyanate (54 mg) and triethylamiine (500 ⁇ l), followed by stirring at room temperature for 15 hours.
  • Step 1 Synthesis of 4-methanesulfonylaminobenzyl cyanide
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea (5-8)
  • Step 1 Synthesis of (2-methanesulfoliylaniinophenyl)acetonitrile
  • Step 3 Sythesis of 1-(4-t-butylbenzyl)-3-(2-methanesulfonylaminophenethyl)thiourea (5-9)
  • Step 1 Synthesis of (4-nitrobenzyl)carbamic acid t-butyl ester (6-2)
  • Step 2 Synthesis of (4-methylsulfanylcarbonylaminobenzyl)carbamic acid t-butyl ester (6-3)
  • Step 4 Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylsulfanylcarbonylaminobenzyl)thiourea (6-5)
  • Step 1 Synthesis of 4-(1,3-bis(t-butoxycarbonyl)-2-guanidino)phenyliodide (7-2)
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-[4- ⁇ 1,3-bis(t-butoxycarbonyl)-2-guanidino ⁇ benzyl]thiourea (7-5)
  • Step 4 Synthesis of 1-(4-t-butylbenzyl)-3-(4-guanidinobenzyl)thiourea (7-6)
  • Step 1 Syntheis of (4-aminobenzyl)carbanic acid t-butyl ester (8-1)
  • Step 2 Synthesis of (4-methanesulfonylaminobenzyl)carbamic acid t-butyl ester (8-2)
  • Step 3 Synthesis of 4-methanesulfonylaimnobenzylammonium trifluoroacetate (8-3)
  • Step 4 Synthesis of 1-[2-(1-methyl-1H-pyrro1-2-yl)ethyl]-3-(4-methanesulfonylaminobenzyl)thiourea (8-4)
  • the compound (300 mg) was dissolved in THF (5.0 ml) and to the solution was added tetrabutylanumonium fluoride (131 mg), followed by stirring at room temperature for 45 minutes.
  • Step 1 Synthesis of 2-(N-t-butyloxycarbonylamino)methyl-4-methanesulfonylamino-l1-t-butyldiphenylsilylo xybenzene (10-5)
  • Step 1 Synthesis of 2,4-difluoro-3-[N-(t-butoxycarbonylamino)methyl]aniline (11-1)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanesulfonylaminobenzyl)thiourea (11-2)
  • the obtained oxime was dissolved in methanol (20 ml) and to the solution was added 10% palladium/carbon (414 mg), followed by stirring at room temperature under hydrogen atmosphere for 3 days.
  • the reaction mixture was filtered to remove the precipitate and the filtrate was concentrated under reduced pressure to yield the compound 12-1b (643 mg, 53%).
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(3-methanesulfonylaminobenzyl)thiourea (12-3b)
  • the water was added thereto to quench the reaction.
  • the compound 12-2b was dissolved in dichloromethane (15 ml) and the solution was cooled to 0C, followed by adding trifluoroacetic acid (3.0 ml) thereto and stirring for 2 hours.
  • the resulting mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (10 ml), followed by adding triethylamine (140 ⁇ l) thereto and stirring for 1 hour.
  • Step 3 Synthesis of 1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylainiobenzyl)thiourea (13-4a)
  • Example 60 69 Compounds of Example 60 69 are shown in the Scheme 13.
  • Step 1 of the Examples compounds 13-2b - 13-2k were synthesized according to the similar procedure as described in Step 1 of Example 59, and properties and spectral data thereof are shown in below table.
  • Step 2 of the respective examples amines were synthesized according to the similar procedure as described in Step 2 of Example 59, and the following Step 3 were proceeded using the obtained amine compounds which was not purified.
  • the final compounds 13-4b 134k were synthesized according to the similar procedure as described in Step 3 of Example 59 except that amines prepared by Step 2 were used, and properties and spectral data thereof are shown in below table.
  • Step 1 Synthesis of 4-t-butyl-2-trifluoromethanesulfonyloxybenzonitile (13-5)
  • Step 2 Synthesis of methyl 5-t-butyl-2-cyanobenzoate (13-6)
  • Step 4 Synthesis of 1-(4-t-butyl-2-hydroxymethylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea (13-8)
  • Step 5 Synthesis of 1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaninobenzenc)thiourea (13-9a)
  • 1,3-Dicyclohexylcarbodiimide (68 mg) was dissolved in dichloromethane (1 ml), and the solution was stirred and cooled to 0° C. To the solution were added dropwise a mixed solution of the compound 13-8 (130 mg) prepared according to the same procedure as described in Step 4 and 4-(dimethylamino)pyridine (4 mg) in dichloromethane (3 ml), followed by adding acetic acid (34 ⁇ l) thereto. The mixture was stirred at room temperature for 12 hours and concentrated under reduced pressure. The obtained residue was purified by column-chromatograpohy (hexane/ethyl acetate 3/2) to yield the compound 13-9a (52 mg, 37%).
  • Step 1 Synthesis of 2-(4-methylthiobenzyl)isoindol-1,3-dione (14-1)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylthiobenzyl)thiourea (14-3)
  • Step 1 Synthesis of 5-(2-methylsulfonyloxyethyl)-4-methylthiazole
  • reaction solution was washed with water, concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate ⁇ fraction (1/3) ⁇ ) to yield 5-(2-methylsulfonyloxyethyl)-4-methylthiazolei (5.18 g, 67%) as a pale yellow liquid.
  • Step 2 Synthesis of 2-[2-(4-methylthiazol-5-yl)ethyl]isoindol-1,3-dione (14-4)
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea (14-6)
  • the obtained mixture (140 mg) was dissolved in dimethylformamide (5 ml) and to the solution were added 4-t-butylbenzylisothiocyanate (0.2 g) and a small amount of triethylamine, followed by stirring at room temperature for 21 hours.
  • Step 1 Synthesis of ((2-chloro-5-pyridinyl)methyl)isoindol-1 ,3-dione (14-7)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea (14-9)
  • Step 1 Synthesis of 2-(2-thiomorpholin-4-yl)ethyl)isoindol-1,3-dione (15-1)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(2-(thiomorpholin-4-yl)ethyl)thiourea (15-3)
  • reaction mixture (1.62 g) as a solid.
  • the obtained mixture (150 mg) was dissolved in dimethylformamide (5 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (210 mg) and a small amount of triethylamine, followed by stirring at room temperature for 23 hours.
  • the resulting mixture was diluted with dichloromethane, washed with water, and concentrated under reduced pressure.
  • Step 1 Synthesis of 1H-pyrro1-2-carboxaldehyde oxime
  • Step 3 Sythesis of 1-(4-t-butylbenzyl)-3-(1H-pyrrol-2-ylmethyl)thiourea (17-1)
  • Step 1 Synthesis of methyl-IH-pyrrol-2-carboxaldehyde oxime
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-(1-methyl-IH-pyrrol-2-yl)methylthiourea (17-2)
  • Step 1 Synthesis of 5-nitrothiophen-2-carboxaldehyde oxime
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-(5-nitrotbiophen-2-ylmethyl)thiourea (17-4)
  • the compound 17-4 (yield: 40%, yellow solid) was synthesized by reacting the compound prepared in Step 2 with 4-t-butylbenzylisothiocyanate according to the similar procedure as described in Step 3 of Example 124.
  • Step 3 Synthesis of 1-(4-t-butylbenzyl)-3-(2-methylpyridin-3-ylmethyl)thiourea (18-5)
  • 5-Nitro-1H-indazole (20 mg) was dissolved in methanol (1 ml) and to the solution was added a catalytic amount of palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to yield 5-amino-1H-indazole (16 mg, 100%).
  • Step 1 Synthesis of 3-fluoro-4-(N-t-butyloxycarbonylaminomethyl)phenol (20-1a) and 3-fluoro-4-(N-t-butyloxycarbonylainomethyl)phenol t-butyloxycarbonyl ether (20-1b)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(2-fluoro-4-methanesulfonyloxybenzyl)thiourea (20-2a)
  • Step 1 Synthesis of 2,2-dimethyl-N-(6-methyl-2-pyridinyl)propaneamide (21-1)
  • Step 3 Synthesis of N-[6- ⁇ (1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl ⁇ -2-pyridinyl]-2,2-dimethylprop aneamide (21-3)
  • N-[6-(bromomethyl)-2-pyridinyl]-2,2-dimnethylpropaneamide (21-2) (1.9 g) was dissolved in dimethylformamide (20 ml) and to the solution was added potassium phthalimide (1.43 g), followed by stirring at room temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and extrated with water and dichloromethane. An organic layer was concentrated under reduced pressure to yield the compound 21-3 (2.27 g, 96%) as a bright yellow solid.
  • Step 4 Synthesis of 2-[(2-amino-6-pyridinyl)methyl]-1H-isoindol-1,3(2H)-dione (21-4)
  • Step 5 Synthesis of 2-[(2-methanesulfonylamino-6-pyridinyl)methyl]-1H-isoindol-1,3 (2H)-dione (21-5)
  • Step 6 Synthesis of 1-(4-t-butylbenzyl)-3-[(2-methanesulfonylamino-6-pyridinyl)methyi]thiourea (21-7)
  • N-methylpyrrol-2-carboxaldehyde (5 g) was dissolved in anhydrous acetic acid (50 ml), and to an ice-cold of the solution was slowly added dropwise nitric acid (1.84 ml) with stirring. The mixture was stirred at this temperature for I hour, and then at room temperature for 18 hours. After confiing the completion of the reaction, to the mixture was added an ice-water (200 ml), followed by slowly adding solid sodium hydroxide (20 g) thereto and stirring for 1 hour. The obtained mixture was extracted with ether (150 ml ⁇ 3).
  • Step 3 Synthesis of (4-t-butylbenzyl)thiocarbamic acid (1-methyl-4-nitro-1H-pyrrol-2-yl)methyl ester (22-3)
  • Step 4 Synthesis of 4-methanesulfonylamino-2-cyano-N-methylpyrrole (22-7)
  • Step 5 Synthesis of (4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)methylamine (22-8)
  • Step 6 Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea (22-9)
  • Step 1 Synthesis of (4-methanesulfonylaminomethyl)-1-nitrobenzene (23-1)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-[(4-methanesulfonylarninomethyl)phenyl]thiourea (23-2)
  • Vaniline (200 mg) and benzylamine (129 mg) were dissolved in methanol (3 ml) and the solution was stirred for 30 minutes.
  • a catalytic amount of 10% platinum/carbon to be subjected to the hydrogenation reaction (I atm) .
  • the resulting mixture was filtered and evaporated under reduced pressure to remove methanol.
  • Step 1 Synthesis of (3-fluoro-4-methanesulfonylamino)cinmamic acid methyl ester (26-1)
  • Step 3 Synthesis of N-(4-t-butylbenzyl) 3-(3-fluoro-4-methanesulfonylaminophenyl)propionamide (26-3)
  • Step 1 Synthesis of 6-methoxy-1 ,2,3,4-tetrahydro-naphthalen-1-ylaine (32-1)
  • Step 2 Synthesis of 1-(4-chlorobenzyl)-3-(6-methoxy-1,2,3,4-tetrahydronaphthalen- 1-yl)thiourea (32-2)
  • R T Spectral data 183 32-4
  • Step 1 Synthesis of 4-t-butylcinnamic acid ethyl ester (34-2)
  • Step 2 Synthesis of ethyl 3-(4-t-butylphenyl)propionate (34-3)
  • Step 3 Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 3-(4-t-butylphenyl)propionamide (34-5)
  • Step 1 Synthesis of N-t-butyloxycarbony1-4-methylaminosulfonylaminobenzylamine (35-1a)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylaminosulfonylaminobenzyl)thiourea (35-2a)
  • Step 1 Synthesis of N-t-butyloxycarbony1-4-N,N-dimethylaminosulfonylaminobenzylamine (35-1b)
  • Compound 35-1b (393 mg, 53%) was synthesized by adding dimethylsulfamoylchloride (266 ,uQ) and then by being allowed to warm up to 60° C. according the procedure as described in Example 194.
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(4-N,N-dimethylaminosulfonylaminobenzyl)thiourea (35-2b)
  • Step 1 Synthesis of N-t-butyloxycarbony1-4-N-(t-butyloxycarbonylaminosulfonyl)aminobenzylamine (35-1c)
  • Compound 35-1c (333 mg, 54%) was synthesized by adding N-(t-butyloxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl]azanide (464 mg) and then by being allowed to warm up to 60° C. according the procedure as described in Example 194.
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(4-aminosulfonylaminobenzyl)thiourea (35-2c)
  • Step 1 Synthesis of 4-methanesulfonylamino-3-nitrobenzonitrile (35-4)
  • Step 2 Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-3-nitrobenzyl)thiourea (35-5)
  • Step 1 Synthesis of 4-methanesulfonylaminoacetophenone (36-1)
  • Step 3 Synthesis of 1-(4-methanesulfonylaminophenyl)ethylamine (36-3)
  • Step 4 Synthesis of 1-(4-t-butylbenzyl)-3-(1-(4-methanesulfonylphenyl)ethyl)thiourea (36-4)
  • Neonatal(2-day old or younger than 2-day old) SD rats were put in ice for 5 minutes to anesthetize and disinfected with 70% ethanol.
  • DRG of all part of spinal cord were dissected (Wood et al., 1988, J. Neurosci. 8, pp3208-3220) and collected in DME/F12 medium to which 1.2 g/l sodium bicarbonate, 50 mg/l gentamycin were added. The DRG were incubated sequentially at 37° C. for 30 min in 200 U/mi collagenase and 2.5 mg/ml trypsin, separately.
  • the ganglia were washed twice with DME/F12 medium supplemented with 10% horse serum, triturated through a fire-polished Pasteur pipette, filtered through Nitex 40 membrane to obtain single cell suspension. This was subjected to centrifugation, then re-suspended in cell culture medium at certain level of cell density.
  • DME/F12 medium supplemented with 10% horse serum diluted 1:1 with identical medium conditioned by C6 glioma cells (2 days on a confluent monolayer) was used, and NGF(Nerve Growth Factor) was added to final concentration of 200 ng/ml.
  • cytosine arabinoside 100 ⁇ M was added to kill dividing nonneuronal cells
  • medium was changed to one without Ara-C.
  • the resuspended cells were plated at a density of 1500-1700 neurons/well onto Terasaki plates previously coated with 10 ⁇ g/ml poly-D-ornithine.
  • DRG nerve cells from the primary culture of 2-3 days were equilibrated by washing 4 times with HEPES (lOmM, pH 7.4)-buffered Ca 2+ , Mg 2+ -free HBSS (H-HBSS).
  • H-HBSS HEPES-buffered Ca 2+ , Mg 2+ -free HBSS
  • the solution in each well was removed from the individual well.
  • Medium containing the test compound plus capsaicin (final concentration 0.5 ⁇ M) and 45 Ca (final concentration 10 ⁇ Ci/ml) in H-HBSS was added to each well and incubated at room temperature for 10 min. Terasaki plates were washed six times with H-HBSS and dried in an oven. To each well, 0.3% SDS (10 ⁇ l) was added to elute 45 Ca.
  • Agonistic activities of the test compounds for vanrilloid receptor were determined as a concentration of the test compound showing 50% of the 45 Ca influx, compared to the maximal amount of 45 Ca influx in case of using 3 ⁇ M capsaicin and results are given as EC 50 (Table 1d).
  • Antagonistic activities of test compounds were assayed based on electrical change of cation channel connected to vanilloid receptor and experiments were conducted according to reference method (Oh et al., 1996, J. Neuroscience 16, pp1659-1667) (Table 1a, 1b and 1c). TABLE 1a Results of Calcium Influx and Patchclamp Tests Calcium Uptake Patchelamp Test Examples Test(IC 50 ) (antagonistic activities) 5 1.1 9 0.23 13 0.037 ++ 15 1.2 17 0.0084 ++ 18 0.72 19 0.0058 ++ 30 1.5 32 0.031 + 33 0.11 36 1.1 44 0.11 + 51 0.7
  • mice Male ICR mice (mean body weight 25 g) were maintained in a controlled lighting environment (12 h on/12 h off) for experiment. Animals received an intraperitoneal injection of 0.3 ml of the chemical irritant phenyl-p-quinone (dissolved in saline containing 5% ethanol to be a dose of 4.5mg/kg) and 6 min later, the number of abdominal constrictions was counted in the subsequent 6 min period. Animals (10 animals/group) received 0.2 ml of test compounds solution in vehicle of ethanoVTween 80/saline (10/10/80) intraperitoneally 30 min before the injection of phenyl-p-quinone.
  • a reduction in the number of writhes responding to the test drag compound relative to the number responding in saline control group was considered to be indicative of an analgesic effect.
  • mice Male JCR mice(body weight 25-30 g), 10 animals/group, were treated topically on th right ear with 30 ⁇ l of TPA (2.5 ⁇ g) solution in acetone and after 15 min, 30 ⁇ l of acetone or test compound solution in acetone was applied topically. After six hours, a identica treatment was applied again. After twenty four hours following the tratment of TPA, the animals were sacrificed and ear tissue was dissected using 6 mm-diameter punch. Ear tissue dissected were weighed to the nearest 0.1 mg on an electrobalance. The increased weight of the tissue compared to control group was considered as an index of inflammation. The percent inhibition is defined by the following equation:
  • C and T represent an increase of ear weight in TPA-treated and TPA+drug-treated group, respectively (Table 3).
  • vanilloid receptor antagonist According to the present study using ethano1-induced ulcer model, the vanilloid receptor antagonist was found out to exhibit significant anti-ulcerous activities, contrary to ranitidine, which is a representative antiulcerant but did not show anti-ulcer activity in the present study. This study is the first to demonstrate the anti-ulcerous potential of vanilloid receptor antagonist. Based on the result, possibility that vanilloid receptor antagonist will be developed as an anti-ulcerant is suggested.
  • the compounds according to the present invention are useful in the prevention or treatment of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma and chronic obstructive pulmonary diseases, irritation in slin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease, etc.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

Description

    TECHNICAL FIELD
  • The present invention relates to novel thiourea derivatives and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions thereof. Here, the modulator means the thing that can be bonded to the receptor to act as an antagonist or an agonist. [0001]
    • BACKGROUND ART
  • As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arttralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulnonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides pharmaceutical compositions for prevention or treatment of these diseases. Yet, the diseases described above are only for enumeration, not to limit the scope of clinical application of vanilloid receptor modulator. [0002]
  • Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a main pungent component in hot peppers. Hot peppers have been used, for a long time, not only as a spice but also as traditional medicine in the treatment of gastric disorders and when applied locally, for the relief of pain and inflammation (Szallasi and Blumberg, 1999, Pharm, Rev. 51, ppl59-211). Capsaicin has a wide spectrum of biological actions, and not only exhibits effects on the cardiovascular and respiratory systems but also induces pain and irritancy on local application. Capsaicin, however, after such induction of pain, induces desensitization, both to capsaicin itself and also to other noxious stimuli to make the pain stopped. Based on this property, capsaicin and its analogues such as olvanil, nuvanil, DA-5018, SDZ-249482, resiniferatoxin are either used as analgesic agent, therapeutic agent for incontinentia urinae or skin disorder, or under development (riggleworth and Walpole, 1998, Drugs of the Future 23, pp 531-538). [0003]
  • Transmissions of mechanical, thermal and chemical noxious stimuli are mainly occurred by primary afferent nerve fibers of fine unmyclinated nerve (C-fiber) and thin myclinated nerve (A-fiber), and main reaction site of capsaicin and its analog called vanilloid is present at the nerve fiber transmitting the noxious stimuli. Capsaicin acts at the receptor existing on these neurons to induce potent stimuli by causing potent inflow of mono-and di-valent cations such as calcium and sodium, then exhibits potent analgesic effect by blocking the nervous fimction (Wood et al., 1988, J. Neurosci, 8, pp3208-3220). Vanilloid receptor (VR-1) has been recently cloned and its existence becomes clear(Caterina et al., 1997, Nature 389, pp816-824). It was clarified that this receptor transmits not only stimuli by capsaicin anlogues(vanilloid) but also various noxious stimuli such as proton and thermal stimuli (Tominaga et al., 1998, Neuron 21, pp531-543). Based on this, it is considered that vanilloid receptor finctions as a integrative modulator against various noxious stimuli and carries out critical role in transmissions of pain and noxious stimuli. Recently, knock-out mouse in which gene encoding for vanilloid receptor was deleted was prepared (Caterina et al., 2000, Science 288, pp306-313; Davis et al., 2000, Nature 405, ppl83-187). Compared to normal mice, the mouse was found out to exhibit much reduced reaction to thermal stimuli and thermal pain, while exhibiting no difference in general behavior, reconfirming the importance of the receptor in transmission of noxious signal. However, except proton, no other endogenous ligand, not exogenous ligand such as capsaicin, actually involved in transmission of noxious stimuli at vanilloid receptor was known. It is considered that leucotriene metabolite represented by 12-hydroperoxyeicosatetraenoic acid (12-BPETE) (Hwang et al., 2000, PNAS 11, pp61[0004] 55-6160) and arachidonic aicd derivatives such as anandamide (Zygmunt et al., 2000, Trends Phannocol. Sci. 21, pp43-44) act as the most likely endogenous ligand for the receptor and proton acts as a cofactor with receptor-stimulating activity, rather than as a direct ligand.
  • As such, a capsaicin-sensitive sensory nerve cell and a vanilloid receptor existing in the cell are distributed over the entire body and play basic function in transmission of noxious stimuli and pain, further act as crucial factor in expression of neurogenic inflammation, thereby to have close relation with the cause of neuropathies, nerve injury, stroke, asthma, chronic obstructive pulmonary diseases, urinary bladder hypersensitiveness, irritable bowel syndrome, inflammatory bowel disease, fervescence, skin disorder and inflammatory disease. Lately, their correlation even with neuropathic disease is suggested (WO 99/00125). Recently, attention has focused to the role of afferent sensory nerve responding to capsaicin in gastrointestinal injury, and it was proposed that the afferent nerve might have a dual character that it exhibits protective action against gastric damage by improving gastric microcirculation through releasing peripheral neuropeptide such as CGRP (calcitonin gene-related peptide), while inducing gastric injury by stimulating sympathetic nervous system (Ren et al., 2000, Dig. Dis. Sci. 45, pp830-836). It is determined that vanilloid receptor modulator has very high potential to be used for prevention or treatment of the said various diseases by modulating the activity of the vanilloid receptor conducting such varied functions. [0005]
  • As described above, there has been widely studied for clinical application of vainiloid receptor agonist, and it is understood that there is a possibility that the agonist derived from the present studies will be developed for clinical application. Though it may be, theoretically, anticipated that antagonist for this receptor would exhibit substantial degree of inhibitory action against pain and neurogenic inflammation, it was found out that the competitive antagonist for this receptor, capsazepine, almost the only one known until now, failed to exhibit significant analgesic and anti-inflammatory effects (Perkins and Campbell, 1992, Br. J. Pharmacol. 107, pp329-333). Therefore, not much progress was made on this field. However, recently, there has been a report on significant results for analgesic action of capsazepine in animal studies (Kwak et al., 1998, Neurosci. 86, pp619-626; Santos and calixto, 1997, Neurosci. Lett. 235, pp73-76), in particular, the inventors of the present invention clearly demonstrated through animal studies the analgesic and anti-inflanmmatory effects of the strong vanilloid receptor antagonists which were identified through experiments in our laboratory, and based on this, strongly suggest the development potential of vanilloid receptor antagonist as an analgesic, anti-infla matory and anti-ulcerous agent. Yet, though the vanilloid receptor antagonist or agonist derived from the present studies will mainly act based on the antagonistic or agonistic activity of itself, even a possibility that it could exhibit the pharmacological activity through transformation into agonist or antagonist via metabolism after absorption into body is not to be excluded. [0006]
  • The present invention is to provide novel compounds which are acted as a modulator for vanilloid receptor and exhibit excellent analgesic, anti-inflammatory and anti-ulcer effects, and pharmaceutical compositions containing the same. [0007]
    • DISCLOSURE OF THE INVENTION
  • In order to attain the above objects, the present invention provides a novel compound of the following formula (I): [0008]
    Figure US20030153596A1-20030814-C00001
  • wherein, [0009]
  • X represents S, O or —NCN; [0010]
  • Y represents single bond, NRW, O or S; [0011]
  • R[0012] 1 represents
    Figure US20030153596A1-20030814-C00002
  • pyridinyhnethyl, pyrrolylmethyl, oxazolylmethyl, pyrazolylmethyl, imidazolylrnethyl, anthracenylmethyl, naphthylmethyl, quinolinylmethyl, alkoxycarbonyl or alkylcarbonyloxy (wherein, m is 0, 1, 2, 3 or 4; R[0013] 4 and R5 are independentyl hydrogen, lower alkyl having I to 5 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, alkoxycarbonyloxy, benzyloxy, acetoxymethyl, propinoyloxymethyl, butoxyallcl, trimethylacetoxy, trimethylacetoxymethyl or halogen; and R6 and R7 are independently hydrogen, lower alkyl having 1 to 5 carbon atoms);
  • R[0014] 2 represents R8—(CH2)n—
  • {wherein, n is 0, 1, 2, 3 or 4; R[0015] 8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzimidazolyl, chromonyl or benzothiazolyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or
    Figure US20030153596A1-20030814-C00003
  • (wherein, R[0016] 9 is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, lower alkoxy having 1 to 5 carbon atoms, hydroxy, nitro, cyano, —NHSO2R2, —S(O)pR12, NR13R14, carboxyl; R10 is hydrogen, nitro, NHSO2R2, S(O)pR12 or NR13R14; R11 is hydrogen or cyano; R12 is lower alkyl having 1 to 5 carbon atoms, methylphenyl, NR13R14, tifluoromethyl or alkenyl; R13 and R14 are independently hydrogen or lower alkyl having 1 to 5 carbon atoms; and p is 0 or 2.); or or
    Figure US20030153596A1-20030814-C00004
  • (wherein, Z is 0, S, NH or —NCH[0017] 3; R15 is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, nitro, cyano, —NHSO2R12, —S(O)pR12, N,N-dimethylaminomethyl or alkoxycarbonylamino; and p and R12 have the same meanings as defined in R9);
    Figure US20030153596A1-20030814-C00005
  • (wherein, W is O, S, NH, NR[0018] 16, —N(SO2CH3)— or —CH2—; and R16 is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, methancsulfonylamino or halogen; or benzyl or phenethyl substituted or unsubstitued with lower alkyl having 1 to 5 carbon atoms, alkoxy, hydroxy, nitro, methanesulfonylamnino or halogen);
    Figure US20030153596A1-20030814-C00006
  • (wherein, R[0019] 17, R18, R19, R20 and R21 are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, amninoalkoxy, alkoxycarbonylamino, —NHCH2CO2H, alkoxyalkylcarbonylammo, alkoxycarbonylalkylarnino, nitro, formyl, acetyl, formylamino, acetoxyamino, cyano, —OSO2CH3, —NHSO2R12, —N(SO2R12)CH3, —N(SO2R12)2, —S(O)pR12, —NR13R14, thiocarbamoyl, —C(═O)NHNH2, —C(═O)NHOH, —C(═O)NHOCH3, —PO(═O)(OCH3)2, carboxyl, NHBoc, —NHC(═O)SCH3 or guanidine; R22 and R23 are independently hydrogen, halogen, alkoxy or hydroxy; and p, R12, R13 and R14 have the same meanings as defined in R9);
  • or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and [0020]
  • R[0021] 3 represents hydrogen, alkyl or cycloalkyl having 1 to 8 carbon atoms, lower alkylphenyl having 1 to 5 carbon atoms, pyridinylethyl, bisphenylmethyl; or phenylallcyl substituted with lower allcyl having 1 to 5 carbon atoms, halogen or methanesulfonylamino.
  • Preferably, in the above formula (I), [0022]
  • X represents S, O or —NCN; [0023]
  • Y represents NR[0024] 3 or 0;
  • R[0025] 1 represents
    Figure US20030153596A1-20030814-C00007
  • (wherein, m is 0, 1 or 2; and R[0026] 4 and R5 are independently hydrogen, lower alkyl having 1 to 4 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);
  • R[0027] 2 represents R8—(CH2)n—
  • {wherein, n is 0, 1, 2 or 3; and R[0028] 8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, benzinidazolyl or chromonyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or
    Figure US20030153596A1-20030814-C00008
  • (wherein, R[0029] 9 is hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, nitro, cyano, —NHSO2R12, —NR13R14 or carboxyl; Rk° is hydrogen, nitro, NHSO2R12 or —NR13R14; R11 is hydrogen or cyano; R12 is lower alkyl having 1 to 4 carbon atoms, methylphenyl, —NR13R14 or trifluoromethyl; R13 and R14 are independently hydrogen or lower alkyl having 1 to 4 carbon atoms; and p is 0 or 2);
    Figure US20030153596A1-20030814-C00009
  • (wherein, Z is O, S, NH or —NCH[0030] 3; R15 is hydrogen, lower alkyl having 1 to 4 carbon atoms, nitro, cyano or NHSO2R12; and R12 has the same meanings as defined in R9); or
    Figure US20030153596A1-20030814-C00010
  • (wherein, W is O, S, NH, NR[0031] 16 or —CH2—; and R16 is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, nitro or methanesulfonylamino; or benzyl or phenethyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, alkoxy, hydroxy or methanesulfonylamino);
  • or [0032]
    Figure US20030153596A1-20030814-C00011
  • (wherein, R[0033] 17, R18, R19, R20 and R21 are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonyl amino, —NHCH2CO2H, alkoxyalkylcarbonylaminno, alkoxycarbonylalkylamino, nitro, fonnyl, acetyl, fonnylamino, acetoxyamnino, cyano, —OSO2CH3, —NHSO2R12, —N(SO2R12)CH3, —N(SO2R12)2, —S(O)pR2, NR13R14, thiocarbamoyl, —C(═O)NHNH2, —C(═O)NHOH, —C(═O)NHOCH3, carboxyl, NHBoc, —NHC(═O)SCH3, guanidine; R22 and R23 are independently hydrogen, alkoxy or hydroxy; and p, R12, R13 and R14 have the same meanings as defined in R9);
  • or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and [0034]
  • R[0035] 3 represents hydrogen, alkyl having 1 to 4 carbon atoms, lower alkcylphenyl having 1 to 3 carbon atoms, pyridinylethyl or bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 4 carbon atoms, halogen or methanesulfonylamino.
  • More preferably, in the above formula (I), X represents S, O or —NCN; [0036]
  • Y represents NR[0037] 3 or O;
  • R[0038] 1 represents
    Figure US20030153596A1-20030814-C00012
  • (wherein, m is 1 or 2; and R[0039] 4 and R5 are independently hydrogen, t-butyl, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxymethoxy, methoxyethoxy, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);
  • R[0040] 2 represents R8—(CH2)n—{wherein, n is 1, 2 or 3; R8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl or benzimidazolyl substituted or unsubstituted with methyl, nitro or halogen;
  • or [0041]
    Figure US20030153596A1-20030814-C00013
  • (wherein, R[0042] 9 is hydrogen, halogen, methyl, nitro or methanesulfonylamino; R10 is hydrogen or nitro; and R11 is hydrogen or cyano);
  • or [0043]
    Figure US20030153596A1-20030814-C00014
  • (wherein, Z is O, S, NH or —NCH[0044] 3; and R15 is hydrogen, methyl, nitro, cyano or methanesulfonylamino);
  • or [0045]
    Figure US20030153596A1-20030814-C00015
  • (wherein, W is O, S, NH, NR[0046] 16 or —CH2—; and R16 is pyridinyl, pyrimnidinyl; or benzyl or phenethyl substituted or unsubstituted with methyl, methoxy or hydroxy);
  • or [0047]
    Figure US20030153596A1-20030814-C00016
  • (wherein, R[0048] 17, R18, R19, R20 and R21 are independently hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, methoxy, methylenedioxy, methanesulfonylaminomethyl, methoxycarbonyli hydroxy, sulfamoyl, alkoxycarbonylamino, —NHCH2CO2H, methoxymethylcarbonylamino, alkoxycarbonylalkylamino, nitro, acetyl, fonnylamino, acetoxyamino, cyano, —OSO2CH3, —NHSO2R12, —N(SOR12)CH3, —N(SO2R12)2, —S(O)pR12, NR13R14, thiocarbamoyl, —C(═O)NHNH2, —C(═O)NHOH, —C(═O)NHOCH3, carboxyl, NHBoc, —NHC(═O)SCH3, guanidine; R22 and R23 are independently hydrogen, methoxy or hydroxy; and p, R12, R13 and R14 have the samne meanings as defined in R9);
  • or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and [0049]
  • R[0050] 3 represents hydrogen, methyl, isopropyl, isobutyl, cyclohexyl, benzyl, phenethyl or bisphenylmethyl; or phienylalkyl substituted with t-butyl, halogen or methanesulfonylamino.
  • Preferable examples of the compounds of formula (I) according to the present invention are as follows: [0051]
  • 1-(4-t-butylbeiizyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea; [0052]
  • 1-(4-t-butylbenzyl)-3-(4-amino-2,5-difluorobenzyl)thiourea; [0053]
  • 1-(4-t-butylbenzyl)-3-(4-sulfamoylbenzyl)thiourea; [0054]
  • 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylamiobenzyl)thiourea; [0055]
  • 1-phenethyl-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea; [0056]
  • 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea; [0057]
  • 1-(4-t-butylbenzyl)-3-(3-methoxycarboxyl-4-methanesulfonylaminobenzyl)thiourea; [0058]
  • 1-(4-t-butylbenzyl)-3-(3-carboxyl-4-methanesulfonylamninobenzyl)thiourea; [0059]
  • 1-(4-t-butylbenzyl)-3-((3-N-hydroxyaminocarbonyl-4-methanesulfonylamino)benzyl)thiourea; [0060]
  • 1-(4-t-butylbenzyl)-3-(3-methoxycarboxylbenzyl)thiourea; [0061]
  • 1-(4-t-butylbenzyl)-3-(3-carboxylbenzyl)tiourea; [0062]
  • 1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methainesulfonylaminobenzyl)thiourea; [0063]
  • 1-(4-t-butylbenzyl)-3-(2,5-dfluoro-4-methanesulfonylaminobenzyl)thiourea; [0064]
  • 1-(4-t-butylbenzyl)-3-(3-methanesulfonylamino-6-pyridinyl)methylthiourea; [0065]
  • 1-(4-t-butylbenzyl)-3-(2,6-dic1loro-5-methanesulfonylaminobenzyl)thiourea; [0066]
  • 1-(4-t-butylbenzyl)-3-(4-methanesuffonylaminophenethyl)thiourea; [0067]
  • 1-(4-t-butylbenzyl)-3-(4-inethanesulfonylaminobenzyl)thiourea; [0068]
  • 1-(4-t-butylbenzyl)-3-[2,6-difluoro-3-(N-methanesulfonylaniino)benzyl]thiourea; [0069]
  • 1-(4-t-butylbenzyl)-3-[3-(N-methanesulfonylamino)benzyl]thiourea; [0070]
  • 1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0071]
  • 1-(4-t-butyl-2-ethoxybenzyl)-3-(4-methanesulfonylaimnobenzyl)thiourea; [0072]
  • 1-(4-t-butyl-2-propoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0073]
  • 1-(4-t-butyl-2-butoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0074]
  • 1-(4-t-butyl-2-isopropoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0075]
  • 1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamifnobenzyl)thiourea; [0076]
  • 1-(4-t-butyl-2-neopentoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0077]
  • 1-(4-t-butyl-2-methoxymethoxybenzyl)-3-(4-methatiesulfonylaminobenzyl)thiourea; [0078]
  • 1-(4-t-butyl-2-methoxyethoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0079]
  • 1-(4-t-butyl-2-benzyloxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0080]
  • 1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; [0081]
  • 1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea; [0082]
  • 1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea; [0083]
  • 1-(4-t-butylbenzyl)-3-(2-pyridin-2-ylethyl)thiourea; [0084]
  • 1-(4-t-butylbenzyl)-3-(2,5-difluorobenzyl)thiourea; [0085]
  • 1-(4-t-butylbenzyl)-3-(3-fluorophenethyl)thiourea; [0086]
  • 1-(4-t-butylbenzyl)-3-(4-sulfamoylphenethyl)thiourea; [0087]
  • 1-(4-t-butylbenzyl)-3-(4-morpholinylethyl)thiourea; [0088]
  • 1-(4-t-butylbeiizyl)-3-[2-(lH-imidazol-4-yl)ethyl]thiourea; [0089]
  • 1-(4-t-butylbenzyl)-3-[2-thiophen-2-ethyl]thiourea; [0090]
  • 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea; [0091]
  • 1-benzyl-1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea; [0092]
  • 1-(3-(4-hydroxy-3-methoxyphenyl)propyl)- I-phenethyl-3-phenethylthiourea; [0093]
  • 1-bisphenylmethyl- I-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea; or [0094]
  • N″-cyano-N-(4-t-butylbenzyl)-N′-(4-methanesulfonylaninobenzyl)guanidine. [0095]
  • More preferable examples of the compounds of formula (I) according to the present invention are follows: [0096]
  • 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzy)thiourea; [0097]
  • 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea; [0098]
  • 1-(4-t-butylbenzyl)-3-(3-methoxycarboxyl-4-methanesulfonylaminobenzyi)thiourea; [0099]
  • 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea; or [0100]
  • 1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamino)thiourea. [0101]
  • The compounds according to the present invention can chemically be synthesized by the following reaction schemes. However, these are given only for illusion of the invention and not intended to limit them. [0102]
    Figure US20030153596A1-20030814-C00017
  • As depicted in the above Scheme 1, the nitrile compound 1-1 or 1-3 is reduced with lithium aluminium hydride or hydrogen to afford an arnine 1-2 or 1-4, and then suitable isothiocyanate or isocyanate is reacted therewith to prepare thiourea or urea compound 1-5˜13. [0103]
    Figure US20030153596A1-20030814-C00018
  • As depicted in the above Scheme 2, pipsyl chloride is treated with ammonia solution to afford compound 2-2 and the nitrile compound 2-3 is obtained therefrom using palladium catalyst. The compound 2-3 is subjected to catalytic reduction using palladium and concentrated hydrochloric acid to prepare amine compound 2-4, and compounds 2-5, 2-6 and 2-7 are synthesized therefrom according to the procedure as described in Scheme 1. [0104]
    Figure US20030153596A1-20030814-C00019
  • As depicted in the above Scheme 3, 2-fluoro-4-iodo phenylamine compound 3-1 is mesylated, and cyano group is introduced thereinto in the presence of palladium catalyst. And the compound 3-3 is reduced to afford primary amine compound 3-4. The obtained intermediate is reacted with isocyanate or isothiocyanate to synthesize compounds 3-5˜3-7. And their derivatives such as compound 3-8˜3-10 (Example 16˜18) and 4-6˜4-13 (Example 24 31) are synthesized according to the similar procedure as the synthetic method of the compounds 3-5˜3-7. [0105]
    Figure US20030153596A1-20030814-C00020
  • As depicted in the above Scheme 4, the compound 4-1 obtained according to the procedure as described in Example 19 is reacted with oxalyl chloride to give acid chloride, and then the acid chloride is subjected to various reaction to yield compounds 4-2˜4-5. [0106]
    Figure US20030153596A1-20030814-C00021
  • As depicted in the above Scheme 5, amine compound 5-1 is mesylated and the obtained compound 5-2 is hydrogenated to afford amine compound 5-3, and then 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 5-4˜5-9. [0107]
    Figure US20030153596A1-20030814-C00022
  • As depicted in the above Scheme 6, the amine group of 4-nitrobenzylamine hydrochloride compound 6-1 is protected. Nitro group thereof is reduced to give amino group and then methylchlorothiol formate is reacted therewith to prepare compound 6-3, followed by reacting 4-t-butylbenzylisothiocyanate therewith to obtain compound 6-5. [0108]
    Figure US20030153596A1-20030814-C00023
  • As depicted in the above Scheme 7, guanidine group and cyano group are introduced into 4-iodoaniline 7-1 to prepare compound 7-3, and the compound 7-3 is reduced in the presence of palldium catalyst to give amine compound 7-4. The compound 7-4 is reacted with 4-t-butylbenzylisothiocyanate, followed by deprotection to synthesize compound 7-6. [0109]
    Figure US20030153596A1-20030814-C00024
  • As depicted in the above Scheme 8, 4-aminobenzylamine is selectively protected with t-butoxycarbonyl group (Boc) to prepare compound 8-1 and methanesulfonyl chloride is reacted with NH2 group thereof to yield compound 8-2. Boc group is removed therefrom in acidic condition, and then 2-(1-methyl-1H-pyrrol-2-yl)ethylisocyanate is reacted therewith to yield compound 8-4. [0110]
    Figure US20030153596A1-20030814-C00025
  • Compounds 9a˜9h are synthesized by reacting 4-t-butylbenzylisothiocyanate with corresponding benzylamine derivatives, respectively. [0111]
    Figure US20030153596A1-20030814-C00026
  • As depicted in the above Scheme 10, hydroxy group of 2-hydroxy-4-nitrobenzaldehyde is protected with TBDPS, and then oxime 10-1 is prepared therefrom. The compound 10-1 is reduced with hydrogen in the presence of palladium catalyst and protected with Boc group to afford compounds 10-2 and 10-3. The compond 10-2 is reacted with t-butylbenzylisothiocyanate, and then TBDPS is removed therefrom to synthesize compound 10-4. Two protecting groups of compound 10-3 are removed using trifluoroacetic acid and the deprotected compound is protected with Boc group in the presence of triethylamine to synthesize compound 10-5. TBDPS and Boc group are removed from the compound 10-5 and t-butylbenizylisothiocyanate is reacted therewith in the presence of triethylamine to give compound 10-6. [0112]
    Figure US20030153596A1-20030814-C00027
  • As depicted in the above Scheme 11, 2,6-difluoro-3-nitrobenzonitrile is reduced and then proteced with Boc group to prepare compound 11-1. The amino group of the compound 11-1 is mesylated, and after removing of the Boc group therefrom, the mesylated compound is reacted with 4-t-butylbenzylisothiocyanate to give compound 11-2. [0113]
    Figure US20030153596A1-20030814-C00028
  • As depicted in the above Scheme 12, the carbonyl group of nitrobenzaldehyde is converted into oxime group, and the oxime group and nitro group are reduced with hydrogen in the presence of Pd/C catalyst to prepare amine compound 12-1. The amine compound 12-1 is selectively protected and mesylated to afford compound 12-2. Boc group is removed from compound 12-2, and, in the presence of triethylamine, t-butylbenzylisothiocyanate compound is reacted therewith to synthesize compound 12-3a˜12-3 g. [0114]
    Figure US20030153596A1-20030814-C00029
  • As depicted in the above Scheme 13, 4-t-butyl-2-hydroxybenzonitrile 13-1 as a starting material is 0-alkylated and reduced to prepare amine compound 13-3. 4-Methanesulfonaminobenzylisothiocyanate is reacted therewith to yield thiourea compound 13-4a˜13-4k. And compound 13-1 is reacted with 0-triflate, and subsequently with carbon monoxide in the presence of palladium acetate catalyst to yield ester 13-6. The ester 13-6 is reduced, and then reacted with 4-methanesulfonaminobenzylisothiocyanate to prepare alcohol compound 13-8. The prepared compound 13-8 is sbjected to condensation reaction with acid to yield the corresponding tlliourea compound 13-9a and 13-9b. [0115]
    Figure US20030153596A1-20030814-C00030
  • As depicted in the above Scheme 14, respective compounds 14-1 and 14-4 are obtained from 4-(methylthio)benzylalcohol and 4-methylthiazol-5-ethanol, respectively, under Mitsunobu condition, or obtained by introducing mesyl group into 4-(methylthio)benzylalcohol and 4-methylthiazol-5-ethanol, respectively, followed by reacting potassium phthalimide therewith. Phthalimide group is removed from compounds 14-1 and 14-4 with hydrazine to give amine compounds 14-2 and 14-5, respectively. The obtained amine compounds 14-2 and 14-5 are separately reacted with one equivalent of 4-t-butylbenzylisothiocyanate to the objective thiourea compounds 14-3 and 14-6, respectively. 2-Chloro-5-chloromethylpyridine is reacted with potassium phtlialimide to yield compound 14-7, and then compound 14-9 is synthesized according to the same procedure as the synthetic method of the compounds 14-3 and 14-6. [0116]
    Figure US20030153596A1-20030814-C00031
  • Thiomorpholine is reacted with 2-(bromoethyl)phthalimide in the presence of base to yield compound 15-1. Phthaloyl group of the compound 15-1 is treated with hydrazine to prepare amine compound 15-2 and 4-t-butylbenzylisothiocyanate is reacted therewith to afford the objective compound 15-3. [0117]
    Figure US20030153596A1-20030814-C00032
  • As depicted in the above Scheme 16, compound A and isothiocyanate compound B of the above formula are reacted with each other in the presence of suitable solvent (dichloromethane, acetonitrile, ethylacetate, dimethylformamide) using suitable condition (triethylamine) to yield thiourea compound C (Example 76 122). [0118]
    Figure US20030153596A1-20030814-C00033
  • As depicted in the above Scheme 17, pyrrolecarboxaldehyde and 5-nitro-2-thiophenaldehyde are respectively converted to oximes, and the oximes are reduced to prepare primary amine hydrochloride. The prepared intermediates are reacted with isothiocyanates to give compounds 17-1˜17-4, respectively. [0119]
    Figure US20030153596A1-20030814-C00034
  • As depicted in the above Scheme 18, ethyl-2-methyl nicotinate 18-1 is reduced to prepare alcohol, and then amine is introduced thereinto. The prepared intennediate is reacted with 4-t-butylbenzylisothiocyanate to yield compound 18-5. [0120]
    Figure US20030153596A1-20030814-C00035
  • As depicted in the above Scheme 19, 5-nitro-1H-indazole is reduced to prepare amine, and then isothiocyanate is reacted therewith to afford compounds 19-1 and 19-2. [0121]
    Figure US20030153596A1-20030814-C00036
  • As depicted in the above Scheme 20, 2-fluoro-4-hydroxybenzonitrile is reduced with sodium borohydride in the presence of nickel catalyst, and proctected with Boc group to prepare protected amine compounds 20-1a and 20-1b. Phenol group of compound 20-1a is mesylated, and Boc group is removed therefrom, followed by reacting with t-butylbenzylisothiocyanate to give compound 20-2a. And compound 20-2b is obtained from compound 20-1b, according to the similar procedure as the synthetic method of compound 20-2a. [0122]
    Figure US20030153596A1-20030814-C00037
  • depicted in the above Scheme 21, 2-aminopicoline is reacted with pivaloyl chloride to yield compound 21-1. The compound 21-1 is brominated with NBS to prepare compound 21-2 and potassium phthalimide is reacted therewith to obtain compound 21-3 protected with phthaloyl group. Pivaloyl group is removed from compound 21-3 in the presence of concentrated sulfuiric acid, and methanesulfonylchloride is reacted therewith to prepare compound 21-5. The prepared compound 21-5 is treated with hydrazine and reacted with 4-t-butylbenzylisothiocyanate to yield compound 21-7. [0123]
    Figure US20030153596A1-20030814-C00038
  • Nitro group is selectivlely introduced into pyrrolecarboxaldehyde under nitric acid/acetic anhydride condition and the compound 22-1 was reduced with borane to prepare alcohol 22-2. The prepared compound 22-2 is reacted with 4-t-butylbenzylisothiocyanate in the presence of sodium hydride to yield compound 22-3. And pyrrolecarboxaldehyde is reacted with hydroxylamine hydrochloride in the presence of 1-methyl-2-pyrrolidinone (NMP) as a solvent to produce nitrile compound 22-4 and nitro goup is introduced thereinto under the similar condition as above. The nitro goup is reduced and mesylated to give compound 22-7. The nitrite group of the compound 22-7 is reduced in the presence of palladium/carbon and 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 22-9. [0124]
    Figure US20030153596A1-20030814-C00039
  • As depicted in the above Scheme 23, 4-nitrobenzylamine hydrochloride is converted to methanesulfonyl derivatives 23-1. Nitro group of the compound 23-1 is reduced with tin (II) chloride and 4-t-butylbenzylisothiocyanate is reacted therewith to give compound 23-2. [0125]
    Figure US20030153596A1-20030814-C00040
  • As depicted in the above Scheme 24, amine compound D is reacted with isothiocyanate compound B in suitiable solvent to yield thiourea compound E (Example 136˜141). [0126]
    Figure US20030153596A1-20030814-C00041
  • As depicted in the above Scheme 25, benzaldehyde, phenylacetaldehyde and cinnamaldehyde derivatives are subjected to reductive amination with alkylamine to prepare the corresponding sencondary amines, respectively, and phenethylisothiocyanates are reacted therewith to obtain compounds 25-1˜25-26 (Example 142˜167, respectively). [0127]
    Figure US20030153596A1-20030814-C00042
  • As depicted in the above Scheme 26, 2-fluoro-4-iodo methanesulfonylbenzylamine 3-2 is subjected to cross coupling using palladium to prepare compound 26-1 and the compound 26-1 is hydrogenated in the presence of palladium/carbon to give compound 26-2. The compound 26-2 is reacted with 4-t-butylbenzylamine to sythesize amide compound 26-3. [0128]
    Figure US20030153596A1-20030814-C00043
  • 4-t-butylbenzoylchloride is reacted with 3-fluoro-4-methanesulfonylaminobenzylamine hydrochloride (3-4) to yield amide compound 27. [0129]
    Figure US20030153596A1-20030814-C00044
  • As depicted in the above Scheme 28, 3-fluoro-4-methanesulfonylaminobenzyl amine hydrochloride 3-4 is reacted with 4-t-butylbenzyl bromide and carbon disulfide in the presence of cesium carbonate to yield compound 28. [0130]
    Figure US20030153596A1-20030814-C00045
  • As depicted in the above Scheme 29, 4-t-butylbenzylamine is reacted with triphosgene to prepare isocyanate, and 3-fluorophenethylamine is reacted therewith to afford compound 29. [0131]
    Figure US20030153596A1-20030814-C00046
  • As depicted in the above Scheme 30, 2-fluorobenzoyl chloride is reacted successively with KSCN and 4-t-butylbenzylamine to obtain final compound 30. [0132]
    Figure US20030153596A1-20030814-C00047
  • As depicted in the above Scheme 31, cyanoguanidine compounds are synthesized by two methods. As one method, 4-t-butylbenzylamine is reacted with dimethyl N-cyanodithioiminocarbonate or diphenyl cyanocarbonimidate, and then amine is reacted therewith to yield final compounds 31-1˜31-6 (Example 173˜178). And thiourea compound is reacted with lead cyanamide to give compounds 31-7˜31-[0133] 9 (Example 179˜181).
    Figure US20030153596A1-20030814-C00048
  • As depicted in the above Scheme 32, tetralone is converted to oxime and the oxime is reduced with nickel catalyst and sodium borohydride to prepare amine compounds 32-1, 32-3 and 32-5. These compounds are reacted with various benzylisothiocyanates to give compounds 32-2, 32-4 and 32-6˜32-10. And methoxy group of compounds 32-3 and 32-5 are treated with hydrobromic acid to form hydroxy group and the resulting compound are reacted with various benzylisothiocyanates in the presence of triethylamine to yield compounds 32-11 and 32-12. [0134]
    Figure US20030153596A1-20030814-C00049
  • As depicted in the above Scheme 33, 2-amino-3-formylchromone 33-1 or 3,5-dimethylpyrazole-1-methanol 33-3 is, repectively, reacted with 4-t-butylbenzylisothiocyanate in the presence of base to give compounds 33-2 or 33-4. [0135]
    Figure US20030153596A1-20030814-C00050
  • As depicted in the above Scheme 34, 4-t-butylbenzaldehyde is reacted with phosphonate to prepare compound 34-2, and the compound 34-2 is reduced and hydrolyzed to give 4-t-butylhydrocinnamic aicd 34-4. The obtained compound is reacted with compound 3-4 which is prepared according to the procedure as described in Example 13, to synthesize final compound 34-5. [0136]
    Figure US20030153596A1-20030814-C00051
  • As depicted in the above Scheme 35, N-t-butyloxycarbonyl-p-aminobenzylamine 8-1 is reacted with sulfamoyl chloride in basic condition to prepare compound 35-1. The prepared compound 35-1 is deprotected with trifluoroacetic acid to afford amine, and 4-t-butylbenzylisothiocyanate is subjected to condensation reaction therewith to yield thiourea compounds 35-2a, 35-2b and 35-2c. 3-Nitro-4-aminobenzonitrile is mesylated to give compound 35-4, and then nitrile group of the compound 35-4 is reduced with borane to afford amine. 4-t-Butylbenzylisothiocyanate is subjected to condensation reaction therewith to synthesize thiourea compound 35-5. [0137]
    Figure US20030153596A1-20030814-C00052
  • As depicted in the above Scheme 36, oxime 36-2, prepared from 4-aminoacetophenone as a starting material, is reduced to yield compound 36-3. Isothiocyanates are reacted therewith to give compounds 36-4 and 36-5. And compound 36-1 is reduced with methylamine to afford benzylamine derivatives, and 4-t-butylbenzylisothiocyanate is reacted therewith to synthesize compound 36-6. [0138]
  • The compound of formula (I) according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants, or diluents. For instance, the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them. For topical administration, the compounds of the present invention can be formulated in the form of ointment or cream. [0139]
  • The pharmaceutical composition containing the compound of the present invention as an active ingredient can be used for preventing or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as astluna or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases. [0140]
  • Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. [0141]
  • The compound according to the present invention may also be used in the forms of pharmaceutically acceptable salts thereof, for example, alkali metals salts such as sodium salts, potassium salts and the like; alkali earth metals salts such as calcium salts, magnesium salts and the like; amines such as triethanolamine or ammonium salts, and may be used either alone or in combination or in admixture with other pharmaceutically active compounds. [0142]
  • The compounds of the present invention may be formulated into injections by dissolving, suspending or emulsifying in water-soluble solvent such as saline and 5% dextrose, or in water-insoluble solvents such as vegetable oils, synthetic fatty acid glyceride, higher fatty acid esters and propylene glycol. The formulations of the invention may include any of conventional additives such as dissolving agents, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives. [0143]
  • The preferable dose level of the compounds according to the present invention depends upon a variety of factors including the condition and body weight of the patient, severity of the particular disease, dosage form, and route and period of administration, but may appropriately be chosen by those skilled in the art. The compounds of the present invention are preferably administered in an amount ranging from 0.001 to 100 mg/kg of body weight per day, and more preferably from 0.01 to 30 mg/kg of body weight per day. Doses may be administered once a day, or several times a day with each divided portions. The compounds of the present invention are used in a pharmaceutical composition in an amount of 0.0001˜10% by weight, and preferably 0.001˜1% by weight, based on the total amount of the composition. [0144]
  • The pharmaceutical composition of the present invention can be administered to a mammalian subject such as rat, mouse, domestic animals, human being and the like via various routes. The methods of administration which may easily be expected include oral and rectal administration; intravenous, intramuscular, subcutaneous, intrauterine, duramatral and intracerebroventricular injections. [0145]
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.[0146]
    • EXAMPLE 1
  • Synthesis of 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea (1-5) [0147]
    Figure US20030153596A1-20030814-C00053
  • Step 1: synthesis of (1H-indol-5-yl)methylamine [0148]
  • To an ice cold suspension of aluminium chloride (126mg) in ether (1.5 ml) was added a suspension of lithium aluminium hydride (55 mg) in ether (1.5 ml), followed by stirring for 5 min. A solution of 5-cyanoindole (103 mg) in ether (5 ml) was added dropwise thereto. The mixture was stirred at room temperature for 6 hours, followed by adding aqueous Rochel solution thereto and then stirring for 5 hours. The resulting mixture was basified with 1M aqueous sodium hydroxide solution, extracted twice with ethyl acetate (50 ml), washed with saturated aqueous sodium chlroride solution, dried over magnesium sulfate and then filtered to yield (1H-indol-5-yl)methylamine (93 mg, 88%). [0149]
  • [0150]
  • [0151] 1H NMR(300 MHz, CD3OD): δ 7.46(d, 1H, J=l.OHz), 7.29(d, 1H, J=8.3 Hz), 7.14(d, 1H, J=3.2 Hz), 7.02(dd, 1H, J=1.7, 8.3 Hz), 6.34(dd, 1H, J=0.7, 3.2 Hz), 3.89(s, 211)
  • Step 2: synthesis of 1-(1H-indol-5-yhmethyl)-3-phenethylthiourea (1-5) [0152]
  • (1H-indol-5-yl)methylamine (8.5 mg) prepared in Step 1 was dissolved in dimethylformamide (100 μl) and the solution was diluted with dichloromethane (1 ml). To the diluted solution was added phenethylisothiocyanate (40 μl) and the mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on a silica gel column eluting with ethyl acetate/hexane (2/3) to yield 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea (15 mg, 83%). [0153]
  • 1H NMR(300 MHz, CDCl[0154] 3): δ 8.17(s, 1H), 7.53(s, 1H), 7.28(d, 1H, J=8.3 Hz), 7.11-7.19(m, 5H), 6.98-7.04(m, 2H), 6.46(t, 1H, J=2.2 Hz), 6.03(s, 11), 5.59(s, 1H), 4.44(s, 2H), 3.66(m, 2H), 2.77(t, 2H, J=6.8 Hz)
    • EXAMPLE 2
  • Synthesis of 1-(1H-indol-5-ylmethyl)-3-phenethylurea (1-6) [0155]
    Figure US20030153596A1-20030814-C00054
  • (1H-indol-5-yl)methylamine (12.5 mg) was reacted with phenethylisocyanate (30 g) according to the similar procedure as described in step 2 of Example 1, to give 1-(1H-indol-5-ylmethyl)-3-phenethylurea (1-6) (19 mg, 76%). 1H NMR(300 MHz, CDCl[0156] 3): δ 8.16(s, 111), 7.44(s, 1H), 7.27(d, 1H, J=8.3 Hz), 7.02-7.21(m, 7H), 6.43-6.45(m, 1H), 4.48(t, 1H), 4.31(d, 2H, J=5.6 Hz), 4.22(m, 1H), 3.37(q, 2H, J=6.8 Hz), 2.71(t, 2H, J=6.8 Hz)
    • EXAMPLE 3
  • Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7) [0157]
    Figure US20030153596A1-20030814-C00055
  • Step 1: synthesis of 4-t-butylbenzylisotbiocyanate [0158]
  • Di-2-pyridyl thionocarbonate (45 mg) was dissolved in methylenechloride (2 ml) and to the solution were added 4-t-butylbenzylamine (29 mg) and triethylamine (20 μl), followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and the obtained residue was chromatographed on a silica gel column eluting with ethyl acetate/hexane (1/10) to yield 4-t-butylbenzylisothiocyanate (26 mg, 71%). [0159]
  • [0160] 1H NMR(30OMHz, CDCl3): δ 7.39(d, 2H, J=8.5 Hz), 7.23(d, 2H, J=8.3 Hz), 4.65(s, 2H), 1.30(s, 9H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7) [0161]
  • (1H-indol-5-yl)methylamine (15 mg) was reacted with 4-t-butylbenzylisothiocyanate (20 mg) according to the similar procedure as described in Step 2 of Example 1, to synthesize 1-(4-t-buylbenzyl)-3-(1H-indol-5-ylmethyl)thiourea (1-7) (21 mg, 70%). [0162]
  • [0163] 1H NMR(300 MHz, CDCl3): δ 8.33(s, 1H), 7.48(s, 1H), 7.19-7.33(m, 4H), 7.03-7.10(m, 4H), 6.47(t, 1H), 6.18(s, 1H), 6.06(s, 1R), 4.58(d, 2H, J=13 Hz), 1.26(s, 9H)
    • EXAMPLE 4
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylbenzyl)thiourea (1-8) [0164]
    Figure US20030153596A1-20030814-C00056
  • Lithium aluminum hydride (0.38 g) was dissolved in anhydrous ether (20 ml). The solution was cooled to 0° C. and 4-(methylsulfonyl)benzonitrile (1.81 g) was slowly added dropwise thereto. The mixture was stirred for 3 hours while allowed to slowly warm up to room temperature and the reaction was quenched with 20% aqueous sodium hydroxide solution and water. The water layer was washed with ether, and then the ether layer was mixed with the organic layer. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column-chromatography (acetone) to yield a liquid (0.3 g). [0165]
  • The obtained liquid was dissolved in dichloromethane (10 ml) and 4-t-butylbenzylisothiocyanate (0.33 g) was added thereto, followed by stirring at room temperature for 19 hours. The reaction mixture was concentrated and then purified by column-chromatography (hexane/ethyl acetate =1/1) to yield compound 1-8 (0.02 g) as a white solid. [0166]
  • [0167] 1H NMR(300 MHz, CDCl3): δ 7.85-7.81(m, 2H), 7.41-7.30(m, 4H), 7.27-7.23(m, 2H), 6.25(brs, 1H), 6.05(brs, 1H), 4.88(d, 2H, S=6 Hz), 4.60-4.55(m, 211), 3.01(s, 3H), 1.31(s, 9H)
    • EXAMPLE 5
  • Synthesis of 1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrro1-2-yl)ethyl]thiourea (1-9) [0168]
    Figure US20030153596A1-20030814-C00057
  • Step 1: Synthesis of (1-methyl-1H-pyrro1-2-yl)ethylamine [0169]
  • 1-methyl-2-pyrroleacetonitrile (2 g) was slowly added dropwise to a suspension of lithium aluminium hydride (695 mg) in ether (100 ml) while the temperature was adjusted to −78° C. The miture was stirred for 1 hour, and then stirred for 3 hours at room temperature. After confirming the completion of the reaction using TLC, 15% aqueous sodium hydroxide solution (10 ml) and water (20 ml) were added dropwise and the resulting mixture was stirred for 1 hour. The reaction mixture was extracted three times with ether. The organic layer was washed with saturated aqueous sodium chloride solution and concentrated under reduced pressure to yield amine compound. The amine compound, which was not purified, was used in the following reaction. [0170]
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrro1-2-yl)ethyl]thiourea (1-9) [0171]
  • Amine (250 mg) prepared in Step 1 and 4-t-butylbenzylisothiocyanate (420 mg) were dissolved in ethyl acetate (20 ml) and the solution was stirred at room temperature for 12 hours. The resulting mixture was concentrated under reduced pressure to remove the solvent and the residue was purified by column-chromatography (ethyl acetate/hexane=[0172] {fraction (1/3)}) to yield compound 1-9 (498 mg, 75%) as a liquid.
  • [0173] 1H NMR (300 MHz, CDCl3) δ0 7.37(d, 2H), 7.19(d, 2H), 6.54(m, 1H), 6.01(m, 1H), 5.83(s, 1H), 4.46(brs, 2H), 3.72(brs, 2H), 2.841(t, 2H, J=6.9 Hz), 1.31(s, 9H)
    • EXAMPLE 6
  • Synthesis of 1-(4-amino-3,5-dichlorobenzyl)-3-(4-t-butylbenzyl)thiourea (1-10) [0174]
    Figure US20030153596A1-20030814-C00058
  • 4-amino-3,5-dichlorobenzomitrile (260 mg) was dissolved in methanol (20 ml) and a small amount of concentrated hydrochloric acid and 5% palladium/carbon catalyst was added thereto. After the mixture was stirred for 15 hours, the reaction mixture was filtered through celite and concentrated. The obtained mixture was dissolved in dichloromethane (10 ml), and 4-t-butylbenzylisothiocyanate (200 mg) and triethylamine (2 ml) was added thereto, followed by stirring at room temperature for 15 hours. The resulting mixture was extracted with water and dichloromethane, and the residue was purified by column-chromatography (hexane/ethyl acetate=1/1) to yield compound 1-10 (72 mg, 13%, as a liquid. 1H NMR (300 MHz, CDCl[0175] 3) δ 7.40-7.00(m, 6H), 5.92(brs, 2H), 4.58(m, 2H), 4.45(m, 2H), 3.71(brs, 2H), 1.31(s, 9H)
    • EXAMPLE 7
  • Synthesis of 1-(4-t-butylbenzyl)-3-(pyrazin-2-y1-methyl)thiourea (1-11) [0176]
    Figure US20030153596A1-20030814-C00059
  • Pyrazinecarbonitrile (500 mg) and 10% palladiui/carbon (450 mg) were dissolved in anhydrous methanol (30 ml) and the mixture was stirred under hydrogen atmosphere for 12 hours. [0177]
  • The resulting mixture was filtered, and then the filtrate was concentrated under reduced pressure. The obained compound (200 mg) and 4-t-butylbenzylisothiocyanate (330 mg) were dissolved in ethyl acetate (30 ml). The solution was stirred for 12 hours and then concentrated. The resulting residue was purified by colunmn-chromatography (ethyl acetate/hexne=3/1) to yield the compound 1-11 (271 mg, 53%). [0178]
  • 1H NMR (300 MHz, CDCl[0179] 3) δ 8.51(s, 1H), 8.41(s, 1H), 8.16(s, 1H), 7.38(m, 2H), 7.29(m, 2H), 5.10(s, 21), 4.86(d, 2H, J=2.25 Hz), 1.33(s, 9H)
    • EXAMPLE 8
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-cyanopyrazin-2-ylmethyl)thiourea (1-12) [0180]
    Figure US20030153596A1-20030814-C00060
  • 2,3-pyrazinedicarbonitrile (200 mg) and 10% palladium/carbon (200 mg) were dissolved in anhydrous methanol (30 ml) and the rirxture was stirred under hydrogen atmosphere for 12 hours. The resulting mixture was filtered, and then the filtrate was dried under reduced pressure to give an amine. The obtained amine (150 mg) and 4-t-butylbenzylisothiocyanate (180 mg) were dissolved in ethyl acetate (30 ml). The solution was stirred for 12 hours to complete the reaction and purified by colum-chromatography (ethyl acetate/hexane=3/1) to yield the compond 1-12 (77 mg, 25%) as a white solid. [0181]
  • [0182] 1H NMR (300 MHz, CDCl3) δ0 8.76(m, 1H), 8.67(m, 1H), 7.38(m, 41), 5.38(s, 2H), 4.98(d, 2H, J=2.7 Hz), 1.32(s, 9H)
    • EXAMPLE 9
  • Synthesis of 1-(4-amino-2,5-difluorobenzyl)-3-(4-t-butylbenzyl)thiourea (1-13) [0183]
    Figure US20030153596A1-20030814-C00061
  • Step 1: Synthesis of 4-amino-2,5-difluorobenzylamine [0184]
  • 4-amnino-2,5-difluorobenzonitrile (400 mg) and Raney nickel Catalyst were added to methanol (20 ml) and the mixture was stirred under hydrogen atmosphere at room temperature for 18 hours. After confirmiing the completion of the reaction, the resulting mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The following procedure was carried out, using the concentrate which was not purified. [0185]
  • Step 2: Sythesis of 1-(4-amino-2,5-difluorobenzyl)-3-(4-t-butylbenzyl)thiourea (1-13) [0186]
  • The compound (330 mg) obtained in Step 1 and 4-t-butylbenzylisothiocyanate (428 mg) were dissolved in ethyl acetate (40 ml) and the solution was stirred at room temperature for 6 hours. The mixture was concentrated under reduced pressure and the residue was purified by column-chromatography (ethyl acetate/hexane=1/3) to yield the compound 1-13 (190 mg, 25%). [0187]
  • [0188] 1H NMR(300 MHz, CDCl3): δ 7.37(m, 2H), 7.22(m, 2H), 6.95(m, 1H), 6.43(m, 1H), 6.08(brs, 1H), 5.90(brs, 1H), 4.59(s, 2H), 4.57(s, 2H), 3.83(s, 2H), 1.31(s, 9H)
    • EXAMPLE 10
  • Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)thiourea (2-5) [0189]
    Figure US20030153596A1-20030814-C00062
  • Step 1: Synthesis of 4-iodo-1-sulfamoylbenzene (2-2) [0190]
  • Pipsylchloride (100 mg) was dissolved in 28% ammonia solution (4 ml) and the solution was stirred at room temperature for 1 hours. The resulting mixture was extracted with ethyl acetate (20 ml), washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was chromatographed on column eluting with ethyl acetate/hexane (1/2) to yield the compound 2-2 (89 mg, 100%/0). [0191]
  • [0192] 1H NMR(300 MHz, CD3OD): δ 7.91(td, 1H, J=9.OHz), 7.63(td, 1H, J=9.OHz)
  • Step 2: Synthesis of 4-cyano-1-sulfamoylbenzene (2-3) [0193]
  • The compound 2-2 (58 mg) prepared in Step 1 was dissolved in dimethylformamide (2 ml) and to the solution were added zinc cyanide [Zn(CN)[0194] 2] (58 mg) and tetrakistriphenylphosphine palladium (10 mg), followed by stirring at 80° C. for 12 hours. The resulting mixture was basified with aqueous sodium bicarbonate solution, diluted with ethyl acetate (30 ml), washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was chromatographed on silica gel column eluting with ethyl acetate/hexane (1/2) to yield the compound 2-3 (30 mg, 80%).
  • [0195] 1H NMR(300 MHz, CDCl3): δ 7.92-7.96 (m, 211), 7.69-7.73 (m, 2H), 6.47 (s, 2H)
  • Step 3: Sythesis of 4-sulfamoylaminobenzene (2-4) [0196]
  • The compound 2-3 (52 mg) prepared in Step 2 was dissolved in methanol (2 ml) and to the solution were added a catalytic amount of 10% palladium/carbon and concentrated hydrochloric acid (10 μl), followed by stirring under hydrogen gas atmosphere at room temperature for 1 hour. The resulting mixture was diluted in ether, filtered through celite, neutralized with 1N aqueous sodium hyroxide solution, and then washed with water and saturate aqueous sodium chloride solution. The obtained residue was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to yield the compound 2-4 (26 mg, 50%). [0197]
  • [0198] 1H-NMR(300 MHz, CD3OD): δ 7.77 (dd, 2H, J=1.7, 6.6 Hz), 7.41 (d, 2H, J=8.5 Hz), 3.80 (s, 2H)
  • Step 4: Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)thiourea (2-5) [0199]
  • The compound 2-4 (10 mg) prepared in Step 3 was dissolved in dimethylformamide (100 le). The solution was diluted with dichloromethane (2 ml) and to the solution was added phenethylisothiocyanate (1.0 ml), followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and the obtained residue was chromatographed on a column eluting with ethyl acetate/hexane (1/1) to yield the compound 2-5 (11 mg, 59%). [0200]
  • [0201] 1H NMR(300 MHz, CD3OD): δ 7.82-7.85 (m, 2H), 7.42 (d, 2H, J=8.5 Hz), 7.16-7.30 (m, 5H), 4.78 (br s, 2H), 3.72 (br s, 2H), 2.88 (t, 2H, J=7.1 Hz)
    • EXAMPLE 11
  • Synthesis of 1-phenethyl-3-(4-sulfamoylbenzyl)urea (2-6) [0202]
    Figure US20030153596A1-20030814-C00063
  • Compound 2-6 (13 mg, 79%) was synthesized according to the same procedure as described in Step 4 of Example 10 except that compound 2-4 (9 mg) was reacted with phenethylisocyanate (100 ut). [0203]
  • [0204] 1H NMR(300 MHz, CD3OD): δ 7.82-7.84 (m, 2H), 7.39 (d, 2H, J=8.3 Hz), 7.15-7.32 (m, 51), 4.35 (s, 2H)
    • EXAMPLE 12
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-sulfamoylbenzyl)thiourea (2-7) [0205]
    Figure US20030153596A1-20030814-C00064
  • Compound 2-7 (7 mg, 96%) was synthesized according to the same procedure as described in Step 4 of Example 10 except that compound 2-4 (7 mg) and 4-t-butylbenzylisothiocyanate (10 mg) were used as reactants. [0206]
  • [0207] 1H NMR(300 MHz, acetone-d6): δ 7.81 (d, 2H, J=8.3 Hz), 7.48 (d, 2H, J=8.3 Hz), 7.36 (dd, 2H, J=1.7, 6.3 Hz), 7.26 (d, 2H, J=8.3 Hz), 4.91 (br s, 2H), 4.75 (br s, 2H), 1.29 (s, 9H)
    • EXAMPLE 13
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea (3-5) [0208]
    Figure US20030153596A1-20030814-C00065
  • Step 1: Synthesis of 2-fluoro-4-iodo-1-methanesulfonylaminobenzene (3-2) [0209]
  • 2-fluoro-4-iodophenylamine (1.50 g) was dissolved in dichloromethane (40 ml) and to the solution were added pyridine (1.02 ml) and methanesulfonylchloride (700 μl). The mixture was stirred at room temperature for 1 hour and 1.5 N aqueous hydrochloric acid was added thereto to quench the reaction. The resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was column-chromatographed (ethyl acetate/hexane=1/1) to yield the compound 3-2 (1.89 g, 95%). [0210]
  • [0211] 1H NMR(300 MHz, CDCl3): δ 7.47(dd, 2H, J=1.2, 1.7 Hz) 7.30(t, 1H, J=8.3 Hz) 6.51(s, 1H) 3.01(s, 3H)
  • Step 2: Synthesis of 4-cyano-2-fluoromethanesulfonylaniinobenzene (3-3) [0212]
  • The compound 3-2 (1.81 g) prepared in Step 1 was dissolved in dimethylformamide (10 ml) and to the solution were added zinc (11) cyanide (845 mg) and tetrakistriphenylphosphine palladium (187 mg), followed by stirring at 80-90° C. for 1.5 hours. The resulting mixture was diluted with ethyl acetate (20 ml), washed with water and saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. The remaining liquid was concentrated under reduced pressure and the obtained residue was chromatographed on column eluting with ethyl acetate/hexane ({fraction (1/2)}) to yield the compoind 3-3 (1.03 g, 80%). 1H NMR(300 MHz, CDCl[0213] 3): δ 7.65(t, 1H, J-8.OHz) 7.41(d, 1H, J=9.8 Hz) 7.37(dd, 1H, J=9.5, 1.7 Hz) 6.83(s, 1H) 3.07(s, 3H)
  • Step 3: Sythesis of 3-fluoro-4-methanesulfonaminobenzylamine hydrochloride (3-4) [0214]
  • The compound 3-3 (1.03 g) prepared in Step 2 was dissolved in methanol (20 ml) and to the solution were added a catalytic amount of 10% palladium/carbon and concentrated hydrochloric acid (3 ml), followed by stirring at room temperature under hydrogen gas atmosphere for 1 hour. The resulting mixture was diluted in ether, filtered through celite, concentrated under reduced pressure, and then washed with ethyl acetate to yield the compound 3-4 (1.13 g, 92%). [0215]
  • [0216] 1H NMR (300 MHz, CD3OD): δ 7.57(t, 1H, J=8.3 Hz) 7.33(dd, 1H, J=9.8, 1.8 Hz) 7.27(d, 1H,J=8.5 Hz) 4.11(s, 2H) 3.02(s, 3H)
  • Step 4: Synthesis of 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)tbiourea (3-5) [0217]
  • Compound 3-4 (1.13 g) prepared in Step 3 was dissolved in dimethylformamide (6 ml) and the solution were diluted in dichloromethane (35 ml). To the diluted solution was added 4-t-butylbenzylisothiocyanate (1.09 g) and triethylamine (1.2 ml) in order, and then the mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure, diluted with ethyl acetate (20 ml), and then washed with water and saturatated aqueous sodium chloride solution. The residue was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by chromatography on column eluting with ethyl acetate/hexane ([0218] {fraction (2/3)}) to yield the compound 3-5 (1.23 g, 65%).
  • [0219] 1H NMR(300 MHz, CDCl3): δ 7.41(t, 1H, J=8.2 Hz) 7.34(d, 2H, J=8.OHz) 7.20(d, 2H, J=8.OHz) 7.01(d, 1H, J-11.9 Hz) 6.97(d, 1H, J=9.8 Hz) 6.69(brs, 1H) 4.68(s, 2H) 4.54(s, 2H) 2.97(s, 3H) 1.28(s, 9H)
    • EXAMPLE 14
  • Synthesis of 1-phenethyl-3-(3-fluoro-4-methanesulfonaminobenzyl)urea (3-6) [0220]
    Figure US20030153596A1-20030814-C00066
  • Compound 3-6 (17 mg, 36%) was synthesized according to the same procedure as desribed in Step 4 of Example 13 .except that compound 3-4 (28 mg) was reacted with phenethylisocyanate (38 gt). [0221]
  • [0222] 1H NMR(300 MHz, CD3OD): 8 7.40(t, 1H, J=8.2 Hz) 7.28-7.06(m, 7H) 4.69(s, 2H, CH2) 3.87 (t, 2H) 2.98(s, 3H) 2.87(t, 2H, J=7.1 Hz)
    • EXAMPLE 15
  • Synthesis of 1-phenethyl-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea (3-7) [0223]
    Figure US20030153596A1-20030814-C00067
  • Compound 3-7 (8.3 mg, 24%) was synthesized according to the same procedure as desribed in Step 4 of Example 13 except that compound 3-4 (20 mg) and phenethylisothiocyanate (27 μl) were used as reactants. [0224]
  • [0225] 1H NMR(300 MHz, CD3OD): δ 7.40(t, 1H, J=8.2 Hz) 7.29-7.14(m, 5H) 7.10-7.03(m, 2H) 4.26(s, 2H) 3.36 (t, 2H) 2.95(s, 3H) 2.76(t, 2H, J=7.1 Hz)
  • Compounds 3-8, 3-9 and 3-10 were synthesized according to the similar procedure as described in the Example 13, and NMR data thereof are shown below. [0226]
    Figure US20030153596A1-20030814-C00068
    Compounds
    Examples No. Ra Rb Spectra data
    16 3-8 NHSO2Me CH3 1H NMR(300MHz, CD3OD): δ 7.32(d, 2H),
    J=8.0Hz) 7.30(d, 1H, J=8.3Hz) 7.17(d, 2H,
    J=8.3Hz) 7.10(s, 1H) 7.04(d, 1H, J=8.0Hz)
    6.37(brs, 1H) 4.59(s, 2H) 4.55(s, 2H) 2.97(s,
    3H) 2.25(s, 3H) 1.28(s, 9H)
    17 3-9 NHSO2Me Cl 1H NMR(300MHz, CDCl3): δ 7.50(d, 1H,
    J=8.3Hz) 7.37(d, 2H, J=8.3Hz) 7.35(d, 1H,
    J=2.0Hz) 7.23(d, 2H, J=8.3Hz) 7.13(d, 1H,
    J=7.1Hz) 6.92(brs, 1H) 4.69(s, 2H) 4.58(s,
    2H) 2.978(s, 3H) 1.30(s, 9H)
    18 3-10 NHSO2Me CO2Me 1H NMR(400MHz, CDCl3): δ 10.38(brs,
    1H) 7.99(s, 1H) 7.57(d, 1H, J=8.5Hz) 7.41(d,
    1H, J=8.4Hz) 7.36(d, 2H, J=8.0Hz) 7.23(d,
    2H, J=8.0Hz) 4.71(s, 2H) 4.62(s, 2H) 3.93(s,
    3H) 2.84(s, 3H) 1.31(s, 9H)
    Figure US20030153596A1-20030814-C00069
    Figure US20030153596A1-20030814-C00070
    Figure US20030153596A1-20030814-C00071
    • EXAMPLE 19
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-carboxy1-4-methanesulfonylaminobenzyl)thiourea (4-1) [0227]
    Figure US20030153596A1-20030814-C00072
  • Compond 3-10 (1.08 g) prepared according to the procedure as described in Example 13 was dissolved in acetone (20 ml) and to the solution was added 2.5 M aqueous lithium hydroxide solution (15 ml). The mixture was stirred at room temperature for 5 hours and the solvent was removed therefrom. The residue was dissolved in ethyl acetate and then extracted to yield the compound 4-1 (980 mg, 94%/). [0228]
  • [0229] 1H NMR(300 MHz, CD3OD): δ 8.07(d, 1H, J=2.2 Hz) 7.63(d, 1H, J=8.5 Hz) 7.51(d, 1H) 7.34(d, 2H, J=8.5 Hz) 7.20(d, 2H, J=8.OHz) 4.73(s, 2H) 4.66(s, 2H) 3.03(s, 3H) 1.29(s, 9H)
    • EXAMPLE 20
  • Synthesis of 1-(4-t-butylbenzyl)-3-((3-N-methoxyaminocarbony1-4-methanesulfonylamino)benz yl)thiourea (4-2) [0230]
    Figure US20030153596A1-20030814-C00073
  • Compound 4-1 (50 mg) prepared according to the procedure as described in Example 19 was dissolved in benzene (2 ml) and to the solution was added dropwise oxalyl chloride (100 μl), followed by refluxing for 2 hours. The resulting nixture was concentrated under reduced pressure, and to the concentrate was added methoxylamine (92 mg). The mixture was dissolved in pyridine (2 ml), and the solution was stirred at room temperature for 24 hours and then concentrated under reduced pressure. To the concentrate was added ethyl ether, and the mixture was filtered and concentrated under reduced pressure. The obtained residue was chromatogrphed on column eluting ethyl acetate to yield the compound 4-2 (16 mg, 30%). [0231]
  • [0232] 1H NMR(300Mlz, CDCl3): δ 10.14(s, 111) 9.38(s, 11) 7.55(m, 3H) 7.32(m, 4H) 5.04(s, 2H) 5.01(s, 21) 3.82(s, 3H) 3.00(s, 3H) 1.25(s, 91)
  • Compound 4-3 was synthesized according to the similar procedure as described in the Example 20, and NMR data thereof are shown below. [0233]
    Figure US20030153596A1-20030814-C00074
    Example Compound No. R′ R″ Spectral data
    21 4-3 NHSO2Me CONHOH 1H NMR(300MHz, CD3OD): δ 8.09(d,
    1H, J=2.0Hz) 7.51(d, 1H, J=8.3Hz)
    7.44(dd, 1H, J=2.2, 8.6Hz) 7.31(m, 4H)
    5.05(s, 4H) 2.92(s, 3H) 1.27(s, 9H)
  • [0234]
    Figure US20030153596A1-20030814-C00075
    • EXAMPLE 22
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-hydrazido-4-methanesulfonylaminobenzyl)thiourea (4-4) [0235]
    Figure US20030153596A1-20030814-C00076
  • Compound 4-1 (76 mg) prepared according to the procedure as described in Example 19 was dissolved in benzene (3 ml) and to the solution was added dropwise oxalyl chloride (200 μl), followed by refluxing for 3 hours. The resulting mixture was concentrated under reduced pressure and to the concentrate was added hydrazine (55 mg). The mixture was dissolved in tetrahydrofuran (3 ml), and the solution was stirred at 0° C. for 2 hours and then concentrated under reduced pressure. The obtained residue was chromatogrphed on silica gel column (ethyl acetate/hexane=1/1) to yield the compound 4-4 (5 mg, 6%). [0236]
  • [0237] 1H NMR(300 MHz, DMSO-d6): δ 10.9(s, 1H), 10.2(s, 1H), 7.75(s, 1H), 7.64(d, 1H), 7.55(d, 1H), 7.41(s, 4H), 5.04(s, 2H), 5.00(s, 2H), 3.14(s, 3H), 1.20(s, 9H)
    • EXAMPLE 23
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-cyano-4-methanesulfonylaminobenzyl)thiourea (4-5) [0238]
    Figure US20030153596A1-20030814-C00077
  • Compound 4-1 (50 mg) prepared according to the procedure as described in Example 19 was dissolved in benzene (3 ml) and to the solution was added dropwise oxalyl chloride (100 ul), followed by refluxing for 3 hours. The resulting mixture was concentrated under reduced pressure and to the concentrate was added sulfamide (106 mg). The mixture was dissolved in sulfolane (2 ml) and the solution was refluxed at 120° C. for 3 hours. To the reaction mixture was added 1 N-aqueous sodium hydroxide solution to quench the reaction. The resulting mixture was extracted with ether, washed several times with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was column-chromatogrphed (ethyl acetate/hexane=1/1) to yield the compound 4-5 (8 mg, 16%). [0239]
  • [0240] 1H NMR(300 MHz, CDCl3): δ 10.8(s, 1H), 7.65(m, 2H), 7.58(m, 1H), 7.33(d, 4H), 5.05(s, 4H), 3.01(s, 3H), 1.24(s, 9H)
  • Compounds 4-6- 4-13 were synthesized according to the similar procedure as described in the Example 13, and NMR data thereof are shown below. [0241]
    Figure US20030153596A1-20030814-C00078
    Example Compound No. Rc Rd Spectral data
    24 4-6 NHCO2Me F 1H NMR(300MHz, CDCl3): δ 7.97(t,
    1H), 7.35(d, 2H), 7.68(d, 2H), 6.95(d,
    2H), 6.82(s, 1H), 4.62(s, 2H), 4.46(s, 2H),
    3.76(s, 3H), 1.26(s, 9H)
    25 4-7 NHCOCH2OMe F 1H NMR(300MHz, CDCl3): δ 8.49(s,
    1H), 8.07(t, 1H, J=8.0Hz), 7.36(d, 2H,
    J=8.0Hz) 7.23(d, 2H, J=8.0Hz), 7.03(d,
    1H, J=11.2Hz), 6.93(d, 1H, J=8.3Hz)
    6.66(brs, 1H) 4.67(s, 2H), 4.62(s, 2H),
    3.49(s, 3H), 1.32(s, 9H)
    26 4-8 NHCO2Et F 1H NMR(300MHz, CDCl3): δ 7.95(s,
    1H) 7.33(d, 2H, J=8.0Hz) 7.17(d, 2H,
    J=8.0Hz) 6.94(d, 2H) 6.77(s, 1H), 4.60(s,
    2H) 4.55(s, 2H), 4.19(q, 2H, J=7.2Hz),
    1.27(m, 12H)
    27 4-9 NHCH2CO2Et F 1H NMR(300MHz, CDCl3): δ 7.31(d,
    2H, J=8.5Hz), 7.15(d, 2H, J=8.3Hz),
    6.86(s, 1H), 6.83(s, 1H), 6.46(t, 1H),
    J=8.4Hz), 6.10(d, 1H), 4.53(s, 2H),
    4.48(s, 2H), 4.20(q, 2H, J=7.1Hz),
    3.75(s, 2H), 1.27(m, 12H)
    28 4-10 NHCH2CO2Me F 1H NMR(300MHz, CDCl3): δ 7.39(d,
    2H, J=8.3Hz), 7.23(d, 2H, J=8.3Hz),
    6.93(s, 1H), 6.90(s, 1H), 6.52(t, 1H),
    J=8.4Hz), 6.36(s, 1H), 4.60(s, 2H),
    4.53(s, 2H), 3.83(s, 2H), 3.74(s, 3H),
    1.34(s, 9H)
    29 4-11 NHCH2CO2H F 1H NMR(300MHz, CD3OD): δ 7.32(d,
    2H, J=8.5Hz), 7.18(d, 2H, J=8.3Hz),
    6.90(m, 2H), 6.56(t, 1H, J=8.6Hz),
    4.65(s, 2H), 4.55(s, 2H), 3.70(s, 2H),
    1.28(s, 9H)
    30 4-12 H CO2Me 1H NMR(300MHz, CDCl3): δ
    7.95-7.98(d, 2H, J=7.3Hz), 7.30-7.51(m,
    4H), 7.20-7.25(d, 2H, J=8.3Hz),
    4.75-4.79(d, 2H, J=5.4Hz), 4.61-4.64(d,
    2H, J=4.4Hz), 3.92(s, 3H), 1.33(s, 9H)
    31 4-13 H CO2H 1H NMR(300MHz, CD3OD): δ
    7.97-7.98(s, 1H), 7.88-7.91(d, 1H,
    J=7.6Hz), 7.32-7.53(m, 4H,), 7.18-7.22(d,
    2H, J=8.0Hz), 4.79(s, 2H), 4.67(s, 2H),
    1.28(s, 9H)
    Figure US20030153596A1-20030814-C00079
    Figure US20030153596A1-20030814-C00080
    Figure US20030153596A1-20030814-C00081
    Figure US20030153596A1-20030814-C00082
    Figure US20030153596A1-20030814-C00083
    Figure US20030153596A1-20030814-C00084
    Figure US20030153596A1-20030814-C00085
    Figure US20030153596A1-20030814-C00086
    • EXAMPLE 32
  • Synthesis of 1-(4-t-butylbenl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylithiourea (5-4) [0242]
    Figure US20030153596A1-20030814-C00087
  • Step 1: Synthesis of 4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene [0243]
  • 4-amino-2,3,4,5-tetrafluoronitrile (105 mg) was dissolved in tetrahydrofuran (4 ml) and the solution was cooled to 0° C. To the solution was added dropwise 1.6 M n-butyl lithium and the mixtrure was stirred for 10 minutes, followed by adding dropwise methanesulfonyl chloride (100 μl). After 1 hour, the reaction was quenched with 1.5 N aqueous hydrochloric acid. The resulting mixture was extracted with ethyl acetate, and then concentrated under reduced pressure. The obtained residue was chromatographed on column eluting with ethyl acetate/hexane (1/1) to yield 4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene (20 mg, 10%). [0244] 1H NMR(300 MHz, CDCl3): δ 6.84(brs, 1H) 3.08(s, 3H)
  • Step 2: Synthesis of 2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride [0245]
  • 4-cyano-2,3,5,6-tetrafluoro-1-methanesulfonylaminobenzene (11 mg) prepared in Step 1 was dissolved in methanol (5 ml) and to the solution were added a catalytic amount of 10% palladium/carbon and concentrated hydrochloric acid (300 μl), followed by stirring at room temperature under hydrogen gas atmosphere for 1 hour. The resulting mixture was diluted in ether, filtered through celite, concentrated under reduced pressure, and then washed with ethyl acetate to yield 2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride (7.0 mg, 59%). [0246]
  • [0247] 1H NMR(300 MHz, CD3OD): δ 4.32(s, 2H) 3.18(s, 3H)
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiourea (5-4) [0248]
  • 2,3,5,6-tetrafluoro-4-methanesulfonylaminobenzylamine hydrochloride (20 mg) prepared in Step 2 was dissolved in dimethylformamide (800 μl), and the solution was diluted with dichloromethane (6 ml). To the diluted solution were added t-butylbenzylisothiocyanate (20 mg) and triethylamine (200 μl), and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, diluted with ethyl acetate (20 ml), and then washed with water and saturated aqueous sodium chloride solution. The resulting mixture was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, and the obtained residue was chromatographed on column eluting ethyl acetate/hexane ([0249] {fraction (2/3)}) to yield the compound 5-4 (28 mg, 91%).
  • [0250] 1H NMR(300 MHz, CD3OD): δ 7.34(dd, 2H, J-1.8, 6.5 Hz) 7.20(d, 2H, J=8.3 Hz) 4.87(s, 2H) 4.63(s, 2H) 3.13(s, 3H) 1.29(s, 9H)
    • EXAMPLE 33
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonylaminobenzyl)tlhiourea (5-5) [0251]
    Figure US20030153596A1-20030814-C00088
  • Step 1: Synthesis of 2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene [0252]
  • To an ice-cold solution of 4-amino-2,5-difluorobenzonitrile (1.0 g) in anhydrous tetrahydrofuran (50 ml) was slowly added n-butyl lithium (2.6 ml) through an injector with stirring, followed by stirring 30 minutes. To the mixture was slowly added methanesulfonyl chloride (550 μl), followed by stirring at room temperature for 24 hours. After confirming the completion of the reaction using TLC, the resulting mixture was concentrated under reduced pressure, diluted with 1 N aqueous hydrochloric acid (100 ml), extracted with dichloromethane (50 ml x3). The combined organic layer was dried over magnesium sulfate, filtered, and then concectrated under reduced pressure. The obtained residue was purified by column-chromatography (ethyl acetate/hexane 2/3) to yield 2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene (1.2 g, 79.6%). [0253]
  • [0254] 1H NMR(300 MHz, CDCl3): δ 7.54(m, 1H), 7.40(m, 1H), 7.01(brs, 1H), 3.18(s, 3H)
  • Step 2: Sythesis of 2,5-difluoro-4-methanesulfonaminobenzyl hydrochloride [0255]
  • 2,5-difluoro-4-cyano-1-methanesulfonylaminobenzene (250 mg), a catalytic amount of 10% palladium/carbon catalyst and methanol (20 ml) were added to a reactor. The reactor was filled with hydrogen gas while the mixture was stirred. Concentrated hydrochloric acid (250 μl) was slowly added thereto through an injector, followed by stirring for 18 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to afford a compound (250 mg, 85%) as a solid. The obtained compound was washed with ether, and the following procedure was carried out using the washed compound. [0256]
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonaminebenzyl)thiourea (5-5) [0257]
  • 2,5-difluoro-4-methanesulfonaminobenzyl hydrochloride (250 mg) prepared by Step 2 was dissolved in dimethylformamide (5 ml) and to the solution was added triethylamine (128 μl) with stirring, followed by stirring for 30 minutes. To the mixture was added t-butylbenzylisothiocyanate (189 mg), followed by stirring for 6 hours. After the completion of the reaction, the resulting mixture was diluted with water (30 ml), and extracted with ethyl acetate (30 ml×3). The organic layer was dried over magnesium sulfate, filtered, and then concentrated under reduced pressure. The obtained residue was purified by colunm-chromatography (ethyl acetate/hexane=[0258] {fraction (1/2)}) to yield the compound 5-5 (264 mg, 52.4%).
  • [0259] 1H NMR(300 MHz, CDCl3): δ 7.36(m, 2H), 7.31(m, 111), 7.23(m, 2H), 7.17(m, 11), 6.69(brs, 1Il), 6.31(brs, 1R), 6.04(brs, 1H), 4.77(d, 2H, J=5.7 Hz), 4.53(d, 2H, J=4.8 Hz), 3.04(s, 3H), 1.31(s, 9H)
    • EXAMPLE 34
  • Synthesis of 1-(4-t-butylbenzyl)-3-[(5-methanesulfonylaminopyridin-2-yl)methyl]thiourea (5-6) [0260]
    Figure US20030153596A1-20030814-C00089
  • Step 1: Synthesis of 3-methanesulfonylamino-6-cyanopyridine [0261]
  • 5-Amino-2-cyanopyridine (5 g) was dissolved in pyridine (30 ml). The solution was cooled to 0° C. and to the solution was added dropwise methanesulfonyl chloride (3.6 ml), followed by stirring at room temperature for 17 hours. The resulting mixture was concentrated under reduced pressure, extracted with water and dichloromethane, and then dried. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=2/1) to yield an orange colored solid (6.4 g, 77%). [0262]
  • [0263] 1H NMR(300 MHz, CDCl3): δ 8.47-8.46(m, 1H), 7.84-7.69(m, 2H), 6.89(brs, 1H, 3.16(s,3H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-[(5-methanesulfonylaminopyridin-2-yl)methyl]thiourea (5-6) [0264]
  • The compound (1.97 g) prepared in Step 1 was dissolved in methanol (50 ml) and to the solution were added concentrated hydrochloric acid (2 ml) and a catalytic amount of 5% palladium/carbon, followed by stirring under hydrogen atmosphere for 21 hours. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain foamy compound (3 g). Part (135 mg) of the obtained compound was dissolved in dimethylformamide (5 ml) and to the solution were added triethylamine (101 mg) and 4-t-butylbenzylisothiocyanate (100 mg), followed by stirring at room temperature for 20 hours. The mixture was concentrated under reduced pressure, extracted with water and dichloromethane, and then purified by column-chromatography (ethyl acetate) to yield the compound 5-6 (98 mg, 48%) as a brown liquid. [0265]
  • [0266] 1H NMR(300 MHz, CDCl3): δ 8.33-8.31(m, 1H), 7.66-7.62(m, 1H), 7.40-7.26(m, 5H), 6.99(brs, 1H), 6.76(brs, 1H), 4.77-4.60(m, 4H), 3.04(s, 3H), 1.32(s,9H)
    • EXAMPLE 35
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3,5-dichloro-4-methanesulfonylaminobenzyl)thiourea (5-7) [0267]
    Figure US20030153596A1-20030814-C00090
  • 4-Amino-3,5-dichlorobenzonitrile (1 g) was dissolved in acetonitrile (50 ml) and to the solution were added triethylamine (890 μl) and methanesulfonyl chloride (670 mg), followed by refluxing for 8 hours. The mixture was extracted with water and dichloromethane, dried, concentrated, and then purified by column-chromatography (hexane/ethyl acetate=4/1) to obtain a compound (80 mg) as a liquid. The obtained compound was dissolved in methanol (10 ml), and then the solution was stirred for 15 hours in the presence of a small amount of concentrated hydrochloric acid and 5% palladium/carbon catalyst to hydrogenate the compound. The reaction solution was filtered through celite and concentrated. The concentrate was dissolved in dichloromethane (5 ml) and to the solution were added 4-t-butylbenzylisothiocyanate (54 mg) and triethylamiine (500 μl), followed by stirring at room temperature for 15 hours. The resulting mixture was extracted with water and dichloromethane, and then purified by column-chromatography (hexane/ethyl acetate=2/1) to yield the compound 5-7 (38 mg) as a liquid. 1H NMR(300 MHz, CDCl[0268] 3): δ 7.42-7.23(r, 6H), 6.23(brs, 1H), 5.87(brs, 11), 4.85-4.82(ni, 211), 4.58-4.56(m, 2H), 3.57(s, 3H), 1.31(s,9H)
    • EXAMPLE 36
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea (5-8) [0269]
    Figure US20030153596A1-20030814-C00091
  • Step 1: Synthesis of 4-methanesulfonylaminobenzyl cyanide [0270]
  • To an ice-cold solution of 4-aminobenzyl cyanide (1 g) in dichloromethane (30 ml) were added dropwise triethylamine (1.58 ml) and methanesulfonyl chloride (700 μl), followed by stirring at room temperature for 12 hours. After confirming the completion of the reacion using TLC, to the mixture was added 1 N aqueous hydrochloric acid (50 ml). The resulting mixture was extracted with dichloromethane (30 ml×3), washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then filtered. [0271]
  • The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane=2/3) to yield 4-methanesulfonylarninobenzyl cyanide (1.35 g, 85%). [0272]
  • [0273] 1H NMR(300 MHz, CDCl3): δ7.34(d, 2H, J=8.4 Hz), 7.24(d, 2H, J=8.7 Hz), 6.51(bs, 1H), 3.74(s, 2H), 3.03(s, 3H)
  • Step 2: Synthesis of 4-methanesulfonaminophenethylamine [0274]
  • 4-Methanesulfonylbenzyl cyanide (200 mg) and Raney nickel (catalytic amount) were added to methanol (15 ml) and the mixture was stirred for 6 hours with the reactor filled with hydrogen gas. After confirming the completion of the reaction, the resulting mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The following procedure was carried out using the concentrate which was not purified. [0275]
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea (5-8) [0276]
  • 4-Methaiiesulfonaniinophenethylamine (200 mg) prepared in Step 2 and 4-t-butylbenzylisothiocyanate (190 mg) were dissolved in ethyl acetate (30 ml) and the solution was subjected to reaction for 6 hours. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane=[0277] {fraction (1/2)}) to yield the compound 5-8 (210 mg, 53%). 1H NMR(300 MHz, CDCl3): δ 7.38(d, 2H, J=8.4 Hz), 7.21(d, 2H, J=8.4 Hz), 7.14(s, 4H), 6.56(s, 1H), 6.05(brs, 1H), 5.69(brs, 1H), 4.51(brs, 2H), 3.72(d, 2H, J=4.8 Hz), 2.99(s, 3H), 2.86(t, 2H, J=6.9 Hz), 1.32(s, 9E[)
    • EXAMPLE 37
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2-methanesulfonylamiinophenethyl)thiourea (5-9) [0278]
    Figure US20030153596A1-20030814-C00092
  • Step 1: Synthesis of (2-methanesulfoliylaniinophenyl)acetonitrile [0279]
  • To an ice-cold solution of 2-aminophenylacetonitrile (500 mg) in dichloromethane (20 ml) were added triethylamine (330 μl) and methanesulfonyl chloride (530 μl) and the mixture was stirred for 16 hours, under argon gas atmosphere. After confirming the completion of the reaction using TLC, the resulting mixture was diluted with 1 N aqueous hydrochloric acid solution (30 ml), and extracted with dichloromethane (50 ml×3). The organic layer was washed with brine, dried over magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane=[0280] {fraction (1/2)}) to yield (2-methanesulfonylaminophenyl)acetonitrile (573 mg, 72%).
  • [0281] 1H NMR(300 MHz, CDCl3): δ7.56(m, 1H), 7.37(m, 311), 6.55(brs, 11), 3.99(s, 2H), 3.06(s, 3H)
  • Step 2: Synthesis of 2-methanesulfonylaminophenethylamine [0282]
  • (2-Methanesulfonylaminophenyl)acetonitrile (300 mg) was mixed with 10% palladium/carbon (catalytic amount) in methanol (20 ml) and the mixture was stirred under hydrogen gas atmosphesre for 48 hours. After confirming the completion of the reaction using TLC, the resulting mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The following procedure was carried out using the concectrate which was not purified. [0283]
  • Step 3: Sythesis of 1-(4-t-butylbenzyl)-3-(2-methanesulfonylaminophenethyl)thiourea (5-9) [0284]
  • 2-Methanesulfonylaniinophenethylamine (200 mg) prepared in Step 2 and t-butylbenzeneisothiocyanate (192 mg) were dissolved in ethyl acetate (20 ml) and the solution was stirred for 6 hours. After confirming the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the concetrate was purified by column-chromatography (ethyl acetate/hexane=2/3) to yield the compound 5-9 (165 mg, 42%). [0285]
  • 1H NMR(300 MHz, CDCl[0286] 3): δ7.28(m, 8H), 6.38(brs, 1H), 4.74(s, 1H), 4.72(s, 1H), 3.79(m, 2H), 3.14(m, 4H), 3.01(s, 3H), 1.31(s, 9H)
    • EXAMPLE 38
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfanylcarbonylaminobenzyl)thiourea (6-5) [0287]
    Figure US20030153596A1-20030814-C00093
  • Step 1: Synthesis of (4-nitrobenzyl)carbamic acid t-butyl ester (6-2) [0288]
  • 4-Nitrobenzylamine hydrochloride (110 mg) was dissolved in dichloromethane (2 ml) and to the solution were added dimethylaminopyridine (14 mg) and di-t-butyl dicarbonate (382 mg), followed by adding triethylamine (200 μl) thereto and stirring at room temperature for 3 hours. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on column eluting with ethyl acetate/hexane ({fraction (1/3)}) to yield the compound 6-2 (88.3 mg, 66%). [0289]
  • 1H NMR(300 MHz, CDCl[0290] 3): δ 8.18 (d, 2H, J=8.5 Hz), 7.43 (d, 2H, J=8.8 Hz) 4.40 (d, 2H, J=6.3 Hz), 1.45 (s, 9H)
  • Step 2: Synthesis of (4-methylsulfanylcarbonylaminobenzyl)carbamic acid t-butyl ester (6-3) [0291]
  • The compound 6-2 (88.3 mg) prepared in Step 1 was dissolved in methanol (2 ml) and to the solution was added catalytic amount of 10% palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture was diluted with ether, and filtered through celite. The filtrate was concentrated under reduced pressure to yield compound (76 mg). The obtained compound, which was not purified, was dissolved in dichloromethane (1 ml) and to the solution were added methylchlorothiolformate (100 μl) and pyridine (49 μl). After stirring the mixture at room temperature for 1 hour, the resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was column-chromnatographed (ethyl acetate/hexane=1/1) to yield the compound 6-3 (22 mg, 22%). [0292]
  • [0293] 1H NMR(300 MHz, CDCl3): δ 7.36 (d, 1H, J=8.5 Hz), 7.20-7.25 (m, 211), 7.03 (d, 1H, J=8.3 Hz), 4.25 (s, 2H), 2.40 (s, 3H), 1.44 (s, 9H)
  • Step 3: Synthesis of 4-methylsulfanylcarbonylaminobenzylamine hydrochloride (6-4) [0294]
  • The compound 6-3 (22 mg) prepared in Step 2 was dissolved in ethyl acetate (1 ml) and to the solution was added 5 N aqueous hydrochloric acid (1 ml). The mixture was stirred at 60° C. for 1 hour and concentrated under reduced pressure to yield the compound 6-4 (15 mg, 100%). [0295]
  • [0296] 1H NMR(300 MHz, CD3OD): δ 7.65 (d, 1H, J=8.5Iz), 7.57 (d, 1H, J=8.3 Hz), 7.49 (d, 1H, J=8.5 Hz), 7.38 (d, 1H, J=8.8 Hz), 4.05(s, 2H) 2.35(s, 3H)
  • Step 4: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylsulfanylcarbonylaminobenzyl)thiourea (6-5) [0297]
  • The compound 6-4 (15 mg) prepared in Step 3 was diluted in dichloromethane (1 ml) and to the solution were added 4-t-butylisothiocyanate (20 mg) and triethylamine (100 μl), followed by stirring at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on column eluting with ethylacetate/hexane ([0298] {fraction (1/3)}) to yield the compound 6-5 (20 mg, 83%).
  • [0299] 1H NMR(300 MHz, CDCl3): δ 7.16-7.35 (m, 8H), 4.56 (br, 4H), 2.35 (s, 3H), 1.26 (s, 9H)
    • EXAMPLE 39
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-guanidinobenzyl)thiourea (7-6) [0300]
    Figure US20030153596A1-20030814-C00094
  • Step 1: Synthesis of 4-(1,3-bis(t-butoxycarbonyl)-2-guanidino)phenyliodide (7-2) [0301]
  • 4-lodoaniline 7-1 (100 mg) was dissolved in dimethylformarnide (2 ml) and to the solution were added 1,3-bis(t-butoxycarbonyl)-2-methyl-2-thiopseudourea (200 mg), mercury (II) chloride (186 mg) and triethylarnine (200 td), followed by stirring for 1 hour. Aftrer the completion of the reaction, the resulting mixture was concentrated under reduced pressure at the temperature not more than 50° C. and the obtained residue was chromatographed eluting with ethyl acetate/hexane ({fraction (1/3)}) to yield the compound 7-2 (137 mg, 66%/). [0302]
  • [0303] 1H NMR(300 MHz, CDCl3): δ 11.60 (br, 1H) 10.33 (br, 1H), 7.58-7.63 (d, 2H, J=8.8 Hz), 7.35-7.38 (d, 2H, J=8.8 Hz), 1.51 (s, 9H), 1.48 (s, 9H)
  • Step 2: Synthesis of 4-[1,3-bis(t-butoxycarbonyl)-2-guanidino]benzonitrile (7-3) [0304]
  • The compound 7-2 (137 mg) prepared in Step 1 was dissolved in dimethylformamide (2 ml) and to the solution were added zinc (II) cyanide (40 mg) and tetrakistriphenylphosphine palladium (14 mg), followed by stirring at 80° C. for 1 hour. The reaction was quenched with water. The resulting mixture was extracted with ethyl acetate, and the organic phase was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was chromatographed on column eluting with ethyl acetate/hexane ({fraction (1/3)}) to yield the compound 7-3 (95 mg, 89%). [0305]
  • [0306] 1H NMR(300 MHz, CDCl3): δ 11.58 (br, 1H) 10.62 (br, 11), 7.76-7.79 (d, 2H, J=8.8 Hz), 7.58-7.61 (dd, 2H, J=2.0, 6.8 Hz), 1.52 (s, 9H), 1.50 (s, 9H)
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-[4- { 1,3-bis(t-butoxycarbonyl)-2-guanidino}benzyl]thiourea (7-5) [0307]
  • The compound 7-3 (20 mg) prepared in Step 2 was dissolved in methanol (2 ml) and to the solution was added catalytic amount of palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to give the compound 7-4. The compound 7-4 was diluted with dichloromethane (3 ml). To the solution was added 4-t-butylbenzylisothiocyanate (40 mg) and the mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed eluting with ethyl acetate/hexane ({fraction (1/3)}) to yield the compound 7-5 (35 mg, 95%). [0308]
  • [0309] 1H NMR(300 MHz, CD3OD): δ 7.18-7.49 (m, 8H), 4.66-4.69 (br, 4H), 1.56 (s, 9H), 1.45 (s, 91), 1.29 (s, 9H)
  • Step 4: Synthesis of 1-(4-t-butylbenzyl)-3-(4-guanidinobenzyl)thiourea (7-6) [0310]
  • The compound 7-5 (35 mg) prepared in Step 3 was dissolved in ethyl acetate (1.0 ml) and to the solution was added 5 N aqueous hydrochloric acid (1 ml). The mixture was stirred at 60° C. for 1 hour and concentrated under reduced pressure to yield the compound 7-6 (18 mg, 100%). [0311]
  • [0312] 1H NMR(300 MHz, acetone-d6): δ 7.07-7.37 (m, 8H), 4.73(s, 2H), 4.66 (s, 2H), 1.17 (s, 9H)
    • EXAMPLE 40
  • Synthesis of 1-[2-(1-methyl-I-pyrro1-2-yl)ethyl]-3-(4-methanesuffonylaminobenzyl)thiourea (8-4) [0313]
    Figure US20030153596A1-20030814-C00095
  • Step 1: Syntheis of (4-aminobenzyl)carbanic acid t-butyl ester (8-1) [0314]
  • 4-Aminobenzylamine (1.02 g) was dissolved in anhydrous tetrahydrofuran (10 ml) and to the solution was added di-t-butyldicarbonate (2.002 g), followed by stirring at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to remove the solvent. The obtained residue was purified by column-chromatography (ethyl acetate/hexane=[0315] {fraction (2/3)}) to yield the compound 8-1 (1.78 g, 96%) as a yellow solid.
  • [0316] 1H NMR (300 MHz, CDCl3): δ7.09-7.05 (m, 2H), 6.6-6.62 (m, 2H), 4.70 (brs, 1H), 4.18(d, 2H, J=5.7 Hz), 3.64(brs, 2H), 1.45 (s, 911)
  • Step 2: Synthesis of (4-methanesulfonylaminobenzyl)carbamic acid t-butyl ester (8-2) [0317]
  • Compound 8-1 (1 g) was dissolved in anhydrous dichloromethane and the solution was cooled to 0° C. To the solution was added triethylamine (630 μl) and methanesulfonyl chloride (350 μl) in order and the mixture was stirred at room temperature for 24 hours. After confirming the completion of the reaction using TLC, the resulting mixture was neutralized with hydrochloric acid solution, diluted with water, and then extracted three times with dichloromethane. The extracted organic layer was washed with water and saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then dried under reduced pressure. The obtained residue was purified by coluimn-chromatography (hexane/ethyl acetate=2/1) to yield the compound 8-2 (1.28 g, 95%) as a white solid. [0318]
  • [0319] 1H NMR (300MIz, CDCl3): δ 7.1-7.3 (m, 4H), 6.77 (s, 11), 4.88 (brs, 1H), 4.28 (d, 2H), 2.99 (s, 3I1), 1.46 (s, 9H)
  • Step 3: Synthesis of 4-methanesulfonylaimnobenzylammonium trifluoroacetate (8-3) [0320]
  • (4-Methanesulfonylaminobenzyl)carbamic acid t-butyl ester 8-2 (500 mg) was dissolved in anhydrous dichloromethane (30 ml) and the solution was cooled to 0C, followed by slowly adding trifluoroacetic acid (5 ml) thereto. The mixture was stirred at 0° C. for 1 hour and 30 minutes and then, after confirming the completion of the reaction using TLC, concentrated under reduced pressure to yield an orange colored residue. The residue was washed with ether and filtered to yield the compound 8-3 (420 mg, 80%) as a pink solid. [0321]
  • [0322] 1H NMR (300 MHz, DMSO-d6): δ 8.14 (brs, 3M), 7.39 (d, 2H), 7.22 (d, 2H), 3.97 (s, 2H), 2.99 (s, 3H)
  • Step 4: Synthesis of 1-[2-(1-methyl-1H-pyrro1-2-yl)ethyl]-3-(4-methanesulfonylaminobenzyl)thiourea (8-4) [0323]
  • Compound 8-3 (500 mg) was dissolved in dimethylformamide (2 ml) and to the solution was added triethylamine (230 fd), followed by stirring for 1 hour. To the mixture was added 2-(2-isothiocyanatoethyl)-1-methyl-1H-pyrrole (280 mg), followed by adding ethyl acetate (10 ml) thereto. The mixture was stirred for 12 hours, filtered under reduced pressure, and then purified by column-chromatography (ethyl acetate/hexane=4/1) to yield the compound 8-4 (146 mg, 25%) as a red solid. [0324]
  • [0325] 1H NMR (300 MHz, CH3COCH3-d6): δ 7.32(m, 4H), 7.16(m, 1H), 6.42(d, 1H, J=2.1 Hz), 6.02(d, 1H, J=1.95 Hz), 4.76(m, 2H), 3.89(m, 2H), 3.81(m, 21), 3.01(m, 2H), 2.96(s, 3H)
    • EXAMPLE 41
  • Synthesis of 1-(4-anidnobenzyl)-3-(4-t-butylbenzyl)thiourea (9a) [0326]
    Figure US20030153596A1-20030814-C00096
  • 4-t-Butylbenzylisothiocyanate (100 mg) was dissolved in dichloromethane (3 ml) and then cooled to 0° C. To the solution was added 4-nitrobenzylamine (75 mg), followed by stirring at room temperature for 6 hours. After the completion of the reaction, dichloromethane was evaporated therefrom under reduced pressure and the residue was dissolved in methanol (3 ml). To the solution was added catalytic amount of 5% platinum/carbon and the mixture was subjected to hydrogenation reacton under atmospheric pressure. After the completion of the reaction, the methanol was evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate=1/1) to yield the compound 9a (137 mg, 85%) as a white solid. [0327]
  • [0328] 1H NMR (300 MHz, CDCl3): δ 6.70-7.40(m, 81), 6.00-6.40(br, 2H), 4.55(br, 2H), 4.45(br, 2H), 1.28(s, 9H)
  • MS (1E) m/e 327 [M+][0329]
    • EXAMPLE 42
  • Synthesis of 1-(4-acetylaminobenzyl)-3-(4-t-butylbenzyl)thiourea (9b) [0330]
    Figure US20030153596A1-20030814-C00097
  • Compound 9a (100 mg) and triethylamine (50 mg) were dissolved in dichloromethane (3 ml) and cooled to 0° C. To the solution was added anhydrous acetic acid (35 mg). After the completion of the reaction, dichloromethane was evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate=1/1) to yield the compound 9b (107 mg, 95%) as a white solid. [0331]
  • 1H NMR (300 MHz, DMSO-d[0332] 6): δ 8.31(s, 1H), 7.87(br, 2H), 7.50(d, 2H, J=8.40 Hz), 7.32(d, 2H, J=8.25 Hz), 7.16-7.17(m, 4H), 4.59(br, 4H), 2.01(s, 3H), 1.25(s, 9H)
  • MS (El) m/e 369 [M+][0333]
    • EXAMPLE 43
  • Synthesis of 1-(4-(N,N-dimethanesulfonyl)aminobenzyl)-3-(4-t-butylbenzyl)thiourea (9c) [0334]
    Figure US20030153596A1-20030814-C00098
  • 4-t-Butylbenzylisothiocyanate (100 mg) was dissolved in dichloromethane (3 ml) and cooled to 0° C. To the solution was added (N,N-dimethylsulfony1-4-amino)benzylamine (136 mg), followed by stirring at room temperature for 6 hours. After the completion of the reaction, dichloromethane was evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate=1/1) to yield the compound 9c (184 mg, 75%) as a white solid. [0335]
  • [0336] 1H NMR (300 MHz, CDCl3): δ 7.00-7.35(m, 8H), 6.30(br, 21), 4.66(s, 2H), 4.49(s, 2H), 3.26(s, 6H), 1.22(s, 9H); MS (El) ni/e 469 [M+]
    9
    Figure US20030153596A1-20030814-C00099
    Examples Compounds No. RD RE Spectral data
    44 9d H— 1H NMR(300MHz, CDCl3): δ 7.37(d, 2H),
    CH3SO2— 7.1-7.3(m, 6H), 6.39(s, 1H), 5.99(brs, 1H),
    4.66(d, 2H), 4.56(m, 2H), 3.00(s, 3H), 1.31(s,
    9H) MS(EI) m/e 405[M+]
    45 9e H— 1H NMR(300MHz, DMSO-d6): δ 7.90(br, 1H),
    CF3SO2— 7.25(m, 8H), 4.50-4.70(br, 4H), 1.25(s, 9H)
    MS(EI) m/e 459[M+]
    46 9f —H 1H NMR(300MHz, CDCl3): δ 8.20-8.40(br,
    —CHO 2H), 8.05(s, 1H), 6.80-7.30(m, 8H), 4.52(br,
    4H), 1.19(s, 9H) MS(EI) m/e 355[M+]
    47 9g —H 1H NMR(300MHz, DMSO-d6): δ 9.64(s, 1H),
    —C(═S)NH2 7,86(br, 2H), 7.20-7.40(m, 8H), 4.61(br, 4H),
    1.26(s, 9H) MS(EI) m/e 386[M+]
    48 9h —H 1H NMR(300MHz, DMSO-d6): δ 9.56(s, 1H),
    —CO2Et 7.81(br, 2H), 7.15-7.45(m, 8H), 4.58(br, 4H),
    4.10(q, 2H, J=7.05Hz), 1.25(s, 9H), 1.23(t,
    3H), J=7.05Hz) MS(EI) m/e 399[M+]
    Figure US20030153596A1-20030814-C00100
    Figure US20030153596A1-20030814-C00101
    Figure US20030153596A1-20030814-C00102
    Figure US20030153596A1-20030814-C00103
    Figure US20030153596A1-20030814-C00104
    • EXAMPLE 49
  • Synthesis of 1-(4-t-butylbenzyl)-3-12-hydroxy-4-(N-t-butoxycarbonyl)amiuobenzyl]thiourea [0337]
    Figure US20030153596A1-20030814-C00105
  • 2-Hydroxy-4-nitrobenzaldehyde (1.67 g), t-butyldiphenylsilylchloride (TBDPSCI) (2.65 g) and imidazole (681 mg) were dissolved in dichloromethane (100 ml) and the solution was stirred at room temperature for 18 hours. The precipitate was filtered off and the filtrate was concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=3/1) to yield the compound 10-1 (4.00 g, 99%). The compound 10-1 (3.00 g) was reduced in the presence of palladium/carbon catalyst to yield an amine. The amine was dissolved in tetrahydrofuran (15 ml) and to the solution was added Boc[0338] 2O (950 mg), followed by stirring at room temperature for 18 hours. To the mixture were added water (20 ml) and ethyl acetate (10 ml). From the mixture, an organic layer was separated and an aqueous layer was extracted with ethyl acetate (10 ml x2). The combined organic layer was washed with brine, dried over magnesium sulfate and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=3/1) to yield the compound 10-2 (380 mg, 20%) and 10-3 (764 mg, 41%). The compound 10-2 was dissolved in ethyl acetate (10 ml) and to the solution was added t-butylbenzylisothiocyanate (150 mg), followed by stirring at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate=3/1) to yield thiourea compound (300 mg, 56%). The compound (300 mg) was dissolved in THF (5.0 ml) and to the solution was added tetrabutylanumonium fluoride (131 mg), followed by stirring at room temperature for 45 minutes. The reaction was quenched with saturated sodium bicarbonate and an aqueous solution layer was extracted with ethyl acetate (10 ml×2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=1/1) to yield the compound 10-4 (52 mg, 27%).
  • 1H NMR (30OMfz, CDCl[0339] 3): δ 7.35(d, J=8.4 Hz, 2H), 7.20(d, J=8.4 Hz, 2H), 7.07(dd, J=2.7, 8.4 Hz, 1H), 6.94(d, J=8.4 Hz, 1H), 6.89(d, J=2.7 Hz, 1H), 6.01(bs, 1H), 5.19(bs, I11), 4.83(d, J=5.7 Hz, 211), 4.15(d, J=6.6 Hz, 2H), 1.44(s, 9H), 1.30(s, 9H)
    • EXAMPLE 50
  • Synthesis of 1-(4-t-butylbenzyl)-3-[2-hydroxy-4-methanesulfonylaminobenzyl]thiourea (10-6) [0340]
    Figure US20030153596A1-20030814-C00106
  • Step 1: Synthesis of 2-(N-t-butyloxycarbonylamino)methyl-4-methanesulfonylamino-l1-t-butyldiphenylsilylo xybenzene (10-5) [0341]
  • The compound 10-3 (700 mg) prepared by Example 49 was dissolved in dichloromethane (10 ml) and the solution was cooled to 0C, followed by adding trifluoroacetic acid (2.0 ml) thereto. The mixture was stirred for 2 hours and concentrated under reduced pressure. The obtained residue (186 mg) was dissolved in TBF (2.0 ml) and to the solution was added triethylamine (90 μl), followed by stirring for 12 hours. To the solution was added Boc[0342] 2O (68 mg) and the mixture was stirred at room temperature for 10 hours. To the resulting mixture were added water (10 ml) and ethyl acetate (10 ml). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (10 ml×2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate={fraction (1/2)}) to yield an alkylamine intermediate (100 mg, 69%), protected with Boc group. The intermediate and triethylamnine (40 ye) were dissolved in dichloromethane (2.0 ml) and the solution was cooled to 0° C. To the solution was added methanesulfonyl chloride (20 i) and the mixture was stirred at room temperature for 2 hours. The water was added thereto to quench the reaction. An organic layer was separated, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=3/2) to yield the compound 10-5 (69 mg, 60%).
  • [0343] 1H NMR (300 MHz, CDCl3): δ 7.68(m, 4H), 7.40(m, 6H), 7.12(d, J=3.0 Hz, 1H), 6.73(dd, J=3.0, 8.7 Hz, 1H), 6.40(d, J=8.7 Hz, 1H), 6.04(s, 1H), 4.94(bs, 1H), 4.46(d, J=5.4ffz, 2H), 2.90(s, 3H), 1.48(s, 9H), 1.I1 (s, 9H).
  • Step 2: Synthesis of [0344]
  • 1-(4-t-butylbenzyl)-3-[2-hydroxy-4-methanesulfonylaminobenzyl]thiourea (10-6) [0345]
  • Compound 10-5 (90 mg) was dissolved in TBF (2.0 ml) and to the solution was added tetrabutylanunoniumfluoride (200 μl), followed by stirring at room temperature for 45 rminutes. The reaction was quenched with saturated aqueous sodium bicarbonate solution and the aqueous layer was extracted with ethyl acetate (10 ml×2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=1/1) to yield a phenol compound (38 mg, 71%). The compound was dissolved in dichloromethane (3.0 ml) and the solution was cooled to 0° C. To the solution was added trifluoroacetic acid (500 μl), and the mixture was stirred for 2 hours and concentrated under reduced pressure. The concentrate was dissolved in ethyl acetate (2.0 ml) and to the solution was added triethylarnine (16 μl), followed by stirring for 1 hour. To the solution was slowly added a solution of t-butylbenzylisothiocyanate (25 mg) in ethyl acetate (1.0 ml), and the mixture was stirred at room temperature for 18 hours and concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate={fraction (1/3)}) to yield the compound 10-6 (37 mg, 73%). [0346]
  • [0347] 1H NMR (300 MHz, CDCl3): δ 7.35(d, J=8.1 Hz, 2H), 7.19(d, J=8.1 Hz, 2H), 7.06(d, J=2.4 Hz, 1H), 7.00(dd, J=2.4, 8.4 Hz, 1H), 6.89(d, J=8.4 Hz, 11), 6.31(bs, 1H), 6.23(bs, 1H), 4.80(d, J=6.3 Hz, 2H), 4.49(bs, 2H), 2.94(s, 3H), 1.30(s, 9H)
    • EXAMPLE 51
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanesulfonylaminobenzyl)thiourea (11-2) [0348]
    Figure US20030153596A1-20030814-C00107
  • Step 1: Synthesis of 2,4-difluoro-3-[N-(t-butoxycarbonylamino)methyl]aniline (11-1) [0349]
  • 2,6-Difluoro-3-nitrobenzonitrile (921 mg) and 10% palladium/carbon (200 mg) were mixed in methanol (15 ml) and to the mixture was added c-HCl (900 μl), followed by stirring under hydrogen atmosphere for 1 day. The mixture was diluted with ethyl acetate (30 ml) and filtered through celite pad. The filtrate was neutralized with 1 N aqueous sodium hydroxide solution and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (10 ml×2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by column-chromatography (methanol/ethyl acetate=2/1) to yield an amine salt (580 mg, 50%). The obtained amine salt was dissolved in tetrahydrofuran (5.0 ml) and to the solution was added triethylamine (700 μl), followed by stirring at room temperature for 12 hours. To the solution was added Boc[0350] 2O (548 mg) and the mixture was stirred at room temperature for 10 hours. To the resulting mixture were added water (10 ml) and ethyl acetate (10 ml) and then the organic layer was separated. The aqueous layer was extrated with ethyl acetate (10 ml×2). The combined organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=1/1) to yield intermediate material 11-1 (531 mg, 82%) protected with Boc.
  • [0351] 1H NMR (300 MHz, CDCl3) δ0 6.67(m, 2H), 4.86(bs, 1U, 4.39(d, J=4.8 Hz, 2H), 3.59(bs, 2H), 1.44(s, 9H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanesulfonylaminobenzyl)thiourea (11-2) [0352]
  • Compound 11-1 (531 mg) was mesylated and treated with trifluoroacetic acid to remove Boc group therefrom. 4-t-butylbenzylisothiocyanate was reacted therewith to yield the compound 11-2 (145 mg, 16%). [0353]
  • [0354] 1H NMR (300 MHz, CDCl3): δ 7.50(dt, J=5.7, 9.0 Hz, 1H), 7.38(d, J-8.1 Hz, 2H), 7.22(d, J=8.1 Hz, 2H), 6.90(dt, J=1.8, 9.0 Hz, 1H), 6.41(bs, 1H), 6.14(bs, 1H), 6.02(bs, 1H), 4.79(d, J=5.7 Hz, 211), 4.55(bs, 2H), 3.00(s, 3H), 1.32(s, 9H)
    • EXAMPLE 52
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-methanesulfonylaminobenzyl)thiourea (12-3b) [0355]
    Figure US20030153596A1-20030814-C00108
  • Step 1: Synthesis of 3-aminomethyl-phenylamine (12-1b) [0356]
  • 3-Nitrobenzaldehyde (1.51 g) and hydroxylamine hydrochhride (1.29 g) were dissolved in methanol (100 ml), and to the solution was slowly added pyridine (2.37 g) at room temperature, followed by stirring for 18 hours. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (30 ml), washed with water (10 ml×2) and saturated aqueous copper sulfate solution (10 ml), dried over magnesium sulfate, concentrated under reduced pressure, and then the residue was purified by column-chromatography (hexane/ethyl acetate=3/1) to yield oxime (1.66 g). The obtained oxime was dissolved in methanol (20 ml) and to the solution was added 10% palladium/carbon (414 mg), followed by stirring at room temperature under hydrogen atmosphere for 3 days. The reaction mixture was filtered to remove the precipitate and the filtrate was concentrated under reduced pressure to yield the compound 12-1b (643 mg, 53%). [0357]
  • [0358] 1H NMR(300 MHz, DMSO-d6): δ 7.08(t, J=8.1 Hz, 1H), 6.66(m, 2H), 6.55(d, J=8.1 Hz, 1H), 2.40 (bs, 2H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(3-methanesulfonylaminobenzyl)thiourea (12-3b) [0359]
  • Compound 12-1b (643 mg) was dissolved in tetrahydrofuran (6.0 ml) and to the solution was slowly added Boc[0360] 2O (1.26 g) at room temperature, followed by stirring for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate=2/1) to yield an intermediate compound (622 mg) protected with Boc group. The intermediate compound and triethylamine (500 μl) were dissolved in dichloromethane (20 ml) and the solution was cooled to 0° C. To the solution was added methanesulfonyl chloride (300 μl) and the mixture was stirred at room temperature for 50 minutes. The water was added thereto to quench the reaction. The organic layer was separated, dried over magnesium sulfate, concentrated under reduced pressure, and then the residue was purified by column-chromatography (hexane/ethylacetate=1/1) to yield the compound 12-2b (871 mg, 47%). The compound 12-2b was dissolved in dichloromethane (15 ml) and the solution was cooled to 0C, followed by adding trifluoroacetic acid (3.0 ml) thereto and stirring for 2 hours. The resulting mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (10 ml), followed by adding triethylamine (140 μl) thereto and stirring for 1 hour. To the solution was slowly added a solution of t-butylbenzylisothiocyanate (421 mg) in ethyl acetate (2 ml) and the mixture was stirred at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl aceate=1/1) to yield the compound 12-3b (385 mg, 95%).
  • [0361] 1H NMR (300 MHz, CDCl3): δ7.33(d, J=8.4 Hz, 2H), 7.25(t, J=8.1 Hz, 1H), 7.18(d,J=8.4 Hz, 2H), 7.13(m, 2H), 7.03(d, J=7.5 Hz, 1H), 6.31(bs, 2H), 4.66(d, J=5.1 Hz, (d, J=4.8 Hz, 2H), 2.95(s, 3H), 1.29(s, 9H).
  • Compounds 12-3a and 12-3c - 12-3 g of Example 53 Example 59 were synthesized according to the synthesizing procedure as described above. [0362]
    12-3
    Figure US20030153596A1-20030814-C00109
    Compounds RF =
    Examples No. RG = Spectral data
    53 12-3a H 1H NMR(300MHz, CDCl3): δ 8.13(bs, 1H), 7.46(d,
    2-NHMs J=8.1Hz, 1H), 7.31(m, 2H), 7.31(d, J=8.4Hz, 2H),
    7.17(d, J=5.4Hz, 1H), 7.16(d, J=8.4Hz, 2H), 6.34(m,
    2H), 4.87(d, J=6.0Hz, 2H), 4.47(bs, 2H), 2.99(s, 3H),
    1.28(s, 9H).
    54 12-3c H 1H NMR(300MHz, CDCl3): δ 7.62(d, J=7.5Hz,
    2-NMs2 1H), 7.47(t, J=7.5Hz, 1H), 7.40(t, J=8.4Hz, 1H),
    7.34(d, J=8.4Hz, 3H), 7.17(d, J=8.4Hz, 2H),
    6.49(bs, 3.43(s, 6H), 1.29(s, 9H).
    55 12-3d H 1H NMR(300MHz, CDCl3): δ7.43(d, J=7.2Hz, 1H),
    3-NMs2 7.38(m, 1H), 7.38(d, J=8.4Hz, 2H), 7.31(m, 1H),
    7.29(m, 1H), 7.22(d, J=8.4Hz, 2H), 6.16(bs, 1H),
    6.04(bs, 1H), 4.78(d, J=5.7Hz, 2H), 4.57(bs, 2H),
    3.40(s, 6H), 1.30(s, 9H).
    56 12-3e 4-F 1H NMR(300MHz, CDCl3): δ7.46(d, J=8.1Hz, 1H),
    3-NHMs 7.47(d, J=8.4Hz, 2H), 7.22(d, J=8.4Hz, 2H), 7.08(d,
    J=8.1Hz, 2H), 6.50(bs, 1H), 6.12(bs, 1H), 5.97(bs,
    1H), 4.71(d, J=5.4Hz, 2H), 4.57(d, J=4.8Hz, 2H),
    3.03(s, 3H), 1.31(s, 9H).
    57 12-3f 4-F 1H NMR(300MHz, CDCl3): δ7.37(d, J=8.4Hz, 2H),
    3-NMs2 7.36(m, 2H), 7.24(d, J=8.4Hz, 2H), 7.15(d, J=9.3Hz,
    1H), 6.20(bs, 1H), 6.04(bs, 1H), 4.74(d, J=5.4Hz, 2H),
    4.55(d, J=5.1Hz, 2H), 3.43(s, 6H), 1.31(s, 9H).
    58 12-3g 6-F 1H NMR(300MHz, CDCl3): δ7.36(d, J=8.1Hz, 2H),
    3-NHMs 7.28(dd, J=2.4, 6.4Hz, 1H), 7.21(d, J=8.1Hz, 2H),
    7.08(m, 1H), 7.00(t, J=9.2Hz, 1H), 6.88(bs, 1H),
    6.34(bs, 1H), 6.18(bs, 1H), 4.76(d, J=5.7Hz, 2H),
    4.55(d, J=4.5Hz, 2H), 2.97(s, 3H), 1.30(s, 9H).
    Figure US20030153596A1-20030814-C00110
    Figure US20030153596A1-20030814-C00111
    Figure US20030153596A1-20030814-C00112
    Figure US20030153596A1-20030814-C00113
    Figure US20030153596A1-20030814-C00114
    Figure US20030153596A1-20030814-C00115
    • EXAMPLE 59
  • Synthesis of 1-(4-t-buty1-2-methoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea (13-4a) [0363]
    Figure US20030153596A1-20030814-C00116
  • Step 1: Synthesis of 4-t-buty1-2-methoxybenzonitrile (13-2a) [0364]
  • 4-t-Butyl-2-hydroxybenzonitrile (1.16 g) and potassium carbonate (376 mg) were dissolved in dimethylformamide (4 ml) and to the solution was added dropwise iodomethane (226 fd), followed by stirring at 50° C. for 2 hours. The resulting mixture was filtered to remove the remaining potassium carbonate and concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=10/1) to yield the compound 13-2a (167 mg, 97%). [0365]
  • [0366] 1H NMR(300 MHz, CDCl3): δ7.45(d, 1H, J-8.OHz), 7.01(dd, 1H, J=1.7, 8.2 Hz), 6.94(d, 1H, J-1.5 Hz), 3.92(s, 3H), 1.31(s, 9H)
  • Step 2: Synthesis of 4-t-butyl-2-methoxybenzylamine (13-3a) [0367]
  • Lithium aluminium hydride (50 mg) was suspended in ether (2 ml) and the suspension was cooled to 0° C. To the suspension was added dropwise a solution of the compound 13-2a (167 mg) prepared by Step 1 in ether (2 ml) and the mixture was refluxed for 2 hours. After the completion of the reaction, the reaction solution was basified with 5 N aqueous sodium hydroxide solution. Then, aqueous Rochel solution was added thereto and stirred for 1 hour, at room temperature. Then, resulting mixture was extracted with ether (50 ml×3) and concentrated under reduced pressure to yield the compound 13-3a (120 mg, 71%). The following Step 3 was proceeded using the compound 13-3a which was not purified. [0368]
  • Step 3: Synthesis of 1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylainiobenzyl)thiourea (13-4a) [0369]
  • The compound 13-3a (132 mg) prepared according to the same procedure as described in Step 2 was dissolved in dichloromethane (5 ml) and to the solution were added triethylamine (143 μl) and 4-methanesulfonaminobenzylisothiocyanate (165 mg) in order, followed by stirring at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate=2/1) to yield the compound 13-4a (190 mg, 70%), [0370]
  • [0371] 1H NMR(300 MHz, CDCl3): δ7.11-7.32(m, 5H), 6.96(d, 1H, J=7.0 Hz), 6.82(s, 1H), 4.67(s, 2H), 4.45(s, 2H), 3.62(s, 3H), 3.00(s, 3H), 1.2(s, 9H); MS (FAB) m/e 436[M++1]
  • Compounds of Example 60 69 are shown in the Scheme 13. In Step 1 of the Examples, compounds 13-2b - 13-2k were synthesized according to the similar procedure as described in Step 1 of Example 59, and properties and spectral data thereof are shown in below table. And in Step 2 of the respective examples, amines were synthesized according to the similar procedure as described in Step 2 of Example 59, and the following Step 3 were proceeded using the obtained amine compounds which was not purified. In the Example 60 69, the final compounds 13-4b 134k were synthesized according to the similar procedure as described in Step 3 of Example 59 except that amines prepared by Step 2 were used, and properties and spectral data thereof are shown in below table. [0372]
    13-2b˜13-2k
    Figure US20030153596A1-20030814-C00117
    Examples-
    step Compounds RH Spectral data
    60-1 13-2b ethyl H NMR(300MHz, CDCl3): δ7.45(d, 1H, J=8.1Hz),
    6.98(dd, 1H, 8.1Hz), 6.92(d, 1H, 1.5Hz), 4.15(q,
    2H, J=6.8Hz), 1.46(t, 3H, J=7.1Hz), 1.30(s, 9H); MS
    (FAB) m/e 450[M+1]
    61-1 13-2c n-propyl 1H NMR(300MHz, CDCl3): δ7.45(d, 1H, J=8.3Hz),
    6.98(dd, H, J=1.7, 8.2Hz), 6.91(d, 1H, J=1.7Hz), 4.02
    (t, 2H, J=6.6Hz), 1.78-1.92(m, 2H), 1.30(s, 9H),
    1.07(t, 3H, 7.3Hz)
    62-1 13-2d n-butyl 1H NMR(300MHz, CDCl3): δ7.44(d, 1H, J=8.0Hz),
    6.98(dd, 1H, J=1.7, 8.0Hz), 6.92(d, 1H, J=1.5Hz),
    4.04(t, 2H, J=3.4Hz), 1.70-1.88(m, 2H), 1.40-1.62(m,
    2H), 1.30(s, 9H), 0.97(t, 3H, J=7.3Hz)
    63-1 13-2e n-pentyl 1H NMR(300MHz, CDCl3): δ7.44(d, 1H, J=8.0Hz),
    6.98(dd, 1H, J=1.7, 8.0Hz), 6.91(d, 1H, J=1.7Hz),
    4.05(t, 2H, J=6.6Hz), 1.84(m, 2H, J=6.8Hz),
    1.34-1.53(m, 4H), 1.30(s, 9H); 0.92(t, 3H, J=7.1Hz)
    64-1 13-2f isopropyl 1H NMR(300MHz, CDCl3): δ7.44(d, H, J=8.0Hz),
    6.97(dd, 1H, J=1.7, 8.0Hz), 6.94(d, 1H, J=1.7Hz),
    4.65(m, 1H, J=5.9Hz), 1.38(d, 6H, J=6.1Hz),
    1.29(s, 9H)
    65-1 13-2g isobutyl 1H NMR(300MHz, CDCl3): δ7.45(d, 1H, J=8.3Hz),
    6.8(dd, 1H, J=1.7, 8.0Hz), 6.90(d, 1H, J=1.5Hz), 3.81
    (d, 2H, J=6.4Hz, 2.08-2.20(m, 1H), 1.30(s, 9H),
    1.06(d, 6H, J=6.8Hz)
    66-1 13-2h neo-pentyl 1H NMR(300MHz, CDCl3): δ7.45(d, 1H, J=8.0Hz),
    6.98(dd, 1H, J=1.7, 8.0Hz), 6.89(d, 1H, 1.7Hz), 3.68
    (s, 2H), 1.30(s, 9H), 1.08(s, 9H)
    67-1 13-2i MOM 1H NMR(400MHz, CDCl3): δ7.51(d, 1H, J=8.1Hz),
    7.19(dd, 1H, J=1.5, 5.2Hz), 7.10(d, 1H, J=1.6Hz),
    5.31(s, 2H), 3.56(s, 3H), 1.34(s, 9H)
    68-1 13-2j methoxyet- 1H NMR(300MHz, CDCl3): δ7.45(d, 1H, J=7.8Hz),
    hoxymethyl 7.02(d, 1H, J=1.7Hz), 6.99(dd, 1H, J=1.7, 3.0Hz),
    4.23(t, 2H, J=4.6Hz), 3.80(t, 2H, J=4.5Hz), 3.47
    (s, 3H), 1.29(s, 9H)
    69-1 13-2k benzyl 1H NMR(300MHz, CDCl3): δ7.50-7.27(m, 6H),
    7.02(d, 1H, J=0.7Hz), 6.98(dd, 1H, J=1.7, 5.3Hz),
    5.21(s, 2H), 1.25(s, 9H), 3.47(s, 3H)
  • [0373]
    13-4b˜13-4k
    Figure US20030153596A1-20030814-C00118
    Examples-
    step Compounds RH Spectral data
    60-3 13-4b ethyl 1H NMR(300MHz, CDCl3): δ7.01-7.10(m, 5H), 6.91
    (d, 1H, J=7.6Hz), 6.77(s, 1H), 4.64(s, 2H), 4.42(s,
    2H), 3.87(q, 2H, J=7.1Hz), 2.94(s, 3H), 1.15-1.24
    (m, 12H); MS(FAB) m/e 450[M++1]
    61-3 13-4c n-propyl 1H NMR(300MHz, CDCl3): δ7.06(m, 5H), 6.95(dd,
    1H, J=1.7, 7.9Hz), 6.1(d, 1H, J=1.5Hz), 4.68(s, 2H),
    4.44(s, 2H), 3.80(t, 2H, J=6.6Hz), 2.98(s, 3H),
    1.52-1.74(m, 2H), 1.29(s, 9H), 0.95(t, 3H, J=7.6Hz);
    MS(FAB) m/e 464[M++1]
    62-3 13-4d n-butyl 1NMR(300MHz, CDCl3): δ7.08-7.33(m, 5H), 6.96
    (d, 1H, J=7.8Hz), 6.83(s, 1H), 4.68(s, 2H), 4.47(s,
    2H), 3.85(t, 2H, J=6.8Hz), 2.98(m, 3H), 1.39-1.80
    4H), 1.29(s, 9H), 0.91(t, 3H, J=7.3Hz); MS(FAB) m/e
    478[M++1]
    63-3 13-4e n-pentyl 1H NMR(300MHz, CDCl3): δ.05-7.35(m, 5H),
    6.75-7.00(m, 2H), 4.61(s, 2H), 2.96(s, 3H),
    1.55-1.70(m, 2H), 1.10-1.48(m, 13H), 0.92(t, 3H,
    J=7.1Hz); MS(FAB) m/e 492[M++1]
    64-3 13-4f isopropyl 1H NMR(300MHz, CDCl3): δ7.06-7.37(m, 5H),
    6.95(dd, H, J=1.7, 7.8Hz), 4.69(s, 2H), 4.33-4.60(m,
    3H), 2.97(s, 3H), 1.29(s, 9H), 1.23(d, 6H, J=6.1Hz);
    MS(FAB) m/e 464[M++1]
    65-3 13-4g isobutyl 1H NMR(300MHz, CDCl3): δ7.06-7.33(m, 5H),
    6.95(d, 1H, J=8.0Hz), 6.81(d, 1H, J=1.7Hz), 4.68(s,
    2H), 4.48(s, 2H), 3.62(d, 2H, J=6.3Hz), 2.98(s, 3H),
    1.30(s, 9H), 0.96(d, 6H, J=6.8Hz); MS(FAB)
    m/e 478[M++1]
    66-3 13-4h neo-pentyl 1H NMR(300MHz, CDCl3): δ7.04-7.21(m, 5H),
    6.95(d, 1H, J=1.8Hz), 6.82(d, 1H, J=1.7Hz), 4.68(s,
    2H), 4.53(s, 2H), 3.54(s, 2H), 2.97(s, 3H), 1.30(s,
    9H), 0.99(s, 9H); MS(FAB) m/e
    492[M++1]
    67-3 13-4i MOM 1H NMR(300MHz, CDCl3): δ6.96-7.30(m, 7H), 5.06
    (s, 2H), 4.66(s, 2H), 4.51(s, 2H), 3.39(s, 3H), 2.98
    (s, 3H), 1.28(s, 9H); MS(FAB) m/e 466[M++1]
    68-3 13-4j methoxy- 1H NMR(300MHz, CDCl3): δ7.10-7.37(m, 5H),
    ethoxy- 6.98(d, 1H, J=7.8Hz), 6.85(s, 1H), 4.68(s, 2H), 4.61(s,
    methyl 2H), 4.00-4.15(m, 2H), 3.60-3.75(m, 2H), 3.30(s,
    3H), 2.97(s, 3H), 1.28(s, 9H); MS(FAB) m/e 480
    [M++1]
    69-3 13-4k benzyl 1H NMR(400MHz, CDCl3): δ7.50-6.95(m, 12H),
    5.01(s, 2H), 4.68-4.40(m, 4H), 3.00(s, 3H), 1.33
    (s, 9H); MS(FAB) m/e 512[M++1]
    Figure US20030153596A1-20030814-C00119
    Figure US20030153596A1-20030814-C00120
    Figure US20030153596A1-20030814-C00121
    Figure US20030153596A1-20030814-C00122
    Figure US20030153596A1-20030814-C00123
    Figure US20030153596A1-20030814-C00124
    Figure US20030153596A1-20030814-C00125
    Figure US20030153596A1-20030814-C00126
    Figure US20030153596A1-20030814-C00127
    Figure US20030153596A1-20030814-C00128
    • EXAMPLE 70
  • Synthesis of 1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzene)thiourea (13-9a) [0374]
    Figure US20030153596A1-20030814-C00129
  • Step 1: Synthesis of 4-t-butyl-2-trifluoromethanesulfonyloxybenzonitile (13-5) [0375]
  • 4-t-butyl-2-hydroxybenzonitrile (800 mg) was dissolved in dichloromethane [0376]
  • (16 ml) and cooled to 0° C. To the solution were added triethylamine (663 Yu) and trifluoromethanesulfonic anhydride (764 μl) in order, followed by stiring for 1 hour. The reaction solution was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl aceate=10/1) to yield the compound 13-5 (1.30 g, 93%). [0377]
  • [0378] 1H NMR(300 MHz, CDCl3): δ7.67(d, 1H, J=8.OHz), 7.49(dd, 1H, J=1.7, 8.3 Hz), 7.43(d, 1H, J=1.5 Hz), 1.34(s, 9H)
  • Step 2: Synthesis of methyl 5-t-butyl-2-cyanobenzoate (13-6) [0379]
  • The compound 13-5 (1.30 g) prepared according to the same procedure as described in Step 1 was mixed with palladium acetate (28 mg) and 1,1′-bis(diphenylphosphino)ferrocene (141 mg), and the atmosphere of the reactor was brought into an atmosphere of carbon monoxide. To the mixture was added dimethylsulfoxide (25 ml) to dissolve the mixture. To the solution was added triethylamine (1.77 ml) and methanol (3.42 ml) successively with stirring and the mixture was stirred at 50° C. for 4 hours. The resulting mixture was filtered to remove the catalyst and the filtrate was evaporated under reduced prssure. The obtained residue was purified by column-cbromatography (hexane/ethyl acetate=20/1) to yield the compound 13-6 (400 mg, 44%). [0380]
  • [0381] 1H NMR(300 MHz, CDCl3): δ8.13(d, 1H, J=2.0 Hz), 7.72(d, 1H, J=8.1 Hz), 7.64(dd, 1H, J=2.2, 8.2 Hz), 3.99(s, 3H), 1.34(s, 9H)
  • Step 3: Synthesis of (2-aminomethyl-5-t-butylphenyl)methanol (13-7) [0382]
  • Lithium aluminium hydride (105 mg) was supended in ether (3 ml) and the suspension was cooled to 0° C. To the suspension was added dropwise a solution of the compound 13-6 (140 mg) prepared by Step 2 in ether (4 ml) and the mixture was refluxed for 2 hours. After the completion of the reaction, the reaction mixture was basified with 5 N aqueous sodium hydroxide solution, followed by adding aqueous Rochel solution thereto and then stirring for 1 hour. Then, the resulting mixture was extracted with ether (50 ml×3) and concentrated under reduced pressure to yield the compound 13-7 (320 mg, 90%). The following Step 4 was proceeded using the compound 13-7 which was not purified [0383]
  • Step 4: Synthesis of 1-(4-t-butyl-2-hydroxymethylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea (13-8) [0384]
  • The compound 13-7a (320 mg) prepared according to the same procedure as described in Step 3 was dissolved in dichloromethane (7 ml) and to the solution were added triethylamine (231 μl) and 4-methanesulfonaminobenzylisothiocyanate (401 mg) successively, followed by stirring at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate=1/1) to yield the compound 13-8 (460 mg, 64%). [0385]
  • [0386] 1H NMR(300 MHz, CDCl3): δ7.38-7.00 (m, 7H), 4.75-4.60(m, 4H), 4.50(s, 2H), 2.92(s, 3H), 1.25(s, 9H)
  • Step 5: Synthesis of 1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaninobenzenc)thiourea (13-9a) [0387]
  • 1,3-Dicyclohexylcarbodiimide (68 mg) was dissolved in dichloromethane (1 ml), and the solution was stirred and cooled to 0° C. To the solution were added dropwise a mixed solution of the compound 13-8 (130 mg) prepared according to the same procedure as described in Step 4 and 4-(dimethylamino)pyridine (4 mg) in dichloromethane (3 ml), followed by adding acetic acid (34 μl) thereto. The mixture was stirred at room temperature for 12 hours and concentrated under reduced pressure. The obtained residue was purified by column-chromatograpohy (hexane/ethyl acetate 3/2) to yield the compound 13-9a (52 mg, 37%). [0388]
  • [0389] 1H NMR(300 MHz, CDCl3) δ7.40-7.06(m, 7H), 5.10(s, 2H), 4.68(s, 4H), 2.30(s, 3H1), 2.01(s, 3H), 1.30(s, 9H); MS (FAB) m/e 478 [MW+1]
    • EXAMPLE 71
  • Synthesis of 1-(2-trimethylacetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzene) thiourea (13-9b) [0390]
    Figure US20030153596A1-20030814-C00130
  • Compound 13-9b (110 mg, 71%) was synthesized by reacting compound 13-8 (130 mg) with trimethylacetic acid (45 mg) according to the similar procedure as described in Step 5 of Example 70. [0391]
  • [0392] 1H NMR(300 MHz, CDCl3): δ7.43-7.07(m, 7R), 5.10(s, 2H), 4.72(s, 2H), 4.66(s, 2H), 2.97(s, 3H), 1.29(s, 9H), 1.12(s, 9); MS (FAB) ni/e 520 [M+1]
    • EXAMPLE 72
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylthiobenzyl)thiourea (14-3) [0393]
    Figure US20030153596A1-20030814-C00131
  • Step 1: Synthesis of 2-(4-methylthiobenzyl)isoindol-1,3-dione (14-1) [0394]
  • (4-methyltliio)benzylalcohol (1.54 g) was dissolved in anhydrous tetrahydrofuran (10 ml) and to the solution were added phthalimide (1.47 g) and triphenylphosphine (2.62 g). To the mixture was slowly added dropwise a solution of diisopropylazodicarboxylate CHAD) (2.02 g) in anhydrous tetrahydrofuran (4 ml), while the mixture was stirred at room temperature. After 18 hours, the reaction mixture was concentrated and the residue was purified by column-chromatography (hexane/etlhyl acetate=5/1) to yield a white solid (2.00 g, 71%). [0395]
  • [0396] 1H NMR(300 MHz, CDCl3): δ 7.86-7.68(m, 4H), 7.38-7.35(m, 2H), 7.22-7.18(m, 2H), 4.79(s, 2H), 2.44(s, 3H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylthiobenzyl)thiourea (14-3) [0397]
  • 2-(4-methylthiobenzyl)isoindol-1,3-dione (14-1) (1.67 g) was dissolved in ethanol (10 ml) and to the solution was added hydrazine hydrate (300 mg), followed by refluxing. After 24 hours, the resulting mixture was diluted with dichloromethane (50 ml) and washed with 2 N hydrochloric acid solution. An organic layer was washed with aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, concentrated under reduced pressure. The residue was purified by colunin-chromatography to obtain a liquid (0.8 g). The obtained liquid mixture (400 mg) was dissolved in dichloromethane (20 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (0.54 g), followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated and the residue was purified by column-chromatography (dichloromethane) to yield the compound 14-3 (0.52 g, 56%) as a white solid. [0398]
  • 1H NMR(300 MHz, CDCl[0399] 3): δ 7.37-7.15(m, 8H1), 6.00(brs, 2H), 4.60-4.50(m, 4H), 2.47(s, 3H), 1.31(s, 9H)
    • EXAMPLE 73
  • Synthesis of 1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea (14-6) 14-6) [0400]
    Figure US20030153596A1-20030814-C00132
  • Step 1: Synthesis of 5-(2-methylsulfonyloxyethyl)-4-methylthiazole [0401]
  • 2-(4-methylthiazol-5-yl)ethanol (5.01 g) was dissolved in dichloromethane (100 ml) and to the solution was added triethylamine (5.06 g), followed by adjusting the temperature of reactor to 0° C. To the obtained solution was added dropwise methanesulfonyl chloride (4.58 g), and the mixture was stirred for 21 hours while allowed to warm up to room temperature. The reaction solution was washed with water, concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate {fraction (1/3)}) to yield 5-(2-methylsulfonyloxyethyl)-4-methylthiazolei (5.18 g, 67%) as a pale yellow liquid. [0402]
  • [0403] 1H NMR(300 MHz, CDCl3): δ 8.63(s, 1H), 4.37(t, 3H, J=6 Hz), 3.23(t, 3H, J=6 Hz), 2.97(s, 3H), 2.43(s, 311)
  • Step 2: Synthesis of 2-[2-(4-methylthiazol-5-yl)ethyl]isoindol-1,3-dione (14-4) [0404]
  • 5-(2-methylsulfonyloxyethyl)-4-methylthiazole (4.17 g) was dissolved in dimethylformamide (20 ml) and to the solution was added potassium phthalimide (3.84 g), followed by stirring at 70° C. for 5 hours. The mixture was concentrated under reduced pressure and water was added thereto to form precipitate. The resulting mixture was filtered to collect the precipitate. The obtained precipitate was dissolved in dichloromethane. The solution was dried over anhydrous magnesium sulfate, concentrated, and then crystallized (dichloromethane/petroleum ether) to yield the compound 14-4 (3.77 g, 74%) as a pale yellow solid. [0405]
  • [0406] 1H NMR(300 MHz, CDCl3): δ 8.57(s, 1H), 7.86-7.70(m, 4H), 3.91(t, 3H, 3 Hz), 3.18(t, 3H, J=6 Hz), 2.38(s, 3H)
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-[2-(4-methylthiazol-5-yl)ethyl]thiourea (14-6) [0407]
  • 2-[2-(4-methylthiazol-5-yl)ethyl]isoindol-1,3-dione (3 g) was dissolved in a mixture of methanol (10 ml) and tetrahydrofaran (10 ml) and to the solution was added dropwise hydrazine hydrate (610 mg), followed by stirring for 20 hours. To the obtained solution was added 2 N aqueous hydrochloric acid solution (6 ml), and the mixture was stirred for 3 hours and concentrated under reduced pressure to obtain reaction mixture (3.5 g) as a yellow solid. The obtained mixture (140 mg) was dissolved in dimethylformamide (5 ml) and to the solution were added 4-t-butylbenzylisothiocyanate (0.2 g) and a small amount of triethylamine, followed by stirring at room temperature for 21 hours. The resulting mixture was diluted with dichloromethane, washed with water, dried, concentrated under reduced pressure, and then purified by colurn-chromatography (hexane/ethyl acetate=1/1) to yield the compound 14-6 (0.07 g) as a liquid. [0408]
  • [0409] 1H NMR(300MFz, CDCl3): δ 8.53(s,l1H), 7.38-7.18(m, 4H), 6.25(brs, 1H), 5.77(brs, 1H), 4.49(s,2H), 3.78-3.73(m, 2H), 3.08(t, 2H, J=6 Hz), 2.36(s, 3H), 1.31(s, 9H)
    • EXAMPLE 74
  • Synthesis of 1-(4t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea (14-9) [0410]
    Figure US20030153596A1-20030814-C00133
  • Step 1: Synthesis of ((2-chloro-5-pyridinyl)methyl)isoindol-1 ,3-dione (14-7) [0411]
  • 2-chloro-5-chloromethylpyridine (5 g) was dissolved in dimethylformamide (60 ml) and to the solution was added phthalimide (6.29 g), followed by stirring at room temperature for 17 hours. The solvent of the reaction solution was removed under reduced pressure and the residue was extracted with water and dichloromethane to yield a white solid (6.2 g, 74%). 1H NMR(300 MHz, CDCl[0412] 3): δ 8.50-8.49(m, 1H), 7.88-7.72(m, 5H), 7.30-7.26(m, 1H), 4.83(s, 2H), 2.44(s, 3H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea (14-9) [0413]
  • ((2-chloro-5-pyridinyl)methyl)isoindol-1,3-dione (4.7 g) was dissolved in methanol (100 ml) and to the solution was added hydrazine hydrate (7.7 ml), followed by stirring at room temperature for 2 hours. The reaction slolution was extracted with water and dichloromethane and concentrated under reduced pressure to obtain a liquid (1.4 g). The obtained liquid mixture (66 mg) was dissolved in dichloromethane (5 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (95 mg), followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated and purified by coliun-chromatography (hexane/etlhyl acetate=2/1) to yield the compound 14-9 (45 mg, 28%/0) as a white solid. [0414]
  • [0415] 1H NMR(30OMffz, CDCl3): δ 8.16-8.15(m, 1H), 7.61-7.57(m, 1H), 7.38-7.18(m, 4H), 6.48(brs, 2H), 6.21(brs, 2H), 4.74(d, 2H, J=5.7 Hz), 4.54(d,2H, J=4.5 Hz), 1.29(s, 9H)
    • EXAMPLE 75
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2-(thiomorpholin-4-yl)ethyl)thiourea (15-3) [0416]
    Figure US20030153596A1-20030814-C00134
  • Step 1: Synthesis of 2-(2-thiomorpholin-4-yl)ethyl)isoindol-1,3-dione (15-1) [0417]
  • Thiomorpholine (3.75 g) was dissolved in acetone (100 ml) and to the solution were added anhydrous potassium carbonate (5.52 g) and 2-(bromoethyl)phthalimide (9.22 g), followed by refluxing for 26 hours. The obtained mixture was filtered, concentrated, and then dissolved in dichloromethane. The solution was washed with water, dried, concentrated under reduced pressrure, and then purified by colurnn-chromatography (hexane/ethyl acetate=1/1) to yield the compound 15-1 (2 g, 20%) as a yellow solid. [0418]
  • [0419] 1H NMR(300 MHz, CDCl3): δ 7.87-7.70(m, 4H), 3.80(t, 2H, J=6.6 Hz), 2.79-2.57(m, 1OH)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(2-(thiomorpholin-4-yl)ethyl)thiourea (15-3) [0420]
  • 2-(2-thiomorpholin-4-ylethyl)isoindol-1,3-dione 15-1 (2.76 g) was dissolved in a mixture of methanol (20 ml) and tetrahydrofaran (20 ml) and to the solution was added dropwise hydrazine hydrate (550 mg), followed by stirring for 21 hours. To the obtained solution was added 2 N aqueous hydrochloric acid solution (6 ml), and the mixture was stirred for 3 hours and then concentrated under reduced pressure. To the concentrate was added water (15 ml) and the undissolved material was filtered off. [0421]
  • The filtrate was concentrated to obtain reaction mixture (1.62 g) as a solid. The obtained mixture (150 mg) was dissolved in dimethylformamide (5 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (210 mg) and a small amount of triethylamine, followed by stirring at room temperature for 23 hours. The resulting mixture was diluted with dichloromethane, washed with water, and concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate={fraction (1/3)}) to the compound 15-3 (0.12 g) as awhite solid. [0422]
  • [0423] 1H NMR(300 MHz, CDCl3): δ 7.42-7.26(m, 4H), 6.32(brs, 1H), 4.60(s,2H), 3.40(s, 2H1), 2.62-2.20(m, 10H), 1.32(s, 9H)
    • EXAMPLE 76
  • Synthesis of 1-(furan-2-ylmethyl)-3-(4-methoxybenzyl)thiourea (16-1) [0424]
    Figure US20030153596A1-20030814-C00135
  • Furan-2-ylmethylamine (190 mg) was dissolved in dimethylformamide (5 ml) and to the solution were added triethylamine (200 mg) and 4-methoxybenzylisothiocyanate (360 mg), followed by stirring at room temperature for 24 hours. Then, the resulting mixture was diluted with ethyl acetate, washed with water, dried, and concentrated under reduced pressure. The residue was purified by column-chrornatography (hexane/ethyl acetate=1/1) to yield the compound 16-1 (0.5 g, 90%) as a liquid. [0425]
  • [0426] 1H NMR(300 MHz, CDCl3): δ 7.33-7.32(m, 1H), 7.23-7.19(m, 2H), 6.89-6.85(m, 211), 6.32-6.23(m, 2H), 6.20(brs,1H), 6.05(brs,1H), 4.67-4.64(m, 2H), 4.55-4.53(m, 2H), 3.80(s, 3H)
    • EXAMPLE 77
  • Synthesis of 1-(4-t-butylbenzyl)-3-(furan-2-ylmethyl)thiourea (16-2) [0427]
    Figure US20030153596A1-20030814-C00136
  • Furan-2-yhnethylamine (0.58 g) was dissolved in dichloromethane (50 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (1.23 g), followed by stirring at room temperature for 8 hours. Then, the resulting mixture was diluted with ethyl acetate, washed with water, dried, and concentrated under reduced pressure. The residue was purified by columin-chromatography (dichloromethane) to yield the compound 16-2 (1.57 g, 87%) as a liquid. [0428]
  • [0429] 1H NMR(300 MHz, CDCl3): δ 7.37-7.20(m, 5H), 6.31-6.29(m, 1H), 6.21-6.19(m, 1H), 6.10(brs,1H), 4.65-4.63(m, 2H), 4.58-4.50(m, 2M), 1.30(s, 9H)
    • EXAMPLE 78˜EXAMPLE 121
  • Compounds of Example 78 Example 121 are shown in the Scheme 16. The compounds were syntesized according to the similar procedure as described in Example 76 or Example 77, and properties and spectral data are shown in below table. [0430]
    Figure US20030153596A1-20030814-C00137
    Figure US20030153596A1-20030814-C00138
    Figure US20030153596A1-20030814-C00139
    Examples Compounds R = Types Spectral data
    78 16-3
    Figure US20030153596A1-20030814-C00140
         		B 1H NMR(300MHz, CDCl3): δ 7.34-7.18(m, 6H), 6.31-6.28(m, 1H), 6.21-6.20(m, 1H), 5.92(brs, 2H), 4.60-4.50(m, 2H), 3.75-3.65(m, 2H), 2.91(t, 2H, J=6.6Hz)
    79 16-4
    Figure US20030153596A1-20030814-C00141
         		A 1H NMR(300MHz, CDCl3): δ 8.41-8.39(m, 1H), 7.70-7.64(m, 1H), 7.38-7.17(m, 6H), 4.73(m, 2H), 4.64(m, 2H), 1.31(s, 9H)
    80 16-5
    Figure US20030153596A1-20030814-C00142
         		B 1H NMR(300MHz, CDCl3): δ 8.41-8.38(m, 1H), 7.72-7.66(m, 1H), 7.34-7.05(m, 9H), 4.69(m, 2H), 3.77(m, 2H), 2.96(t, 2H, J=6.9Hz)
    81 16-6
    Figure US20030153596A1-20030814-C00143
         		A 1H NMR(300MHz, CDCl3): δ 8.52-8.48(m, 2H), 7.63-7.59(m, 1H), 7.39-7.35(m, 2H), 7.24-7.20(m, 3H), 6.22(brs, 1H), 5.95(brs, 1H), 4.79-4.76(m, 2H), 4.57-4.55(m, 2H), 1.31(s, 9H)
    82 16-7
    Figure US20030153596A1-20030814-C00144
         		A 1H NMR(300MHz, CDCl3): δ 8.51-8.49(m, 2H), 7.40-7.37(m, 2H), 7.25-7.21(m, 2H), 7.10-7.07(m, 2H), 6.30(brs, 1H), 6.00(brs, 1H), 4.80-4.77(m, 2H), 4.58-4.56(m, 2H), 1.31(s, 9H)
    83 16-8
    Figure US20030153596A1-20030814-C00145
         		A 1H NMR(300MHz, CDCl3): δ 8.16-8.14(m, 1H), 7.62-7.55(m, 1H), 7.37-7.22(m, 4H), 7.16-7.05(m, 2H), 4.54(m, 2H), 3.91(m, 2H), 3.04(t, 2H, J=6Hz), 1.32(s, 9H)
    84 16-9
    Figure US20030153596A1-20030814-C00146
         		B 1H NMR(300MHz, CDCl3): δ 8.41-8.38(m, 1H), 7.66-7.60(m, 1H), 7.33-7.13(m, 7H), 6.31(br, 2H), 3.87(m, 2H), 3.66(m, 2H), 3.04(t, 2H, J=6Hz), 2.92(t, 2H, J=6.9Hz),
    85 16-10
    Figure US20030153596A1-20030814-C00147
         		A 1H NMR(300MHz, CDCl3): δ 7.37-7.19(m, 6H), 7.12-6.99(m, 2H), 6.11(brs, 1H), 6.01(brs, 1H), 4.75-4.73(m, 2H), 4.57-4.55(m, 2H), 1.31(s, 9H)
    Figure US20030153596A1-20030814-C00148
    Figure US20030153596A1-20030814-C00149
    Figure US20030153596A1-20030814-C00150
    Figure US20030153596A1-20030814-C00151
    Figure US20030153596A1-20030814-C00152
    Figure US20030153596A1-20030814-C00153
    Figure US20030153596A1-20030814-C00154
    Figure US20030153596A1-20030814-C00155
  • [0431]
    Examples Compounds R = Types Spectral data
    86 16-11
    Figure US20030153596A1-20030814-C00156
         		A 1H NMR(300MHz, CDCl3): δ 7.38-6.88(m, 8H), 6.14(brs, 1H), 5.96(brs, 1H), 4.70-4.67(m, 2H), 4.57-4.55(m, 2H), 1.31(s, 9H)
    87 16-12
    Figure US20030153596A1-20030814-C00157
         		A 1H NMR(300MHz, CDCl3): δ 7.37-7.33(m, 2H), 7.20-7.16(m, 4H), 7.01-6.95(m, 2H), 6.07(brs, 1H), 6.00(brs, 1H), 4.63-4.54(m, 4H), 1.31(s, 9H)
    88 16-13
    Figure US20030153596A1-20030814-C00158
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.23-7.19(m, 2H), 7.10-6.90(m, 4H), 6.08(brs, 1H), 5.85(brs, 1H), 4.69-4.66(m, 2H), 4.56-4.53(m, 2H), 1.31(s, 9H)
    89 16-14
    Figure US20030153596A1-20030814-C00159
         		A 1H NMR(300MHz, CDCl3): δ 7.40-7.37(m, 2H), 7.24-7.21(m, 3H), 6.73-6.66(m, 2H), 6.24(brs, 1H), 5.90(brs, 1H), 4.74-4.71(m, 2H), 4.56-4.54(m, 2H), 1.31(s, 9H)
    90 16-15
    Figure US20030153596A1-20030814-C00160
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.36(m, 2H), 7.24-7.22(m, 2H), 7.02-6.94(m, 3H), 6.16(brs, 1H), 5.92(brs, 1H), 4.78-4.76(m, 2H), 4.56-4.54(m, 2H), 1.31(s, 9H)
    91 16-16
    Figure US20030153596A1-20030814-C00161
         		A 1H NMR(300MHz, CDCl3): δ 7.38-7.20(m, 5H), 6.90-6.74(m, 2H), 6.10(brs, 1H), 5.91(brs, 1H), 4.75-4.72(m, 2H), 4.55-4.50(m, 2H), 1.31(s, 9H)
    92 16-17
    Figure US20030153596A1-20030814-C00162
         		A 1H NMR(300MHz, CDCl3): δ 7.38-7.34(m, 2H), 7.27-7.20(m, 3H), 6.91-6.85(m, 2H), 6.05(brs, 1H), 6.02(brs, 1H), 4.71-4.70(m, 2H), 4.61-4.60(m, 2H), 1.31(s, 9H)
    Figure US20030153596A1-20030814-C00163
    Figure US20030153596A1-20030814-C00164
    Figure US20030153596A1-20030814-C00165
    Figure US20030153596A1-20030814-C00166
    Figure US20030153596A1-20030814-C00167
    Figure US20030153596A1-20030814-C00168
    Figure US20030153596A1-20030814-C00169
  • [0432]
    Examples Compounds R = Types Spectral data
    93 16-18
    Figure US20030153596A1-20030814-C00170
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.25-7.20(m, 3H), 7.15-7.05(m, 1H), 6.95-6.85(m, 1H), 6.16(brs, 1H), 5.88(brs, 1H), 4.80-4.78(m, 2H), 4.53-4.51(m, 2H), 1.31(s, 9H)
    94 16-19
    Figure US20030153596A1-20030814-C00171
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.25-7.06(m, 3H), 6.86-6.78(m, 1H), 6.14(brs, 1H), 5.95(brs, 1H), 4.79-4.76(m, 2H), 4.56-4.50(m, 2H), 1.31(s, 9H)
    95 16-20
    Figure US20030153596A1-20030814-C00172
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.26-6.98(m, 6H), 5.97(brs, 1H), 5.68(brs, 1H), 4.51-4.49(m, 2H), 3.75-3.74(m, 2H), 2.94(t, 2H, J=6.6Hz), 1.32(s, 9H)
    96 16-21
    Figure US20030153596A1-20030814-C00173
         		A 1H NMR(300MHz, CDCl3): δ 7.38-7.19(m, 6H), 6.92-6.84(m, 2H), 6.03(brs, 1H), 5.59(brs, 1H), 4.46(m, 2H), 3.78(m, 2H), 2.89(t, 2H, J=6.6Hz), 1.32(s, 9H)
    97 16-22
    Figure US20030153596A1-20030814-C00174
         		A 1H NMR(300MHz, CDCl3): δ 7.38-6.92(m, 8H), 5.94(brs, 1H), 5.58(brs, 1H), 4.46(m, 2H), 3.73(m, 2H), 2.85(t, 2H, J=6Hz), 1.32(s, 9H)
    98 16-23
    Figure US20030153596A1-20030814-C00175
         		A 1H NMR(300MHz, CDCl3): δ 7.40-7.35(m, 2H), 7.19-7.16(m, 2H), 7.10-6.83(m, 3H), 6.08(brs, 1H), 5.58(brs, 1H), 4.47-4.44(m, 2H), 3.77-3.70(m, 2H), 2.84(t, 2H, J=6.9Hz), 1.31(s, 9H)
    Figure US20030153596A1-20030814-C00176
    Figure US20030153596A1-20030814-C00177
    Figure US20030153596A1-20030814-C00178
    Figure US20030153596A1-20030814-C00179
    Figure US20030153596A1-20030814-C00180
    Figure US20030153596A1-20030814-C00181
  • [0433]
    Examples Compounds R = Types Spectral data
    99 16-24
    Figure US20030153596A1-20030814-C00182
         		A 1H NMR(300MHz, CDCl3): δ 7.38-7.34(m, 2H). 7.19-7.16(m, 2H), 7.08-7.04(m, 2H), 6.84-6.80(m, 2H), 5.90(brs, 1H), 5.62(brs. 1H), 4.48-4.46(m, 2H), 3.79(s, 3H), 3.70-3.68(m, 2H), 2.81(t, 2H, J=6.6Hz), 1.31(s, 9H)
    100 16-25
    Figure US20030153596A1-20030814-C00183
         		A 1H NMR(300MHz, CDCl3): δ 7.37-7.33(m, 2H), 7.22-7.15(m, 3H), 6.79-6.71(m, 3H), 5.93(brs, 1H), 5.64(brs, 1H). 4.47-4.45(m, 2H), 3.79(s, 3H), 3.78-3.72(m, 2H). 2.85(t, 2H, J=6.6Hz), 1.31(s, 9H)
    101 16-26
    Figure US20030153596A1-20030814-C00184
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.25-7.18(m, 3H), 7.10-7.07(m. 1H), 6.92-6.87(m, 1H), 6.82-6.79(m, 1H). 6.23(brs, 1H), 6.04(brs, 1H), 4.60-4.59(m, 2H), 3.61(s, 3H), 3.61-3.50(m, 2H), 2.89(t, 2H, J=6.9Hz), 1.32 (s, 9H)
    102 16-27
    Figure US20030153596A1-20030814-C00185
         		A 1H NMR(300MHz, CDCl3): δ 7.36-7.33(m, 2H), 7.18-7.15(m, 2H), 6.79-6.75(m, 1H), 6.69-6.66(m, 2H), 6.03(brs, 1H), 5.77(brs, 1H), 4.48-4.46(m, 2H), 3.84(s, 3H), 3.83(s, 3H), 3.72-3.70(m, 2H), 2.81(t, 2H, J=6.9Hz), 1.30(s, 9H)
    103 16-28
    Figure US20030153596A1-20030814-C00186
         		A 1H NMR(300MHz, CDCl3): δ 7.37-7.33(m, 2H), 7.20-7.17(m, 2H), 6.48(s, 2H), 6.00(brs, 2H), 4.60-4.55(m, 4H), 3.82-3.79(m, 9H), 1.30(s, 9H)
    Figure US20030153596A1-20030814-C00187
    Figure US20030153596A1-20030814-C00188
    Figure US20030153596A1-20030814-C00189
    Figure US20030153596A1-20030814-C00190
    Figure US20030153596A1-20030814-C00191
  • [0434]
    Examples Compounds R = Types Spectral deta
    104 16-29
    Figure US20030153596A1-20030814-C00192
         		A 1H NMR(300MHz, CDCl3): δ 7.83-7.79(m, 2H), 7.39-7.18(m, 6H), 6.13(brs, 1H), 5.71(brs, 1H), 4.85(s, 2H), 4.50(m, 2H), 3.80-3.75(m, 2H), 2.97(t, 2H, J=7.2Hz), 1.31(s, 9H)
    105 16-30
    Figure US20030153596A1-20030814-C00193
         		A 1H NMR(300MHz, CDCl3): δ 7.40-7.35(m, 2H), 7.20-7.16(m, 2H), 6.78-6.75(m, 1H), 6.66-6.65(m, 1H), 6.58-6.54(m, 1H), 5.94(brs, 1H), 5.67(brs, 1H), 4.48-4.46(m, 2H), 3.65-3.64(m, 2H), 2.74(t, 2H, J=6.6Hz), 1.31(s, 9H)
    106 16-31
    Figure US20030153596A1-20030814-C00194
         		C 1H NMR(300MHz, CDCl3): δ 7.56(brs, 1H), 7.41-7.25(m, 4H), 6.63(brs, 1H), 4.86(d, 2H, J=6Hz), 3.90-3.86(m, 2H), 3.63-3.55(m, 2H), 2.98-2.93(m, 2H), 2.67-2.60(m, 2H), 1.33(s, 9H)
    107 16-32
    Figure US20030153596A1-20030814-C00195
         		A 1H NMR(300MHz, CDCl3): δ 7.29-7.32 (m, 2H), 7.21(d, 2H, J=8.0Hz), 6.39(brs, 1H), 4.55(brs, 2H), 2.86-2.94(m, 6H), 2.42(t, 2H, J=5.4Hz), 2.29(t, 2H, J=4.7Hz), 1.24(s, 9H)
    108 16-33
    Figure US20030153596A1-20030814-C00196
         		B 1H NMR(300MHz, CDCl3): δ 7.34-7.20(m, 5H), 6.29(s, 1H), 3.80-3.70(m, 2H), 3.60-3.50(m, 4H), 3.40-3.30(m, 2H), 2.96(t, 2H, J=6.9Hz), 2.51-2.35(m, 6H)
    109 16-34
    Figure US20030153596A1-20030814-C00197
         		A 1H NMR(300MHz, CDCl3): δ 7.40-7.26(m, 4H), 6.40(brs, 1H), 4.63(m, 2H), 3.50-3.30(m, 6H), 2.52-2.36(m, 6H), 1.31(s, 9H)
    110 16-35
    Figure US20030153596A1-20030814-C00198
         		A 1H NMR(300MHz, CDCl3): δ 7.37-7.26(m, 4H), 6.40(brs, 1H), 4.68(m, 2H), 3.34(m, 2H), 2.42(t, 2H, J=5.1Hz), 2.30(m, 4H), 1.60(m, 2H), 1.30(s, 9H), 1.29-1.09(m, 4H)
    111 16-36
    Figure US20030153596A1-20030814-C00199
         		A 1H NMR(300MHz, CD3OD): δ 7.57(d, 1H, J=1.0Hz), 7.32-7.36(m, 2H), 7.21(d, 1H, J=8.6Hz), 4.63(brs, 2H), 3.72(brs, 2H), 2.83(t, 2H, J=7.1Hz), 1.29(s, 9H)
    112 16-37
    Figure US20030153596A1-20030814-C00200
         		A 1H NMR(300MHz, CDCl3): δ 7.97(brs, 1H), 7.59-7.56(m, 1H), 7.38-7.09(m, 8H), 6.96(brs, 1H), 5.85(brs, 1H), 5.72(brs, 1H), 4.40(m, 2H), 3.79(m, 2H), 3.04(t, 2H, J=6.6Hz), 1.30(s, 9H)
    Figure US20030153596A1-20030814-C00201
    Figure US20030153596A1-20030814-C00202
    Figure US20030153596A1-20030814-C00203
    Figure US20030153596A1-20030814-C00204
    Figure US20030153596A1-20030814-C00205
    Figure US20030153596A1-20030814-C00206
    Figure US20030153596A1-20030814-C00207
    Figure US20030153596A1-20030814-C00208
    Figure US20030153596A1-20030814-C00209
  • [0435]
    Examples Compounds R = Types Spectral deta
    113 16-38
    Figure US20030153596A1-20030814-C00210
         		B 1H NMR(300MHz, CDCl3): δ 8.03(brs, 1H), 7.60-7.05(m, 9H), 5.67(brs, 1H), 5.51(brs, 1H), 3.68(m, 2H), 3.54(m, 2H), 3.03(t, 2H, J=6.6Hz), 2.75(t, 2H, J=6.6Hz)
    114 16-39
    Figure US20030153596A1-20030814-C00211
         		A 1H NMR(300MHz, CDCl3): δ 7.52-7.15(m, 2.67(brs, 2H), 1.25(s, 3H)
    115 16-40
    Figure US20030153596A1-20030814-C00212
         		A 1H NMR(300MHz, CDCl3): δ 8.70(brs, 1H), 8.14-8.09(m, 1H), 7.38-7.20(m, 5H), 6.42-6.30(m, 2H), 5.91(brs, 1H), 4.58(m, 2H), 3.79-3.66(m, 4H), 1.30(s, 9H)
    116 16-41
    Figure US20030153596A1-20030814-C00213
         		A 1H-NMR(300MHz, CDCl3): δ 7.37-7.47 (m, 2H), 7.21-7.24(d, 2H, J=8.3Hz), 6.70-6.78 (m, 3H), 5.98(s, 2H), 4.57-4.60(br, 4H), 1.35 (s, 9H)
    117 16-42
    Figure US20030153596A1-20030814-C00214
         		A 1H-NMR(300MHz, acetone-d6,): δ 7.50(s, 1H), 7.32(dd, 2H, J=1.9, 6.3Hz), 7.22(d, 2H, J=8.5Hz), 7.05(s, 1H), 6.86(s, 1H), 4.66(brs, 2H), 4.01(t, 2H, J=7.1Hz), 3.50(t, 2H, J=6.6Hz), 1.99-2.08(m, 2H), 1.24(s, 9H)
    118 16-43
    Figure US20030153596A1-20030814-C00215
         		A 1H-NMR(300MHz, CDCl3): δ 7.32-7.35(m, 2H), 7.11-7.18(m, 3H), 6.88(dd, 1H, J=3.4, 5.1Hz), 6.74(d, 1H, J=2.9Hz), 6.09(brs, 1H), 5.75(brs, 1H), 4.44(brs, 2H), 4.08(t, 2H, J 7.3Hz), 3.07(t, 2H. J=6.6Hz), 1.29 (s, 9H)
    119 16-44
    Figure US20030153596A1-20030814-C00216
         		A 1H-NMR(300MHz, CDCl3): δ 7.36-7.39(m, 2H), 7.21-7.26(m, 3H), 6.94-6.96(m, 2H), 6.24(brs, 1H), 6.04(brs, 1H), 4.88(d, 2H, J=4.8Hz), 4.57(brs, 2H), 1.33(s, 9H)
    120 16-45
    Figure US20030153596A1-20030814-C00217
         		A 1H NMR(CDCl3) δ 7.37(m, 2H), 7.23(m, 2H), 4.45(bs, 2H), 3.50(m, 2H), 2.73(m, 2H), 2.50(bs, 1H), 2.21(s, 3H). 2.13(m, 1H), 1.88(m, 3H), 1.68(m, 4H), 1.30(s, 9H)
    Figure US20030153596A1-20030814-C00218
    Figure US20030153596A1-20030814-C00219
    Figure US20030153596A1-20030814-C00220
    Figure US20030153596A1-20030814-C00221
    Figure US20030153596A1-20030814-C00222
    Figure US20030153596A1-20030814-C00223
    Figure US20030153596A1-20030814-C00224
    Figure US20030153596A1-20030814-C00225
    • EXAMPLE 121
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2-pyridinyl)thiourea (16-46) [0436]
    Figure US20030153596A1-20030814-C00226
  • 2-aminopyridine (86 mg) was dissolved in acetonitrile (10 ml) and to the solution were added 4-t-butylbelizylisothiocyanate (190 mg) and triethylamine (140 μl), followed by refluxing for 27 hours. The resulting mixture was extracted with water and dichloromethane, dried, concentrated under reduced pressure, and then crystallized (dichloromethane/petroleum ether) to yield the compound (90 mg, 33%) as a white solid. [0437]
  • [0438] 1H NMR(300 MHz, CDCl3): δ 11.99(brs, 1H), 8.13-8.11(m, 1H), 7.67-7.61(m, 1H), 7.41-7.27(m, 4H), 6.96-6.92(m, 1H), 6.68-6.64(m, 1H), 4.99-4.96 (m, 21), 1.32(s, 9H)
    • EXAMPLE 122
  • Synthesis of 1-(4-t-butylbenzyl)-3-((2-hydroxy-1-methyl-2-phenyl)ethyl)thiourea (16-47) [0439]
    Figure US20030153596A1-20030814-C00227
  • Phenylpropanolamine hydrochloride (100 mg) was dissolved in dimethylformamide (5 ml) and to the solution was added triethylamine (80 μl), followed by stirring for 30 minutes. To the obtained reaction mixture was added t-butylbenzeneisothiocyanate (135 mg), and the mixture was stirred for 4 hours, diluted with water (20 ml), extracted with dichloromethane (30 ml×3), dried over magnesium sulfate, and then flitered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane={fraction (1/3)}) to yield the compound 16-47 (159 mg, 83.7%). [0440]
  • [0441] 1H NMR(300 MHz, CDCl3): δ7.32(m, 9H), 6.65(brs, 1H), 5.69(d, 1H, J=7.8 Hz), 4.92(s, 1H), 4.57(s, 2H), 2.66(s, 1H), 1.58(s, 1H), 1.31(s, 9H), 0.98(d, 3H, J=6.9 Hz)
    • EXAMPLE 123
  • Synthesis of 1-(4-t-butylbenzyl)-3-(1H-pyrro1-2-ylmethyl)thiourea (17-1) [0442]
    Figure US20030153596A1-20030814-C00228
  • Step 1: Synthesis of 1H-pyrro1-2-carboxaldehyde oxime [0443]
  • Pyrrole-3-carboxaldehyde (120.4 mg) was dissolved in methanol (4 ml) and to the solution were added hydroxylamine hydrochloride (106 mg) and sodium acetate (127 mg), followed by stirring for 1 hour. The resulting mixture was extracted with ethyl acetate, and then dried over anhydrous magnesium sulfate. The filtrate was concentrated under reduced pressure, and then column-chromatographed (ethyl acetate/hexane={fraction (1/3)}) to yield the compound (122 mg, 100 %). [0444]
  • [0445] 1H NMR(300 MHz, CD3OD): δ 7.19(s, 1H), 6.92 (t, 1H, J=2.1 Hz), 6.52 (q, 1H, J=3.7 Hz), 6.15 (q, 1H, J=3.7 Hz)
  • Step 2: Synthesis of (1H-pyrrol-2-yl)methylamine hydrochloride [0446]
  • 1H-pyrrol-2-carboxaldehyde oxime (60 mg) prepared according to the same procedure as described in Step 1 was dissolved in methanol (2 ml) and to the solution were added a catalytic amount of 10% palladium/carbon and concentrated hydrochloric acid (100 μl), followed by stirring at room temperature under hydrogen gas atmosphere for 1 hour. The resulting mixture was diluted with ether, and then filtered through celite. The filtrate was concentrated under reduced pressure to yield (1H-pyrrol-2-yl)methylarnine hydrochloride (60 mg, 100%). [0447]
  • [0448] 1H NMR(300 MHz, CD3OD): δ 6.78 (q, 1H, J=4.2 Hz), 6.23 (s, 1H), 6.10 (q, 1H, J=5.9 Hz), 4.08 (s, 2H)
  • Step 3: Sythesis of 1-(4-t-butylbenzyl)-3-(1H-pyrrol-2-ylmethyl)thiourea (17-1) [0449]
  • (1H-pyrrol-2-yl)methylamine hydrochloride (60 mg) prepared according to the same procedure as described in Step 2 was dissolved in dichloromethane (2 ml) and to the solution was added 4-t-butylbenzylisothiocyanate (155 mg), followed by stirring at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed (ethyl acetate/hexane={fraction (1/3)}) to yield the compound 17-1 (120 mg, 65%). [0450]
  • [0451] 1H-NMR(300 MHz, CD3OD): δ 7.23-7.35 (t, 2H, J=7.4 Hz), 7.18-7.21 (d, 2H, J=8.5 Hz), 6.65 (d, 1H, J=2.2 Hz), 5.97-5.98 (d, 2H, Jo 2.0 Hz), 4.61 (br, 4H), 1.29 (s, 9H)
    • EXAMPLE 124
  • Synthesis of 1-(4-t-butylbenzyl)-3-(1-methyl-1H-pyrrol-2-yl)methylthiourea (17-2) [0452]
    Figure US20030153596A1-20030814-C00229
  • Step 1: Synthesis of methyl-IH-pyrrol-2-carboxaldehyde oxime [0453]
  • Methyl-2-pyrrolecarboxaldehyde (5 g), hydroxylanine hydrochloride (9.55 g) and sodium acetate (11.28 g) were dissolved in methanol (100 ml) and the solution was refluxed for 12 hours. Afire confirmng the completion of the reaction using TLC, the resulting mixture was purified by colunm-chromatography (ethyl acetate/hexane=3/1) to yield the compound (5.01 g, 88%) as a brown solid. [0454]
  • [0455] 1H NMR (300 MHz, CDCl3): δ 7.40(s, 1H), 7.31(m, 1H), 6.70(m, 1H), 6.23(m, 1H), 3.74(s, 3H)
  • Step 2: Synthesis of (1-methyl-1H-pyrrol-2-yl)methylamine [0456]
  • Sodium borohydride (310 mg) was dried under vacuum and anhydrous tetrahydrofuran (30 ml) was added thereto through an injector, followed by adjusting the temperature down to −15° C. To the mixture at -15° C. was added a solution of methyl-1H-pyrrol-2-carboxaldehyde oxime (500 mg) and nickel (II) chloride hexahydrate (catalytic amount) in anhydrous methanol (30 ml) and the mixture was stirred, followed by stirring at room temperature for 12 hours. After confiring the completion of the reaction, the resulting mixture was filtered and the obtained brown oil was purified by column-chromatography (ethyl acetate) to yield (1-mehtyl-1H-pyrrol-2-yl)methylamine (275 mg, 62%) as solid. [0457]
  • 1H NMR (300 MHz, CDCl[0458] 3): δ 6.63(m, 1H), 6.11(m, 2H), 3.94(m, 2H), 3.72(brs, 2H), 3.64(s, 3H)
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(1-methyl-IH-pyrrol-2-yl)methylthiourea (17-2) [0459]
  • (1-methyl-1H-pyrrol-2-yl)rnethylarnine (65 mg) and 4-t-butylbenzylisothiocyanate (120 mg) were dissolved in ethyl acetate (30 ml) and the solution was stirred for 12 hours. After the completion of the reaction, the resulting mixture was purified by column-chromatography (ethyl acetate/hexane={fraction (1/3)}) to yield the compound 17-2 (140 mg, 75%) [0460]
  • [0461] 1H NMR (300 MHz, CDCl3): δ 7.36(m, 211), 7.19(m, 2H), 6.58(m, 1H), 6.18(brs, 1H), 6.01(m, 2H), 5.69(brs, 1H), 4.63(d, 2H, J=2.1 Hz), 4.52(d, 2H, J-2.4 Hz), 3.52(s, 3H), 1.31(s, 9H)
    • EXAMPLE 125
  • Synthesis of 1-(1-methyl-1H-pyrrol-2-ylmethyl)-3-phenethylthiourea (17-3) [0462]
    Figure US20030153596A1-20030814-C00230
  • (1-methyl-1H-pyrrol-2-yl)methylamine (65 mg) and (2-isothiocyanatoethyl)benzene (100 mg) were dissolved in ethyl acetate (20 ml) and the solution was stirred for 12 hours. After the completion of the reaction, the resulting mixture was purified by column-chromatography (ethyl acetate/hexane={fraction (1/3)}) to yield the compound 17-3 (97 mg, 60%) as a brown liquid. [0463]
  • [0464] 1H NMR (300 MHz, CDCl3): δ 7.25(m, 5H), 6.60(m, 1H), 6.02(m, 1H), 5.97(s, 1H), 4.51(brs, 2H), 3.69(brs, 2H), 2.87(t, 2H, J=6.9 Hz)
    • EXAMPLE 126
  • Synthesis of 1-(4-t-butylbenzyl)-3-(5-nitrothiophen-2-ylmethyI)thiourea (17-4) [0465]
    Figure US20030153596A1-20030814-C00231
  • Step 1: Synthesis of 5-nitrothiophen-2-carboxaldehyde oxime [0466]
  • 5-Nitrothiophen-2-carboxaldehyde oxime (yield: 85%, pale yellow solid) was synthesized according to the similar procedure as described in Step 1 of Example 124 except that 5-nitrothiophen-2-carboxaldehyde was usded as a starting material. [0467]
  • [0468] 1H NMR (300 MHz, CDCl3): δ 8.21(s, 1H), 7.91(d, 1H, S=2.1 Hz), 7.85(d, 1H, J=2.25 Hz), 7.76(s, 1H), 7.26(s, 1H), 7.11(d, 1H, J=2.1 Hz)
  • Step 2: Synthesis of (5-nitrothiophen-2-yl)methylanine [0469]
  • Sodium borohydride (132 mg) was dried under vacuum and then anhydrous tetrahydrofiuran (30 ml) was added thereto through an injector, followed by adjusting the temperature down to −15° C. To the mixture at -15° C. was added a solution of 5-nitrothiophen-2-carboxaldehyde oxime (200 mg; synthesized in Step 1) and nickel chloride (II) hexahydrate (catalytic amount) in anhydrous methanol (20 ml), and the mixture was stirred for 12 hours. After confir g the completion of the reaction, the resulting mixture was filtered to obtain the compound as a brown liquid. [0470]
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(5-nitrotbiophen-2-ylmethyl)thiourea (17-4) [0471]
  • The compound 17-4 (yield: 40%, yellow solid) was synthesized by reacting the compound prepared in Step 2 with 4-t-butylbenzylisothiocyanate according to the similar procedure as described in Step 3 of Example 124. [0472]
  • [0473] 1H NMR (309 MHz, CDCl3): δ 7.71(d, 1H, J=1.95 Hz), 7.37(m, 2H), 7.23(m, 2H), 6.85(d, 1H, J=1.95 Hz), 6.59(brs, 1H), 6.30(brs, 11), 4.96(d, 2H, 33 Hz), 4.55(brs, 2H), 1.29(s, 9H)
    • EXAMPLE 127
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2-methyl-pyridin-3-ylmethyl)thiourea (18-5) [0474]
    Figure US20030153596A1-20030814-C00232
  • Step 1: Synthesis of(2-methylpyridin-3-yl)methanol (18-2) [0475]
  • Ethyl 2-methylnicotinate 18-1 (257 mg) was mixed with dichloromethane (4 ml) and to the mixture at −78° C. was added dropwise 1 M diisobutyl aluminium hydride (4 ml), followed by stirring for 1 hour. The reaction was quenched with methanol and to the mixture was added aqueous Rochel solution (20 ml), followed by stirring for 2 hours. The resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was column-cbromatographed (ethyl acetate/hexane=1/1) to yield the compound 18-2 (166 mg, 87%). [0476]
  • [0477] 1H NMR(300 MHz, CDCl3): δ 8.34 (d, 1H, J=3.4 Hz), 7.74 (d, 1H, J=7.6 Hz), 7.15 (dd, 1H, J=5.1 Hz, J=7.8 Hz), 4.70 (s, 21), 3.21 (br, 1H), 2.51 (s, 3H)
  • Step 2: Synthesis of (2-methylpyridin-3-yl)methylariinophthalimide (18-3) [0478]
  • Compound 18-2 (166 mg) prepared in Step 1 was dissolved in tetrahydrofuran (4 ml) and to the solution were added phthalimide (401 mg) and triphenylphospbine (716 mg), followed by adding diethylazodicarbonate (0.24 ml) thereto and stirring for 30 minutes. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed (ethyl acetate/hexane=1/1) to yield the compound 18-3 (300 mg, 88%). [0479]
  • [0480] 1H NMR(300 MHz, CDCl3): δ 8.40 (dd, 1H, J=1.7 Hz, J=3.2), 7.87-7.83 (m, 2H), 7.76-7.72 (m, 2H), 7.61 (d, 1H, J=6.6 Hz), 7.10 (dd, 1H, J 4.9 Hz, J=7.8 Hz) 4.80 (s, 2H), 2.72 (s, 3H)
  • Step 3: Synthesis of 1-(4-t-butylbenzyl)-3-(2-methylpyridin-3-ylmethyl)thiourea (18-5) [0481]
  • The compound 18-3 (19 mg) prepared in Step 2 was dissolved in ethanol and to the solution was added a drop of methylamine. After stirring the mixture at 55° C. for 30 hours, t-butylbenzylisothiocyanate (62 mg) was added thereto, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed (methanol/dichloromethane={fraction (1/10)}) to yield the compound 18-5 (26.2 mg, 100%). [0482]
  • [0483] 1H NMR(300 MHz, CDCl3): δ 8.56-8.55 (m, 11), 8.37-8.30 (m, 1H), 7.75-7.67(m, 1H), 7.40-7.10 (m, 4H), 4.74 (s, 2H), 4.44 (s, 2H), 3.05 (s, 3H), 1.30 (s, 9H)
    • EXAMPLE 128
  • Synthesis of 1-(1H-indazol-5-yl)-3-phenethylthiourea (19-1) [0484]
    Figure US20030153596A1-20030814-C00233
  • Step 1: Synthesis of 5-amuio-1H-indazole [0485]
  • 5-Nitro-1H-indazole (20 mg) was dissolved in methanol (1 ml) and to the solution was added a catalytic amount of palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 30 minutes. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to yield 5-amino-1H-indazole (16 mg, 100%). [0486]
  • [0487] 1H NMR(300 MHz, CD3OD): δ 7.78 (s, 1H), 7.32 (d, 1H, J=8.7 Hz), 7.01-6.95 (m, 2H)
  • Step 2: Synthesis of 1-(1H-indazol-5-yl)-3-phenethylthiourea (19-1) [0488]
  • 5-Amino-1H-indazole (9 mg) prepared according to the same procedure as described in Step 1 was dissolved in dichloromethane (1 ml) and the solution was stirred at room temperature for 3 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was column-chromatographed eluting with ethyl acetate/hexane ([0489] {fraction (1/2)}) to yield the compound 19-1 (10 mg, 60%).
  • [0490] 1H NMR(300 MHz, CD3OD): δ 7.99 (d, 1H, J=1.0 Hz), 7.51-7.47 (m, 2H), 7.27-7.13 (m, 6H), 3.78 (t, 2H, J=6.8 Hz), 2.90 (t, 2H, J=7.3 Hz)
    • EXAMPLE 129
  • Synthesis of 1-(4-t-butylbenzyl)-3-(1H-indazolyl)thiourea (19-2) [0491]
    Figure US20030153596A1-20030814-C00234
  • Compound 19-2 (25 mg, 65%) was synthesized using 5-amino-1H-indazole (15 mg) and t-butylbenzylisothiocyanate (30 mg) according to the similar procedure as described in Step 2 of Exmaple 128. [0492]
  • [0493] 1H NMR(300 MHz, CD3OD): δ 7.99(s, 1H), 7.65 (s, I), 7.50 (d, 1H, J-- 8.8 Hz), 7.33-7.21 (m, 5H), 4.73 (brs, 2H), 1.27 (s, 9H)
    • EXAMPLE 130
  • Synthesis of 1-(4-t-butylbenzy1)-3-(2-fluoro-4-methanesulfonyloxybenzyl)thiourea (20-2a) [0494]
    Figure US20030153596A1-20030814-C00235
  • Step 1: Synthesis of 3-fluoro-4-(N-t-butyloxycarbonylaminomethyl)phenol (20-1a) and 3-fluoro-4-(N-t-butyloxycarbonylainomethyl)phenol t-butyloxycarbonyl ether (20-1b) [0495]
  • 2-Fluoro-4-hydroxybenzonitrile (686 mg), nickel chloride (I1) (1.18 g) and Boc[0496] 2O (2.18 mg) were dissolved in methanol (40 ml) and the solution was cooled to 0° C. To the solution was slowly added sodium borohydride (1.32 g), and the mixture was stirred at 0° C. for 10 minutes and then at room temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and to the concentrate were added ethyl acetate (60 ml) and sodium borohydride (300 mg), followed by filtering. The filtrate was extracted twice with ethyl acetate. The total filtrate was concentrated under reduced pressure, and then purified by column-chromatography (hexane/ethyl acetate=3/1) to yield the compound 20-1a (134 mg, 11 I/o) and 20-1b (710 mg, 42%). 20-1a:
  • [0497] 1H NMR (300 MHz, CDCl3) 6 7.11(t, J=8.2 Hz, 1H), 6.62(bs, 1H), 6.61(d, J=9.6 Hz, 2H), 4.91(bs, 1H), 4.24(d, J=4.8 Hz, 2H), 1.46(s, 9H) 20-1b:
  • [0498] 1H NMR (300 MHz, CDCl3) δ0 7.37(t, J=8.3 Hz, 11), 6.93(m, 2H), 4.88(bs, 11), 4.32(d, J=5.7 Hz, 2H), 1.55(s, 9H), 1.44(s, 9H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(2-fluoro-4-methanesulfonyloxybenzyl)thiourea (20-2a) [0499]
  • Compound 20-1a (134 mg) prepared in Step 1 was dissolved in dichloromethane (2 ml) and to the solution at 0° C. were added dropwise methanesulfonyl chloride (44 Al) and pyridine (45 μl), followed by stirring at room temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (hexane/ethyl acetate=3/1) to obtain methanesulfonyl compound (55 mg, 31%). The obtained compound was dissolved in dichlorormethane (2.0 ml) and the solution was cooled to 0° C., followed by adding trifluoroacetic acid (100 μl) thereto and stirring for 2 hours. The resulting mixture was concentrated under reduced pressure and dissolved in dimethylformamide (5.0 ml). To the solution was added triethylamine (30 μl) and the mixure was stirred for 1 hour. To the obtained solution was added 4-t-butylbenzylisothiocyanate (40 mg) and the mixture was stirred at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by colum-chromatography (hexane/ethyl acetate=2/1) to yield the compound 20-2a (61 mg, 85%). [0500]
  • [0501] 1H NMR (300 MHz, CDCl3) δ 7.43(t, J=8.7 Hz, 1H), 7.37(d, J=8.1 Hz, 2H), 7.22(d, J=8.1 Hz, 2H), 7.02(m, 2H), 6.20(bs, 1H), 6.00(bs, 1H), 4.79(d, J=5.4 Hz, 211), 4.53(d, J=4.2ffz, 211), 3.16(s, 311), 1.31(s, 9H).
    • EXAMPLE 131
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2-fluoro-4-hydroxy)thiourea (20-2b) [0502]
    Figure US20030153596A1-20030814-C00236
  • The compound 20-1b (710 mg) prepared in Step 1 of Example 130 was dissolved in dichloromethane (10 ml) and the solution was cooled to 0° C., followed by adding trifluoroacetic acid (1.0 ml) thereto and stirring for 2 hours. The resulting mixture was concentrated under reduced pressure and part (211 mg) of the obtained residue was dissolved in dimethylformamide (5.0 ml). To the solution was added triethylamine (120 Ag) and the mixture was stirred for 1 hour. To the obtained solution was slowly added 4-t-butylbenzylisothiocyanate (170 mg) and the mixture was stirred at room temperature for 18 hours. The resulting mixture was concentrated under reduced pressure and purified by colurn-nchromatography (hexane/ethyl acetate 1/1) to yield the compound 20-2b (196 mg, 68%). [0503]
  • [0504] 1H NMR (300 MHz, CDCl3): δ 7.35(d, J=8.4 Hz, 2H), 7.20(d, J=8.4 Hz, 2H), 7.13(t, J=8.4 Hz, 1H), 6.54(m? 2H), 6.08(bs, 1H), 6.02(bs, 1H), 5.75(bs, 1H), 4.59(m, 4H), 1.31(s, 9H)
    • EXAMPLE 132
  • Synthesis of 1-(4-t-butylbenzyl)-3-[(6-methanesulfonylanopyridin-2-yl)methyl]thiourea (21-7) [0505]
    Figure US20030153596A1-20030814-C00237
  • Step 1: Synthesis of 2,2-dimethyl-N-(6-methyl-2-pyridinyl)propaneamide (21-1) [0506]
  • 2-amino-6-picoline (26 g) was dissolved in dichloromethane (280 ml) and the reactor was cooled to 0° C., followed by adding triethylamine (30. g) thereto. To the obtained solution was slowly added dropwise a solution of trimethylacetylchloride (31.8 g) in dichloromethane (20 ml) and the mixture was stirred at room temperature for 3 hours. The resulting mixture was filtered, washed with water, dried over anhydrous magnesium sulfate, concentrated under reduced pressure and then crystallized (dichloromethane/petroleum ether) to yield a pale yellow solid (38 g, 82%). [0507]
  • Step 2: Synthesis of N-[6-(bromomethyl)-2-pyridinyl]-2,2-dimethylpropaneamide (21-2) [0508]
  • 2,2-dimethyl-N-(6-methyl-2-pyridinyl)propaneanide (21-1) (32 g) and N-bromosuccinimide (29.6 g) were added to carbon tetrachloride (300 ml) and to the mixture was added AIBN (15 mg), followed by reluxing for 20 hours under light emitted by 500 W lamp. The resulting mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate=10/1) to yield the compound 21-2 (1.94 g, 5%) as a pure white solid. [0509]
  • [0510] 1H NMR(300 MHz, CDCl3): δ 8.20-8.17(m, 1H), 8.00(brs, 1H), 7.72-7.66(m, 1H), 7.16-7.13(m, 1H), 4.42(s, 2H), 1.34(s, 9H)
  • Step 3: Synthesis of N-[6-{(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl}-2-pyridinyl]-2,2-dimethylprop aneamide (21-3) [0511]
  • N-[6-(bromomethyl)-2-pyridinyl]-2,2-dimnethylpropaneamide (21-2) (1.9 g) was dissolved in dimethylformamide (20 ml) and to the solution was added potassium phthalimide (1.43 g), followed by stirring at room temperature for 24 hours. The resulting mixture was concentrated under reduced pressure and extrated with water and dichloromethane. An organic layer was concentrated under reduced pressure to yield the compound 21-3 (2.27 g, 96%) as a bright yellow solid. I [0512]
  • [0513] 1H NMR(300 MHz, CDCl3): δ 8.15-8.12(m, 1H), 7.92-7.74(m, 4H), 7.66-7.60(m, 1H), 7.00-6.97(m, 1H), 4.90(s, 2M, 1.29(s, 9H)
  • Step 4: Synthesis of 2-[(2-amino-6-pyridinyl)methyl]-1H-isoindol-1,3(2H)-dione (21-4) [0514]
  • N-[6-{(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl} -2-pyridinyl]-2,2-dimethylpropaneamide 21-3 was dissolved in ethanol (20 ml) and to the solution was added concentrated sulfaric acid (2 ml), followed by refluxing for 6 hours. The obtained solution was basified with ammonia solution, extracted with dichloromethane, and then dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate=1/1) to yield the compound 21-4 (400 mg, 23%) as a pale yellow solid. [0515]
  • [0516] 1H NMR(300 MHz, CDCl3): δ 7.90-7.71(m, 41), 7.38-7.32(m, 1H), 6.59-6.56(m, 1H), 6.37-6.33(m, 1H), 4.83(s, 2H), 4.36(brs, 2H)
  • Step 5: Synthesis of 2-[(2-methanesulfonylamino-6-pyridinyl)methyl]-1H-isoindol-1,3 (2H)-dione (21-5) [0517]
  • The compound 21-4 (200 mg) prepared in Step 4 was dissolved in dichloromethane (10 ml) and to the solution were added triethylamine (130 μl) and methanesulfonyl chloride (67 a), followed by stirring at room temperature for 24 hours. The resulting mixture was extracted with water and dichloromethane, dried, concentrated under reduced pressure, and then crystallized (dichloromethane/petroleum ether) to yield the compound 21-5 (260 mg, 99%) as a white solid. [0518]
  • Step 6: Synthesis of 1-(4-t-butylbenzyl)-3-[(2-methanesulfonylamino-6-pyridinyl)methyi]thiourea (21-7) [0519]
  • The compound 21-5 (220 mg) prepared in Step 5 was dissolved in methanol (5 ml) and to the solution was added hydrazine hydrate (270 u), followed by stirring at room temperature for 2 hours. The obtained reaction solution was concentrated under reduced pressure to obtain the compound 21-6. The compound 21-6 (690 mg) was dissolved in dimethylfornamide (20 ml) and to the solution was added 4-t-butylbenzylisothiocya-nate (370 mg), followed by stirring at 100° C. for 7 hours. The reaction mixture was concentrated and purified by column-chromatography hexaneletliyl acetate=[0520] {fraction (1/2)}) to yield the compound 21-7 (58 mg, 23%) as a green foamy solid.
  • [0521] 1H NMR(300 MHz, CDCl3): δ 7.69-7.63(m, 1H), 7.42-7.38(m, 2H), 7.31-7.25(m, 3H), 7.04-6.65(m, 3H), 4.76-4.60(m, 4H), 3.07(s, 3H), 1.31(s,9H)
    • EXAMPLE 133
  • Synthesis of (4-t-butylbenzyl)thiocarbainic acid (1-methyl-4-nitro-1-pyrrol-2-yl)methyl ester (22-3) [0522]
    Figure US20030153596A1-20030814-C00238
  • Step 1: Synthesis of N-methyl-4-nitro-pyrrol-2-carboxaldehyde (22-1) [0523]
  • N-methylpyrrol-2-carboxaldehyde (5 g) was dissolved in anhydrous acetic acid (50 ml), and to an ice-cold of the solution was slowly added dropwise nitric acid (1.84 ml) with stirring. The mixture was stirred at this temperature for I hour, and then at room temperature for 18 hours. After confiing the completion of the reaction, to the mixture was added an ice-water (200 ml), followed by slowly adding solid sodium hydroxide (20 g) thereto and stirring for 1 hour. The obtained mixture was extracted with ether (150 ml×3). The obtained organic layer was washed with aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried over sodium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and purified by column-chromatography (ethyl acetatelhexane=[0524] {fraction (1/4)}) to yield the compound 22-1 (3.5 g, 49.6%).
  • [0525] 1H NMR(300 MHz, CDCl3): δ9.63(s, 1H), 7.68(s, 1H), 7.43(s, 1H), 4.03(s, 3H)
  • Step 2: Synthesis of 2-hydroxymethyl-N-methyl-4-nitro-pyrrole (22-2) [0526]
  • Compound 22-1 (550 mg) was dissolved in anhydrous tetrahydrofuiran (30 ml) and cooled to 0° C. To the solution was slowly added dropwise 1M borane-tetrahydrofaran (3.25 ml), followed by refluxing at 80° C. for 3 hours. After the completion of the reaction, the solvent was evaporated under reduced pressure to be removed, and then the residue was purified by column-chromatography (ethyl acetate/hexane=2/1) to yield the compound 22-2 (500 mg, 90%). [0527]
  • [0528] 1H NMR(300 MHz, CDCl3): δ 7.51(s, 1H), 6.65(s, 1H), 4.59(s, 2H), 3.75(s, 3H)
  • Step 3: Synthesis of (4-t-butylbenzyl)thiocarbamic acid (1-methyl-4-nitro-1H-pyrrol-2-yl)methyl ester (22-3) [0529]
  • Compond 22-2 (100 mg) was dissolved in anhydrous tetrahydrofuran (15 ml) and cooled to 0° C. To the solution was slowly added sodium hydride (190 mg) with stirring, followed by stirring for 30 minutes. To the mixture was added t-butylbenzylisothiocyanate (130 mg), followed by stirring for 6 hours. The solvent was evaporated under reduced pressure to be removed, and then the residue was diluted with water (20 ml). The obtained mixture was extracted with ethyl acetate (20 ml×3), dried over magnesium sulfate, and then filtered. The filtrate was evaporated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane={fraction (1/3)}) to yield the compound 22-3 (130 mg, 56.2%). [0530]
  • [0531] 1H NMR(300 MHz, CDCl3): δ7.51(m, 1H), 7.31(m, 3H), 7.10(m, 1H), 6.83(m, 1H), 6.47(brs, 1H), 5.44(s, 2H), 4.71(d, 2H, 35.7 Hz), 3.68(s, 3H), 1.31(s, 9H)
    • EXAMPLE 134
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea (22-9) [0532]
    Figure US20030153596A1-20030814-C00239
  • Step 1: Synthesis of 2-cyano-N-methylpyrrole (22-4) [0533]
  • N-methyl-2-pyrrolcarboxaldehyde (5 g) and hydroxylamine hydrochloride (3.82 g) were mixed in 1-methyl-2-pyrrolidinone (50 ml) and the mixture was refluxed at 110° C. for 2 hours. After confiring the completion of the reaction, to the reaction mixture was slowly added an ice-water (200 ml) and the resulting mixure was extracted with ethyl acetate (150 ml×3), washed with brine, dried over sodium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane=[0534] {fraction (1/4)}) to yield the compound 22-4 (3.5 g, 72%).
  • [0535] 1H NMR(300 MHz, CDCl3): δ 6.79(m, 2H), 6.16(m, 1H), 3.78(s, 3H)
  • Step 2: Synthesis of 4-nitro-2-cyano-N-methylpyrrole (22-5) [0536]
  • Compound 22-4 (1 g) was dissolved in anhydrous acetic acid (100 ml), and cooled to 0° C. To the solution was slowly added dropwise nitric acid (380 μl) with stirring, followed by stirring at the same temperature for 1 hour and subsequently at room temperature for 18 hours. After confirming the completion of the reaction, to the mixture was added an ice-water (200 ml), followed by slowly adding solid sodium hydroxide (20 g) thereto and stirring for 1 hour. The obtained mixture was extracted with ether (50 ml×3). The obtained organic layer was washed with aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried over sodium sulfate, and then filtered. The filtrate was concentrated under reduced pressure and purified by column-chromatography (ethyl acetate/hexane={fraction (1/3)}) to yield the compound 22-5 (1.05 g, 73.7%). [0537]
  • [0538] 1H NMR(300 MHz, CDCl3): δ 7.65(s, 11T), 7.32(s, 1H), 3.88(s, 3H)
  • Step 3: Synthesis of 2-cyano-4-amino-N-methylpyrrole (22-6) [0539]
  • Compound 22-5 (500 mg) and 10% palladium/carbon (50 mg) were poured into the reactor and dissolved in methanol (10 ml), and then reacted under hydrogen gas atmosphere for 2 hours. After confinning the completion of the reaction, the resulting mixture was filtered through celite, and the filtrate was concentrated under reduced pressure and purified by columu-chromatography (ethyl acetate/hexane=3/1) to yield the compound 22-6 (310 mg, 77.4%). [0540]
  • [0541] 1H NMR(300 MHz, CDCl3): δ6.36(d, 1H, 12.1 Hz), 6.30(d, 1H, J=4.2 Hz), 3.66(s, 3H)
  • Step 4: Synthesis of 4-methanesulfonylamino-2-cyano-N-methylpyrrole (22-7) [0542]
  • Compound 22-6 (310 mg) was dissolved in dichloromethane (30 ml) and cooled to 0° C. To the solution were added triethylamine (430 μl) and methanesulfonyl chloride (210 μl) successively through an injector, followed by stirring at room temperature for 24 hours. The resulting mixture was diluted with 1 N aqueous hydrochloric acid, and an organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl aceate/hexane=1/1) to yield the compound 22-7 (400 mg, 78.5%) [0543]
  • [0544] 1H NMR(300 MHz, CDCl3): δ 6.78(d, 1H, J=1.8 Hz), 6.53(d, 1H, J=1.8 Hz), 5.95(brs, 1H), 3.92(s, 3H), 2.97(s, 3H)
  • Step 5: Synthesis of (4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)methylamine (22-8) [0545]
  • Compound 22-7 (150 mg) and 10% palladiuni/carbon (catalytic amount), together with methanol (10 ml), were poured into reactor and the reactor was filled with hydrogen gas, followed by stirring at room temperature for 24 hours. After the completion of the reaction, the resulting mixture was filtered through celite and concentrated under reduced pressure. The following procedure was carried out using the obtained residue which was not purified. [0546]
  • Step 6: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-1-methyl-1H-pyrrol-2-yl)thiourea (22-9) [0547]
  • The compound 22-8 (95 mg) prepared in Step 5 and 4-t-butylbenzylisothiocyanate (96 mg) were added to ethyl acetate (20 ml) and the mixture was stirred for 16 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane=3/2) to yield the compound 22-9 (105 mg, 55%). [0548]
  • [0549] 1H NMR(300 MHz, CDCl3): δ7.37(d, 2H, J=8.1 Hz), 7.22(d, 2H, J=8.1 Hz), 6.61(d, 1H, J=1.8 Hz), 5.95(d, 1H, J=2.1 Hz), 6.26(brs, 1H), 5.87(brs, 1H), 5.77(brs, 1H), 4.64(d, 2H, J=4.8 Hz), 4.54(d, 2H, J=3.9 Hz), 3.48(s, 3H), 2.91(s, 3H), 1.31(s, 9H)
    • EXAMPLE 135
  • Synthesis of 1-(4-t-butylbenzyl)-3-[(4-methanesulfonylaminomethyl)phenyl]thiourea (23-2) [0550]
    Figure US20030153596A1-20030814-C00240
  • Step 1: Synthesis of (4-methanesulfonylaminomethyl)-1-nitrobenzene (23-1) [0551]
  • 4-nitrobenzylamine hydrochloride (3.77 g) was dissolved in dichloromethane (20 ml) and to the solution at 0° C. was added triethylamine (6.14 ml), followed by adding dropwise methanesulfonyl chloride (1.7 ml) thereto and stirring at room temperature for 23 hours. Afier the completion of the reaction, the resulting mixture was extracted with water and dichloromethane, concentrated under reduced pressure, and then crystallized (dichloromethane/petroleum ether) to yield an ocherous solid (1.2 g, 26%). [0552]
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-[(4-methanesulfonylarninomethyl)phenyl]thiourea (23-2) [0553]
  • The compound 23-1 prepared in Step 1 was dissolved in ethyl acetate (30 ml) and to the solution was added tin (II) chloride dihydrate (6.1 g), followed by refluxing at 50° C. for 2 hours. After allowed to cool down to room temperature, the resulting mixture was basified with saturated aqueous sodium bicarbonate solution, washed with water and brine, dried, and then concentrated under reduced pressure to obtain a yellow solid (610 mg, 59%). The obtained compound (107 mg), which was not purified, was dissolved in acetonitrile (10 ml) and to the solution were added triethylamine (100 μl) and 4-t-butylbenzylisothiocyanate (110 mg), followed by refluxing for 24 hours. The resultant mixture was concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate=[0554] {fraction (1/2)}) to yield the compound 23-2 (73 mg, 34%) as a solid.
  • [0555] 1H NMR(300 MHz, CDCl3): δ 7.84(brs, 1H), 7.46-7.18(m, 8H), 6.26(brs, 1H), 5.00-4.81(m, 3H), 4.31-4.28(m, 2H), 2.92(s, 3H), 1.29(s,911)
    • EXAMPLE 136˜EXAMPLE 141
  • Compounds of Example 136˜Example 141, which are shown in the Scheme 24, were synthesized according to the similar procedure as described in Example 76 or Example 77, and properties and spectral data thereof are shown in below table. [0556]
    Figure US20030153596A1-20030814-C00241
    Examples Compounds R = Types Spectral deta
    136 24-1
    Figure US20030153596A1-20030814-C00242
         		A 1H NMR(300MHz, CDCl3): δ 7.39-7.26(m, 9H), 5.55(brs, 1H), 4.81(d, 2H, J=4.8Hz), 3.83-3.79(m, 4H), 3.53(s, 2H), 2.51-2.47(m, 4H), 1.32(s, 9H)
    137 24-2
    Figure US20030153596A1-20030814-C00243
         		B 1H NMR(300MHz, CDCl3): δ 7.33-7.19(m, 10H), 5.40(brs, 1H), 3.97-3.90(m, 2H), 3.72-3.69(m, 4H), 3.52(s, 2H), 2.94(t, 2H, J=6.9Hz), 2.46-2.42(m, 4H), 1.32(s, 9H)
    138 24-3
    Figure US20030153596A1-20030814-C00244
         		A 1H NMR(300MHz, CDCl3): δ 8.34-8.32(m, 1H), 7.40-7.26(m, 5H), 6.55(t, 1H, J=4.5Hz), 5.57(brs, 1H), 4.85(d, 2H, J=4.2Hz), 3.96-3.94(m, 8H), 1.32(s, 9H)
    139 24-4
    Figure US20030153596A1-20030814-C00245
         		A 1H NMR(300MHz, CDCl3): δ 8.19-8.16(m, 1H), 7.53-7.26(m, 5H), 6.68-6.56(m, 2H), 5.58(brs, 1H), 4.85(d, 2H, J=4.8Hz), 4.04-4.00(m, 4H), 3.74-3.70(m, 4H), 1.32(s, 9H)
    140 24-5
    Figure US20030153596A1-20030814-C00246
         		A 1H-NMR(300MHz, CDCl3): δ 9.15(s, 1H), 9.10(m, 1H), 7.95(s, 1H), 7.34(d, 2H, J=8.6Hz), 7.25(d, 2H, J=8.6Hz), 4.84(d, 2H, J=5.6Hz), 1.25(s, 9H)
    141 24-6
    Figure US20030153596A1-20030814-C00247
         		A 1H NMR(CDCl3): δ 7.35(m, 2H), 7.18(m, 4H), 5.62(bs, 1H), 4.92(s, 2H), 4.87(d, 2H, J=2.25Hz), 3.98(m, 2H), 2.94(m, 2H), 1.32(s, 9H)
    Figure US20030153596A1-20030814-C00248
    Figure US20030153596A1-20030814-C00249
    Figure US20030153596A1-20030814-C00250
    Figure US20030153596A1-20030814-C00251
    Figure US20030153596A1-20030814-C00252
    Figure US20030153596A1-20030814-C00253
    • EXAMPLE 142
  • Synthesis of 1-benzy1-1-l4-hydroxy-3-methoxybenzyl)-3-phenethylthiourea (25-1) [0557]
    Figure US20030153596A1-20030814-C00254
  • Vaniline (200 mg) and benzylamine (129 mg) were dissolved in methanol (3 ml) and the solution was stirred for 30 minutes. To the solution was added a catalytic amount of 10% platinum/carbon to be subjected to the hydrogenation reaction (I atm) . After the completion of the reaction, the resulting mixture was filtered and evaporated under reduced pressure to remove methanol. The obtained residue was dissolved in dichloromethane (3 ml) and to the solution was added phenethylisothiocyanate (196 mg, 1.2 mmol), followed by stirring at room temperature for 5 hours. Then, dichloromethane was evaporated under reduced pressure and the obtained residue was column-chromatographed (hexane/ethyl acetate=1/1) to yield the compound 25-1 (400 mg, 82%) as a white solid. [0558]
  • [0559] 1H NMR (300 MHz, CDCl3): δ 7.25 (m, 10H), 6.94 (m, 311), 6.69(m, 2H), 5.69(s, 111), 5.51(t, 11, J=4.68 Hz), 4.88(s, 2H), 4.75(s, 2H), 3.89(m, 2H), 3.75(s, 3I1), 2.78(t, 2H, J=6.57 Hz): MS (El) m/e 406 [M+]
    • EXAMPLE 143˜EXAMPLE 167
  • Compounds 25-2˜25-26 of Example 143- Example 167, which are shown in the Scheme 25, were synthesized according to the similar procedure as described in Example 142, and properties and spectral data thereof are shown in below table. [0560]
    Figure US20030153596A1-20030814-C00255
    Compounds RM, RN,
    Examples No. RP, m Spectral data
    143 25-2 RM = —OH 1H NMR(300MHz, CDCl3): δ 7.20(m, 1H), 6.82(d,
    RN = —OCH3 1H, J=8.04Hz), 6.66(s, 1H), 6.58(d, 1H, J=8.04Hz)
    RP = —(CH2)2Ph 5.59(s, 1H), 5.30(t, 1H), 4.59(s, 2H), 3.88(m, 4H),
    m = 1 3.81(s, 3H), 2.84(m, 6H); MS(EI) m/e 420[M+]
    144 25-3 RM = —OH 1H NMR(300Mhz, CDCl3): δ 7.20(m, 10H),
    RN = —OCH3 6.83(d, 1H, J=8.04Hz), 6.72(s, 1H), 6.57(d, 1H,
    J=8.04Hz) 5.58(s, 2H), 5.21(t, 1H, J=4.62Hz),
    m = 1 2.82(t, 2H, J=7.68Hz) 2.51(t, 2H, J=8.55Hz)
    MS(EI) m/e 434[M+]
    145 25-4 RM = —OH 1H NMR(300MHz, CDCl3): δ7.19(m, 10H), 6.70(m,
    RN = —OCH3 3H), 5.58(s, 1H) 4.69(s, 2H), 3.79(s, 3H), 3.87(m,
    RP = —(CH2)4Ph 2H), 3.38(m, 2H), 2.84(t, 2H, J=6.6Hz), 2.58(t, 2H,
    m = 1 J=7.7Hz), 1.55(m, 4H); MS(EI) m/e 448[M+]
    146 25-5 RM = —OH 1H NMR(300MHz, CDCl3): δ7.20(m, 5H), 6.74(m,
    RN = —OCH3 3H), 5.63(s, 1H) 5.36(t, 1H), 4.77(s, 2H), 3.94(m,
    RP = —C8H17 2H), 3.85(s, 3H), 3.49(t, 2H, J=7.8Hz), 2.89(t, 2H,
    m = 1 J=6.57Hz), 1.48(t, 2H), 1.28(m, 2H), 0.90(t, 3H)
    MS(EI) m/e 428[M+]
    Figure US20030153596A1-20030814-C00256
    Figure US20030153596A1-20030814-C00257
    Figure US20030153596A1-20030814-C00258
    Figure US20030153596A1-20030814-C00259
  • [0561]
    Compounds RM, RN,
    Examples No. RP, m Spectral data
    147 25-6 RM = —OH 1H NMR(300MHz, CDCl3): δ 6.86(m, 8H), 5.75(s,
    RN = —OCH3 1H), 5.59(s, 1H) 5.35(s, 1H), 4.32(s, 2H), 3.80(s, 3H),
    RP = -isopropyl 3.85(m, 3H), 2.74(t, 2H, J=6.71Hz), 1.18(d, 6H); MS
    m = 1 (EI) m/e 358[M+]
    148 25-7 RM = —OH 1H NMR(300MHz, CDCl3): δ 7.07(m, 5H), 6.67(m,
    RN = —OCH3 3H), 5.56(s, 2H) 5.34(m, 4H), 4.37(s, 2H), 3.86(m,
    RP = -cyclohexyl 2H), 3.79(s, 3H), 2.74(t, 2H, J=6.71Hz), 1.43(m,
    m = 1 10H); MS(EI) m/e 398[M+]
    149 25-8 RM = —OH 1H NMR(300MHz, CDCl3): δ7.08(m, 10H), 6.46(m,
    RN = —OH 3H), 6.38(s, 1H) 3.70(t, 2H, J=7.23Hz), 3.42(t, 2H,
    RP = —(CH2)3Ph J=7.61Hz), 2.78(t, 2H, J=7.32Hz), 1.70(m, 2H); MS
    m = 1 (EI) m/e 420[M+]
    150 25-9 RM = —OH 1H NMR(300MHz, CDCl3): δ7.21(m, 10H), 6.82(d,
    RN = —OCH3 1H, J=8.04Hz), 6.64(s, 1H) 6.56(d, 1H, J=7.56Hz),
    RP = —(CH2)2Ph 5.53(s, 1H), 5.10(m, 1H), 3.87(s, 3H), 3.82(d, 2H,
    m = 2 J=5.13Hz), 3.63(d, 2H, J=5.13Hz), 2.80(m, 6H); MS
    (EI) m/e 434[M+]
    151 25-10 RM = —OH 1H NMR(300MHz, CDCl3): δ7.28(m, 5H), 6.70(m,
    RN = —OCH3 3H), 5.56(m, 2H) 5.20(m, 1H), 3.95(m, 2H), 3.88(s,
    RP = -isopropyl 3H), 3.45(m, 1H), 2.94(t, 2H), 2.69(t, 2H, J=7.53Hz),
    m = 2 1.18(d, 2H, J=6.57Hz)
    MS(EI) m/e 372[M+]
    152 25-11 RM =—OH 1H NMR(300MHz, CDCl3): δ7.18(m, 10H), 6.66(m,
    RN = —OCH3 3H), 5.47(s, 1H) 5.20(m, 1H), 4.77(s, 2H), 3.83(s,
    RP = -benzyl 3H), 3.83(m, 2H), 3.54(t, 2H, J=7.68Hz), 2.79(t, 2H,
    m = 3 J=6.825Hz), 2.46(t, 2H, J=744Hz), 1.82(m, 2H); MS
    (EI)m/e 434[M+]
    153 25-12 RM = —OH 1H NMR(300MHz, CDCl3): δ7.20(m, 10H), 6.69(m,
    RN = —OCH3 3H), 5.51(s, 1H) 5.07(t, 2H, J=7.30Hz), 3.85(m, 5H),
    RP = —(CH2)2Ph 3.71(t, 2H, J=7.68Hz), 3.33(t, 2H, J=7.80Hz),
    m = 3 2.84(m, 4H), 2.47(t, 2H, J=7.30Hz), 1.79(m, 2H);
    MS(EI) m/e448[M+]
    Figure US20030153596A1-20030814-C00260
    Figure US20030153596A1-20030814-C00261
    Figure US20030153596A1-20030814-C00262
    Figure US20030153596A1-20030814-C00263
    Figure US20030153596A1-20030814-C00264
    Figure US20030153596A1-20030814-C00265
    Figure US20030153596A1-20030814-C00266
  • [0562]
    Compounds RM, RN,
    Examples No. RP, m Spectral data
    154 25-13 RM = —OH 1H NMR(300MHz, CDCl3): δ7.22(m, 5H), 6.73(m,
    RN = —OCH3 3H), 5.55(s, 1H) 5.04(t, 1H, J=4.96Hz), 3.88(s, 3H),
    RP = —(CH2)Ph 3.83(m, 2H), 3.48(m, 4H), 3.88(t, 2H, J=6.80Hz),
    m = 3 2.56(t, 2H, J=7.58Hz), 2.51(t, 2H, J=7.45Hz),
    1.85(m, 4H); MS(EI) m/e 462[M+]
    155 25-14 RM = —OH 1H NMR(300MHz, CDCl3): δ7.23(m, 5H), 6.74(m,
    RN —OCH3 3H), 3.84(m, 5H) 3.61(m, 2H), 3.27(m, 2H), 2.87(m,
    RP = —H 2H), 2.59(t, 2H, J=7.94Hz), 2.83(n,, 2H); MS(EI)
    m = 3 m/e 344[M+]
    156 25-15 RM = —OH 1H NMR(300MHz, CDCl3): δ7.23(m, 5H), 6.70(m,
    RN = —OCH3 3H), 5.28(s, 2H) 3.86(m, 5H), 3.64(m, 2H), 3.02(s,
    RP = —CH3 3H), 2.92(t, 2H, J=6.69Hz), 2.52(t, 2H, J=7.43Hz),
    m = 3 1.84(m, 2H); MS(EI) m/e 358[M+]
    157 25-16 RM = —OH 1H NMR(300MHz, CDCl3): δ7.28(m, 5H), 6.73(m,
    RN = —OCH3 3H), 5.50(s, 1H) 5.12(m, 1H), 3.91(m, 5H), 3.55(t,
    RP = —C8H17 2H, J=7.34Hz), 2.93(m, 2H), 2.53(t, 2H, J=7.50Hz),
    m = 3 1.87(m, 2H), 1.44(m, 2H), 1.25(m, 10H), 0.91(m,
    3H); MS(EI) m/e 456[M+]
    158 25-17 RM = —OH 1H NMR(300MHz, CDCl3): δ7.21(m, 5H), 6.70(m,
    RN = —OCH3 3H), 3.88(m, 5H) 5.59(m, 2H), 5.25(m, 2H), 3.H(m,
    RP = -isobutyl 4H), 2.75(m, 1H), 2.56(m, 2H), 1.83(m, 2H), 0.86(m,
    m = 3 2H), 0.79(d, 6H) MS(EI) m/e 400[M+]
    159 25-18 RM = —OH 1H NMR(300MHz, CDCl3): 67.26(m, 5H), 6.67(m,
    RN = —OCH3 3H), 5.53(s, m, 2H) 5.02(t, 1H), 3.85(m, 2H), 3.80(m,
    RP = -isopropyl 2H) 3.09(t, 2H, J=8.28Hz), 2.85(t, 2H, J=6.81Hz),
    m = 3 2.45(t, 2H, J=6.95Hz), 2.72(m, 2H), 1.09(d, 6H); MS
    (EI) m/e 386[M+]
    160 25-19 RM = —OH 1H NMR(300MHz, CDCl3): 67.23(m, 5H), 6.65(xn,
    RN = —OCH3 3H), 5.50(s, 1H) 4.93(m, 2H), 3.85(s, 3H), 3.83(m,
    RP = -cyclo- 2H), 3.13(t, 2H, J=7.8Hz), 2.83(t, 2H, J=6.82Hz),
    hexyl 2.42(t, 2H, J=7.07Hz), 1.65(m, 9H), 1.18(m, 5H);
    m = 3 MS(EI) m/e 426[M+]
    161 25-20 RM = —OH 1H NMR(300MHz, CDCl3): δ7.64(s, 1H), 7.23(m,
    RN = OCH3 15H), 6.52(m, 3H) 5.48(s, 1H), 5.25(t, 1H, J=5.0O
    RP = —CH(Ph)2 Hz), 3.85(m, 5H), 3.33(t, 2H, J=8.30Hz), 2.83(t, 2H,
    m = 3 J=6.823Hz), 2.07(t, 2H, J=4.49Hz), 1.26(m, 2H);
    MS(EI) m/e 510[M+]
    Figure US20030153596A1-20030814-C00267
    Figure US20030153596A1-20030814-C00268
    Figure US20030153596A1-20030814-C00269
    Figure US20030153596A1-20030814-C00270
    Figure US20030153596A1-20030814-C00271
    Figure US20030153596A1-20030814-C00272
    Figure US20030153596A1-20030814-C00273
    Figure US20030153596A1-20030814-C00274
  • [0563]
    Compounds RM, RN,
    Examples No. RP, m Spectral data
    162 25-21 RM = —OH 1H NMR(300MHz, CDCl3): δ7.17(m, 9H), 6.68(m,
    RN = -p-t-butylb 5H), 3.61(m, 2H), 2.81(t, 2H, J=6.83Hz), 2.50(t, 2H,
    enzyl J=7.44Hz), 1.88(m, 2H), 1.31(s, 9H); MS(EI) m/e
    m = 3 490[M+]
    163 25-22 RM = —OH 1H NMR(300MHz, CDCl3): δ7.28(m, 5H), 6.73(m,
    RN = —OH 3H), 6.45(t, 2H, J=8.04Hz) 3.80(m, 4H), 3.05(m,
    RP = -isopropyl 4H), 2.88(m, 2H), 2.54(m, 1H), 2.39(t, 2H, J=6.83
    m = 3 Hz), 1.71(m, 4H), 1.11(d, 6H)
    MS(EI) m/e 372[M+]
    164 25-23 RM = —OCH3 1H NMR(300MHz, CDCl3): δ7.23(m, 5H), 6.69(m,
    RN = —OCH3 3H), 5.31(s, 1H) 3.85(m, 5H), 3.H(t, 2H, J=7.32),
    RP = -isopropyl 2.85(t, 2H, J=6.71Hz), 2.46(t, 2H, J=6.83Hz),
    m = 3 1.75(m, 2H), 1.90(m, 1H), 1.09(d, 6H, J=3.32Hz);
    MS(EI) m/e 400[M+]
    165 25-24 RM = —OH 1H NMR(300MHz, CDCl3): δ7.14(m, 5H), 6.77(m,
    RN = —H 4H), 3.77(m, 7H) 3.10(m, 2H), 2.88(m, 1H), 0.83(m,
    RP = -isopropyl 10H); MS(EI) m/e 356[M+]
    m = 3
    166 25-25 RM = —H 1H NMR(300MHz, CDCl3): δ7.23(m, 5H), 6.69(m,
    RN = OCH3 3H), 5.32(m, 1H) 3.77(m, 5H), 3.11(t, 2H, J=7.07
    RP = —-isopropyl Hz) 2.87(t, 2H, J=6.60Hz), 2.49(t, 2H, J=7.20Hz),
    m = 3 2.73(m, 2H), 1.91(m, 1H), 1.08(d, 6H, J=6.84Hz);
    MS(EI) m/e 370[M+]
    167 25-26 RM = —H 1H NMR(300MHz, CDCl3): δ7.21(m, 10H), 5.48(m,
    RN = —H 1H), 5.038(m, 1H) 3.83(m, 2H), 3.11(t, 2H, J=8.30
    RP = -isopropyl Hz), 2.89(t, 2H, J=6.83Hz), 2.54(t, 2H, J=7.19Hz),
    m = 3 1.78(m, 2H), 1.11(d, 2H, J=6.81Hz);
    MS(EI) m/e 340[M+]
    Figure US20030153596A1-20030814-C00275
    Figure US20030153596A1-20030814-C00276
    Figure US20030153596A1-20030814-C00277
    Figure US20030153596A1-20030814-C00278
    Figure US20030153596A1-20030814-C00279
    Figure US20030153596A1-20030814-C00280
    • EXAMPLE 168
  • Synthesis of N-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminophenyl)propionamide (26-3) [0564]
    Figure US20030153596A1-20030814-C00281
  • Step 1: Synthesis of (3-fluoro-4-methanesulfonylamino)cinmamic acid methyl ester (26-1) [0565]
  • 2-fluoro-4-iodomethanesulfonylaminobenzene 3-2 (200 mg) was dissolved in dimethylformaamide (16 ml) and to the solution were added palladium acetate (7.2 mg), [0566]
  • 1,1′-bis(diphenylphosphino)ferrocene (20 mg), triethylamine (200 A) and methylacrylate (550 mg), followed by stirring at 60° C. for a day. The reaction mixture was cooled to room temperature, diluted with dichloromethane (40 ml) and then washed with water and aqueous hydrochloric acid solution. The obtained mixture was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and then column-chromatographed (ethyl acetate/hexane 1/1) to yield the compound 26-1 (214 mg, 70%). [0567]
  • [0568] 1H NMR(300MElz, CDCl3 +CD3OD): δ 7.62(d, 1H, J=16.3 Hz), 7.55(t, 1H, J=8.3 Hz), 7.46(dd, 1H, J-2.0, 11.7 Hz), 7.41(dd, 1H, J=2.0, 8.3 Hz), 6.50(d, 1H, J=15.8 Hz), 3.77(s, 3H), 3.03(s, 3H)
  • Step 2: Synthesis of methyl [0569]
  • 3-(3-fluoro-4-methanesulfonylaminophcnyl)propionate (26-2) The compound 26-1 (78 mg) prepared according to the same procedure as described in Step 1 was dissolved in methanol (10 ml) and to the solution was added a catalytic amount of 10% palladium/carbon, followed by stirring at room temperature under hydrogen atmosphere for 2 hours. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to yield the compound 26-2 (68 mg, 86%). [0570]
  • [0571] 1H NMR(300 MHz, CDCl3): δ 7.45(t, 1H, J-8.2 Hz), 6.98(d, 2H), 6.46(s, 1H), 3.66(s, 3H), 3.00(s, 3H), 2.91(t, 2H, J=7.6 Hz), 2.60(t, 2H, J=7.6 Hz)
  • Step 3: Synthesis of N-(4-t-butylbenzyl) 3-(3-fluoro-4-methanesulfonylaminophenyl)propionamide (26-3) [0572]
  • The compound 26-2 (30 mg) prepared in Step 2 was dissolved in toluene (4 ml) and to the solution was added 4-t-butylbenzylamine (150 μl), followed by refluxing for 3 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on silica gel column (ethyl acetate/hexane=1/1) to yield the compound 26-3 (28 mg, 58%). [0573]
  • [0574] 1H NMR(300 MHz, CDCl3): δ 7.39(t, 1H, J=8.3 Hz) 7.29(d, 2H), 7.07(d, 2H1), 6.95(m, 2H), 6.33(s, 1H), 5.54(s, 1H), 4.31(d, 2H, J=5.6 Hz), 2.93(s, 3H), 2.92(t, 2H, J=7.4 Hz), 2.41(t, 2H, J=7.6 Hz), 1.24(s, 9H)
    • EXAMPLE 169
  • Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 4-t-butylbenzamide (27) [0575]
    Figure US20030153596A1-20030814-C00282
  • Hydrochloride salt 3-4 (100 mg) prepared according to the same procedure as described in Example 13 was dissolved in dichloromethane (6 ml) and to the solution were added 4-t-butylbenzoylclhloride (85 mg) and triethylamine (60 μl), followed by stirring at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was colunm-chromatographed (ethyl acetate/hexane=1/1) to yield the compound 27 (110 mg, 72%). [0576]
  • [0577] 1H NMR(300 MHz, CDCl3): δ 7.72(d, 2H), 7.49(t, 1H, J=8.0 Hz) 7.43(d, 2H), 7.13(m, 2H), 6.54(s, 1H), 4.59(d, 2H, J=5.9 Hz), 2.93(s, 3H), 2.99(s, 3H), 1.31(s, 9H)
    • EXAMPLE 170
  • Synthesis of (3-fluoro-4-methanesulfonylaminobenzyl)dithiocarbamic acid 4-t-butylbenzyl ester (28) [0578]
    Figure US20030153596A1-20030814-C00283
  • The compound 3-4 (15.4 mg) prepared by Example 13 was dissolved in dimethylformamide (1 ml) and to the solution were added tetrabutylammonium iodide (67 mg), cesium (I) carbonate (59 mg) and carbon bisulfide (7 Id), followed by stirring at 0° C. for 1 hour. To the mixture was added 4-t-butylbenzylbromide (34 0) and stirred at room temperature for 1 hour. After the completion of the reaction, the resulting mixture was concentrated under reduced pressure and the obtained residue was chromatographed on silica gel column eluting with ethyl acetate/hexane ({fraction (1/3)}) to yield the compound 28 (12 mg, 52%). [0579]
  • [0580] 1H NMR(300 MHz, CD3OD): δ 7.43 (t, 1H, J=8.3 Hz), 7.25-7.34 (m, 4H), 7.10-7.16 (t, 2H, J=8.3 Hz), 4.88 (s, 2H), 4.55 (s, 21), 2.97 (s, 3H), 1.30 (s, 9H)
    • EXAMPLE 171
  • Synthesis of 1-(4-t-butylbenzyl)-3-(3-fluorophenethyl)urea (29) [0581]
    Figure US20030153596A1-20030814-C00284
  • 4-t-butylbenzylamine (3.2 g) was dissolved in dichloromethane (10 ml) and to the solution was added triethylamine (2.79 ml), followed by cooling to 0° C. and slowly adding dropwise a solution of triphosgene (1.98 g) in dichloromethane (5 ml). The mixture was stirred at room temperature for 5 hours and water (10 ml) was added thereto. The resulting mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/etliyl acetate=20/1) to yield 4-t-butylbenzylisocyanate (880 mg) as a solid. The obtained compound (400 mg) and 3-fluorophenethylamine (290 mg) were dissolved in dichloromethane (20 ml) and the solution was stirred at room temperature for 22 hours. The solvent was removed therefrom and the residue was purified by columnn-chromatography (hexane/ethyl acetate=4/1) to yield the compound 29 (400 mg, 58%) as a solid. [0582]
  • [0583] 1H NMR(300 MHz, CDCl3): δ 7.35-6.82(m, 8H), 4.91(s, 1H), 4.39(d, 2H, J=5.4 Hz), 3.60-3.48(m, 2H), 2.79(t, 2H, J=6.9 Hz), 1.31(s,9H)
    • EXAMPLE 172
  • Synthesis of 1-(4-t-butylbenzyl)-3-(2-fluorobenzoyl)thiourea (30) [0584]
    Figure US20030153596A1-20030814-C00285
  • Potassium thiocyanate (KSCN) (240 mg) was dissolved in acetone (5 ml) and the solution was allowed to warm up to 50° C. To the solution was added 2-fluorobenzoylchloride (330 mg) and the mixture was stirred at 50° C. for 4 hours. The produced potassium chloride was filtered off and to the obtained solution was 4-t-butylbenzylamine (330 mg), followed by stirrig at room temperature for 24 hours. The resulting mixture was concentrated and the residue was purified by column-chromatography (hexane/ethyl acetate=5/1) to yield the compound 30 (156 mg, 23%) as a liquid. [0585]
  • [0586] 1H NMR(300 MHz, CDCl3): δ 8.18-8.1 1(m, 1H), 7.50-7.07(m, 81), 7.02(brs, 1H), 4.70-4.65(m, 2H), 1.31(s,9H)
    • EXAMPLE 173
  • Synthesis of N″-cyano-N-(4-t-butylbenzyl)-N′-(2-pyridinylethyl)guanidine (31-1) [0587]
    Figure US20030153596A1-20030814-C00286
  • N-(4-t-butylbenzyl) N′-cyano-S-methylisothiourea (180 mg) was dissolved in xylene (10 ml) and to the solution was added 2-(2-aminoethyl)pyridine (86 mg), followed by refluxing for 7 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (acetone/ethyl acetate=1/1) to yield the compound 31-1 (70 mg, 30%) as a liquid. [0588]
  • [0589] 1H NMR(300MIz, CDCl3): δ 8.01(brs, 1H), 7.62-7.56(m, 1H), 7.39-7.35(m, 2H), 7.26-7.20(m, 3H), 7.14-7.03(m, 211), 6.42(brs, 11H), 4.34(d,2H, J=5.1 Hz), 3.71-3.65(m, 2H), 3.03-2.98(m, 2H), 1.32(s, 9H)
    • EXAMPLE 174˜EXAMPLE 178
  • Compounds of Example 174˜Example 178, which are shown in the Scheme [0590] 31+L, were synthesized according to the similar procedure as described in Example 173, and properties and spectral data thereof are shown in below table
    Examples Compounds R = Spectral data
    174 31-2
    Figure US20030153596A1-20030814-C00287
         		1H NMR(300MHz, CDCl3): δ 7.38-7.35(m, 2H), 7.27-7.20(m, 1H), 7.13-7.10(m, 2H), 6.95-6.78(m, 3H), 5.53(brs, 1H), 4.77(brs, 1H), 4.23(d, 2H, J=5.4Hz), 3.49-3.42(m, 2H), 2.79(t, 2H, J=6.9Hz), 1.32(s, 9H)
    175 31-3
    Figure US20030153596A1-20030814-C00288
         		1H NMR(300MHz, CDCl3): δ 7.40-7.35(m, 2H), 7.14-7.10(m, 2H), 7.08-6.99(m, 1H), 6.93-6.86(m, 1H), 6.82-6.77(m, 1H), 5.75(brs, 1H), 4.84(brs, 1H), 4.25(d, 2H, J=5.4Hz), 3.46-3.39(m, 2H), 2.76(t, 2H, J=6.9Hz), 1.32(s, 9H)
    176 31-4
    Figure US20030153596A1-20030814-C00289
         		1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.32-7.23(m, 2H), 7.19-7.16(m, 2H), 7.12-6.98(m, 2H), 5.65(brs, 1H), 5.35(brs, 1H), 4.42(d, 2H, J=6.0Hz), 4.34(d, 2H, J=5.4Hz), 1.32(s, 9H)
    177 31-5
    Figure US20030153596A1-20030814-C00290
         		1H NMR(300MHz, CDCl3): δ 7.39-7.35(m, 2H), 7.23-7.20(m, 2H), 7.12-7.05(m, 1H), 6.95-6.88(m, 1H), 6.16(brs, 1H), 5.88(brs, 1H), 4.79(d, 2H, J=5.4Hz), 4.52(d, 2H, J=4.8Hz), 1.31(s, 9H)
    178 31-6
    Figure US20030153596A1-20030814-C00291
         		1H NMR(300MHz, CDCl3): δ 7.41-7.37(m, 2H), 7.27-7.15(m, 6H), 6.81(brs, 1H), 5.55(brs, 1H), 5.32(brs, 1H), 4.38-4.34(m, 4H), 3.01(s, 3H), 1.31(s, 9H)
    Figure US20030153596A1-20030814-C00292
    Figure US20030153596A1-20030814-C00293
    Figure US20030153596A1-20030814-C00294
    Figure US20030153596A1-20030814-C00295
    Figure US20030153596A1-20030814-C00296
    • EXAMPLE 179
  • Synthesis of N″-cyano-N-(4-t-butylbenzyl)-N′-(2,6-diluoro-3-methanesulfonylaminobenzyl)guanidine (31-7) [0591]
    Figure US20030153596A1-20030814-C00297
  • [0592] 1-(4-t-butylbenzyl)-3-(2,6-difluoro-3-methanestlfonylaminobenzyl)thiourea (44 mg) and lead cyanamide (30 mg) were added to ethyl acetate (10 ml) and the mixture was refluxed for 18 hours. The resulting mixture was purified by column-chromatogrphy (hexane/ethyl acetate=1/1) to yield the compound 31-7 (35 mg, 78%).
  • [0593] 1H NMR (CDCl3): δ 7.47(dt, J=5.7, 8.7 Hz, 1H), 7.37(d, J=8.4 Hz, 2H), 7.21(d, J=8.4 Hz, 2H), 6.90(t, J=8.7 Hz, 1H), 6.67(bs, 1H), 6.28(bs, 1H), 6.16(bs, 1H), 4.78(d, J=5.4 Hz, 2H), 4.55(d, 4.2 Hz, 2H), 3.00(s, 3H), 1.31(s, 9H)
    • EXAMPLE 180
  • Synthesis of N″-cyano-N-(4-t-butylbenzyl)-N′-(2-fluoro-5-methanesulfonylaminobenzyl)guanidine (31-8) [0594]
    Figure US20030153596A1-20030814-C00298
  • Compound 31-8 was synthesized according to the similar procedure as described in Example 179. [0595]
  • [0596] 1H NMR(CDCl3): δ 7.34(d, J=8.1 Hz, 2H), 7.28(dd, J=2.4, 6.0 Hz, 1H), 7.20(d, J=8.1 Hz, 2H), 7.18(m, 1H), 6.98(t, J=9.OHz, 1H), 6.48(bs, 1H), 6.34(bs, 1H), 4.74(d, J=5.7 Hz, 2H), 4.56(d, J=4.2 Hz, 2H), 2.95(s, 3H), 1.29(s, 9H)
    • EXAMPLE 181
  • Synthesis of N″-cyano-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]—N′-[1-(4-t-butylbenzyl)]guanidine (31-9) [0597]
    Figure US20030153596A1-20030814-C00299
  • 1-(4-t-butylbenzyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]thiourea (0.2 g) and lead cyanamide (170 mg) were dissolved in ethyl acetate (20 ml) and the solution was refluxed for 12 hours. After confirming the completion of the reaction, the resulting mixture was filtered to remove the yellow solid, and the obtained residue was concentrated under reduced pressure and purified by column-chromatography (ethyl acetate/hexane=[0598] {fraction (2/3)}) to yield the compound 31-9 (174 mg, 85%) as a yellow solid.
  • [0599] 1H NMR (300 MHz, CDCl3): δ 7.38(d, 2H), 7.21(d, 2H), 7.15(m, 2H), 6.05(d, 1H, J=2.1 Hz), 4.48(m, 2H), 3.86(m, 2H), 2.99(t, 2H, J=6.9 Hz), 1.31(s, 9H)
    • EXAMPLE 182
  • Synthesis of 1-(4-chlorobenzyl)-3-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)thiourea (32-2) [0600]
    Figure US20030153596A1-20030814-C00300
  • Step 1: Synthesis of 6-methoxy-1 ,2,3,4-tetrahydro-naphthalen-1-ylaine (32-1) [0601]
  • 6-methoxy-1-tetralone (881 mg) and hydroxylamine hydrochloride (1.19 g) were dissolved in methanol (50 ml) and to the solution was slowly added pyridine (645 mg) at room temperature, followed by stirring for 18 hours. The resulting mixture was concentrated under reduced pressure. The concentrate was dissolved in ethyl acetate (30 ml), washed with water (10 ml×2) and aqueous saturated copper sulfate solution (10 ml), dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate=3/1) to yield an intermediate material, oxime (886 mg, 93%). [0602]
  • The obtained oxime (586 mg) was dissolved in methanol (50 ml) and the solution was cooled to −30° C., followed by adding nickel(II) chloride hexahydrate (1.46 g) thereto. After the solid was completely dissolved, to the solution was slowly added sodium borohydride (1.16 g) and the mixture was stirred at −30° C. for 30 minutes. Then, the mixture was stirred at room temperature for 90 minutes and concentrated under reduced pressure. The obtained residue was dissolved in 10% hydrochloric acid (30 ml) and the solution was slowly basified with 1 N aqueous sodium hydroxide solution. The obtained solution was extracted with ethyl acetate (50 ml×3) and the organic layers were collected. The total organic layer was washed with brine, dried over magnesium sulfate, concentrated under reduced pressure, and then purified by column-chromatography (dichloromethane/methanol=10/1) to yield the compound 32-1 (385 mg, 71%). [0603]
  • [0604] 1H NMR(CDCl3): δ 7.31(d, J=8.7 Hz, 1H), 6.75(dd, J=8.5, 2.4 Hz, 1H), 6.61(d, J=2.4 Hz, 1H), 3.94(t, J=5.4 Hz, 1H), 3.78(s, 3H), 2.75(m, 2H), 1.96(m, 2H), 1.73(bs, 2H), 1.70(m, 2H)
  • The similar compounds 32-3 and 32-5 were synthesized according to the same procedure as described above. [0605]
    Figure US20030153596A1-20030814-C00301
    Examples- Compounds
    step No. RR = Spectral data
    183-1 32-3 5-OMe 1H NMR(CDCl3): δ 7.17(t, J=7.8Hz, 1H), 7.02(d,
    J=7.8Hz, 1H), 6.71(d, J=7.8Hz, 1H), 3.97(t, J=5.7Hz,
    1H), 3.81(s, 3H), 2.65(m, 2H), 1.94(m, 2H), 1.76(bs, 2H),
    1.73(m, 2H).
    184-1 32-5 7-OMe 1H NMR(CDCl3): δ 7.00(d, J=8.7Hz, 1H), 6.97(d, J=
    3.0Hz, 1H), 6.73(dd, J=8.7, 3.0Hz, 1H), 3.94(t, J=5.6Hz,
    1H), 3.80(s, 3H), 2.70(m, 2H), 2.00(m, 1H), 1.90(m, 1H),
    1.80(bs, 2H), 1.77(m, 2H).
  • Step 2: Synthesis of 1-(4-chlorobenzyl)-3-(6-methoxy-1,2,3,4-tetrahydronaphthalen- 1-yl)thiourea (32-2) [0606]
  • The compound 32-1 (100 mg) prepared according to the same procedure as described in Step 1 was dissolved in ethyl acetate (4 ml) and to the solution were added a solution of 4-chlorobenzylisothiocyanate (123 mg) in ethyl acetate (2 ml), followed by stirring at room temperarure for 18 hours. The obtained reaction mixture was concentrated under reduced pressure and purified by column-chromatography (hexane/ethyl acetate=2/1) to yield the compound 32-2 (201 mg, 99%). [0607]
  • [0608] 1H NMR(DMSO-d6): δ 7.62(d, J=7.5 Hz, 1H), 7.52(bs, 1H), 7.23(d, J=8.4 Hz, 2H), 7.14(d, J=8.4 Hz, 2H), 6.92(bs, 1H), 6.55(d, J=8.7 Hz, 1H), 6.47(s, 1H), 5.30(bs, 1H), 4.50(bs, 2H), 3.53(s, 3H), 2.52(m, 2H), 1.71(m, 1H), 1.55(m, 3H)
  • The similar compounds 32-4 and 32-6˜32-10 were synthesized according to the same procedure as described above. [0609]
    Figure US20030153596A1-20030814-C00302
    RR =
    Compounds RS =
    Examples No. RT = Spectral data
    183 32-4 RR = 5-OMe 1H NMR(DMSO-d6): δ 7.85(d,
    RT = Cl J=8.0 Hz, 1H), 7.69(bs, 1H),
    7.40(d, J=8.4 Hz, 2H),
    7.32(d, J=8.4 Hz, 2H),
    7.12(t, J=8.0 Hz, 1H),
    6.81(d, J=8.0 Hz, 1H),
    5.54(bs, 1H), 4.68(bs, 2H),
    3.76(s, 3H), 2.56(m, 2H),
    1.88(m, 2H), 1.73(m, 2H).
    184 32-6 RR = 7-OMe 1H NMR(CDCl3): δ 7.29(d,
    RT = Cl J=8.7 Hz, 2H), 7.22(d,
    J=8.7 Hz, 2H), 6.99(d,
    J=9.0 Hz, 1H), 6.74(m, 3H),
    6.23(bs, 1H), 5.92(bs, 1H),
    5.40(bs, 1H), 4.56(bs, 2H),
    3.72(s, 3H), 2.67(m, 2H),
    2.05(m, 1H), 1.77(m, 3H).
    185 32-7 RR = 5-OMe 1H NMR(acetone-d6): δ 7.38(d,
    RT = t-butyl J=8.4 Hz, 2H), 7.29(d,
    J=8.4 Hz, 2H), 7.17(bs, 1H),
    7.10(t, J=8.0 Hz, 1H),
    7.04(bs, 1H), 6.91(d, J=8.0 Hz,
    1H), 6.78(d, J=8.0 Hz, 1H),
    5.71(bs, 1H), 4.77(d, J=5.1 Hz,
    2H), 3.80(s, 3H), 2.83(t,
    J=6.0 Hz, 2H), 1.89(m, 1H),
    1.80(m, 3H), 1.30(s, 9H).
    186 32-8 RR = 6-OMe 1H NMR(acetone-d6): δ 7.38(d,
    RT = t-butyl J=8.4 Hz, 2H), 7.29(d,
    J=8.4 Hz, 2H), 7.21(d,
    J=8.4 Hz, 1H), 7.14(bs, 1H),
    7.05(bs, 1H), 6.51(dd, J=8.4,
    2.4 Hz, 1H), 6.62(d, J=2.4 Hz,
    1H), 5.65(bs, 1H), 4.76(d,
    J=5.4 Hz, 2H), 3.76(s, 3H),
    2.73(m, 2H), 2.02(m, 1H),
    1.81(m, 3H), 1.31(s, 9H).
    187 32-9 RR = 7-OMe 1H NMR(acetone-d6): δ 7.37(d,
    RT = t-butyl J=8.4 Hz, 2H), 7.30(d,
    J=8.4 Hz, 2H), 7.20(bs, 1H),
    7.11(bs, 1H), 6.98(d, J=8.4 Hz,
    1H), 6.92(d, J=2.7 Hz, 1H),
    6.73(dd, J=8.4, 2.7 Hz, 1H),
    5.71(bs, 1H), 4.77(d, J=4.8 Hz,
    2H), 3.71(s, 3H), 2.67(m, 2H),
    2.06(m, 1H), 1.81(m, 3H),
    1.30(s, 9H).
    188 32-10 RR = 6-OMe 1H NMR(CDCl3): δ 7.34(d,
    RS = 7-OMe J=8.1 Hz, 2H), 7.21(d,
    RT = t-butyl J=8.1 Hz, 2H), 6.76(s, 1H),
    6.50(d, 1H), 6.32(bs, 1H),
    5.96(bs, 1H), 5.40(bs, 1H),
    4.52(bs, 2H), 3.80(s, 3H),
    3.75(s, 3H), 2.63(m, 2H),
    1.92(m, 2H), 1.70(m, 2H),
    1.29(s, 9H).
    Figure US20030153596A1-20030814-C00303
    32-4
    Figure US20030153596A1-20030814-C00304
    32-6
    Figure US20030153596A1-20030814-C00305
    32-7
    Figure US20030153596A1-20030814-C00306
    32-8
    Figure US20030153596A1-20030814-C00307
    32-9
    Figure US20030153596A1-20030814-C00308
    32-10
    • EXAMPLE 189
  • Synthesis of 1-(4-t-butylbenzyl)-3-(5-hydroxy-1,2,3,4-tetrahyronaphthalen-1-yl)thiourea (32-11) [0610]
    Figure US20030153596A1-20030814-C00309
  • The compound 32-3 (570 mg) prepared by Step 1 of Example 183 was dissolved in 48% hydrobromic acid (10 ml) and the mixture was refluxed for 24 hours. The mixture was cooled to room temperature, and then concentrated under reduced pressure to remove the hydrobromic acid (residue: 766 mg, 97%). Part (500 mg) of the residue was dissolved in dimethylformamide (5 ml) and the solution was cooled to 0° C. To the obtained mixture was added 5 M sodium hydroxide (800 μl), followed by stirring for 15 minutes to obtain a solution. To the solution was slowly added a solution of 4-t-butylbenzylisothiocyanate (421 mg) in dimethylformamide (5 ml) and the mixture was stirred at room temperature for 48 hours. Then, to the obtained solution was added water and the resulting mixture was extracted with ether (50 ml×3). The extracted organic layer was collected, washed with 1 N hydrochloric acid, water and saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by column-chromatography (hexane/ethyl acetate=2/1) to yield the compound 32-11 (550 mg, 73%). [0611] 1H NMR(acetone-d6): δ 7.38(d, J=8.4 Hz, 2H), 7.29(d, J=8.4 Hz, 2H), 7.15(bs, 1H), 7.03(bs, 1H), 6.95(t, J=7.8 Hz, 1H), 6.81(d, J=7.8 Hz, 1H), 6.69(d, J=7.8 Hz, 1H), 5.70(bs, 1H), 4.77(d, J=5.1 Hz, 2H), 2.63(t, J=6.0 Hz, 2H), 2.00(m, 1H), 1.81(m, 3H), 1.30(s, 9H)
  • The similar compound 32-12 was synthesized according to the same procedure as described above. [0612]
    Figure US20030153596A1-20030814-C00310
    Compound RR =
    Example No. RT = Spectral data
    190 32-12 RR = 7-OH 1H NMR(CD3OD): δ
    RT = Cl 7.32(s, 4H), 6.89(d, J=8.4 Hz,
    1H), 6.71(d, J=2.4 Hz, 1H),
    6.59(dd, J=8.4, 2.4 Hz, 1H),
    5.54(bs, 1H), 4.75(bs, 2H),
    2.65(m, 2H), 2.03(m, 1H),
    1.79(m, 3H).
    Figure US20030153596A1-20030814-C00311
    32-12
    • EXAMPLE 191
  • Synthesis of 1-(4-t-butylbenzy1)-3-(3-formylchromone)thiourea (33-2) [0613]
    Figure US20030153596A1-20030814-C00312
  • 2-amino-3-formylchromone 33-1 (100 mg) was dissolved in anhydrous tetrahydroflran (15 ml) and the solution was stirred. To the solution was added sdium hydride (15 mg) at 0° C. and the mixture was stirred for 30 minutes. To the mixture was added 4-t-butylbenzylisothiocyanate (130 mg), followed by stirng for 6 hours. The resulting mixture was neutralized with an iced water and concentrated under reduced pressure. The residue was extracted with ethyl acetate (30 ml×3), dried over magnesium sulfate, and then filtered. The filtrate was purified by column-chromatography (ethyl acetate/hexane=3/2) to yield the compound 33-2 (25 mg, 10%). [0614]
  • [0615] 1H NMR(300 MHz, CDCl3): δ8.75(s, 1H), 8.14(m, 1), 7.77(m, 1H), 7.42(m, 6H, 5.73(s, 2H), 1.33(s, 9H)
    • EXAMPLE 192
  • Synthesis of (4-t-butylbenzyl)thiocarbamic acid—O—(3,5-dimethylpyrazo1-1-ylmethyl)ester (334) [0616]
    Figure US20030153596A1-20030814-C00313
  • 3,5-dimethylpyrazo1-1-methanol 33-3 (200 mg) and sodium hydride (42 mg) were dissolved in anhydrous tetrahydrofiran (20 ml) and the solution was stirred for 1 hour. To the solution was added 4-t-butylbenzylisothiocyanate (330 mg) and the mixture was stirred at room temperature for 12 hours. The resulting mixture was filtered under reduced pressure and the solvent was removed therefrom. The residue was purified by column-chromatography (ethyl acetate/hexane=[0617] {fraction (1/2)}) to yield the compound 33-4 (253 mg, 48%) as a solid.
  • [0618] 1H NMR (300 MHz, acetone-d6) δ 7.29(m, 4H), 7.09(m, 1H), 6.30(s, 2H), 4.68(d, 2H, J=2.85 Hz), 2.33(s, 3H), 2.22(s, 3H), 1.30(s, 91J)
    • EXAMPLE 193
  • Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 3-(4-t-butylphenyl)propionamide (34-5) [0619]
    Figure US20030153596A1-20030814-C00314
  • Step 1: Synthesis of 4-t-butylcinnamic acid ethyl ester (34-2) [0620]
  • 4-t-butylbenzaldehyde (34-1) (69 mg) was dissolved in acetonitrile (16 ml) and to the solution were added diusopropylethylamine (84 mg) and triethyl phosphonoacetate (117 mg), followed by stirring at room temperature for 1 hours. The resulting mixture was diluted with dichloromethane (20 ml), washed with water and aqueous hydrochloric acid solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was colurun-chromatographed (ethyl acetate/hexane=1/5) to yield the compound 34-2 (64 mg, 65%) [0621]
  • [0622] 1H NMR(300 MHz, CDCl3): δ 7.65(d, 1H, J=16.1 Hz), 7.467.34 (m, 4H), 6.38(d, 1H,J=16.1 Hz), 4.24(q, 2H, J=7.2 Hz), 1.31(m, 121)
  • Step 2: Synthesis of ethyl 3-(4-t-butylphenyl)propionate (34-3) [0623]
  • The compound 34-2 (64 mg) according to the same procedure as described in Step 1 was dissolved in methanol (10 ml) and to the solution was added a catalytic amount of 10% palladium/carbon, followed by stirring at room temperature under hydrogen gas atmosphere for 2 hours. The resulting mixture was diluted with ether, filtered through celite, and then concentrated under reduced pressure to yield the compound 34-3 (60 mg, 93%) [0624]
  • [0625] 1H NMR(300 MHz, CDCl3): δ 7.28(d, 2H, J=8.0 Hz), 7.11(d, 2H, J-8.OHz), 4.11(q, 2H, J=7.1 Hz), 2.90(t, 2H, J=7.6 Hz), 2.59(t, 2H, J=7.6 Hz), 1.29(s, 9H), 1.21(t, 3H, J=6.8 Hz)
  • Step 3: Synthesis of N-(3-fluoro-4-methanesulfonylaminobenzyl) 3-(4-t-butylphenyl)propionamide (34-5) [0626]
  • The compound 34-3 (60 mg) prepared according to the same procedure as described in Step 2 was dissolved in 50% aqueous tetrahydrofuiran solution (10 ml) and to the solution was added lithium hydroxide (24 mg). The mixture was stirred at room temperature for 5 hours to hydrolyze the compound 34-3 and the solvent was removed therefrom. The residue was dissolved in ethyl acetate and extracted to the obtain the compound 34-4 (43 mg, 81%). The compound 34-4 was dissolved in benzene (2 ml) and to the solution was added dropwise oxalyl chloride (100 μl), followed by refluxing for 2 hours. The reaction mixture obtained by concentrating the resultant under reduced pressure and hydrochloride compound 3-4 (67 mg) prepared in Example 13 were added to dichloromethane (6 ml), and to the mixture was added triethylamine (60 μl), followed by stirring at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure and the obtained residue was purified by column-chromatography (ethyl acetate/hexane=1/1) to yield the compound 34-5 (34 mg, 38%). [0627]
  • [0628] 1H NMR(300 MHz, CDCl3): δ 7.40(t, 1H, J=8.2 Hz) 7.23(d, 2H, J=8.3 Hz), 7.06(d, 2H, J=8.3 Hz), 6.90(m, 2H), 6.49(s, 1H), 5.68(s, 1H), 4.30(d, 2H, J=5.6 Hz), 2.93(s, 3H), 2.89(t, 2H, J=7.6 Hz), 2.47(t, 2H, J=7.4 Hz ), 1.19(s, 9H)
    • EXAMPLE 194
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylaminosulfonylaminobenzyl)thiourea (35-2a) [0629]
    Figure US20030153596A1-20030814-C00315
  • Step 1: Synthesis of N-t-butyloxycarbony1-4-methylaminosulfonylaminobenzylamine (35-1a) [0630]
  • Sodium hydride (18 mg) was suspended in dimnethylformamide, and to the suspension was added a solution of N-t-butyloxycarbony1-p-aminobenzylamine (150 mg) and methylaminosulfamoylchloride (97 mg) in dimethylfonnamide while the temperature was controlled to 0° C., followed by stirring at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure, and the residue was diluted with ethyl acetate (70 ml), washed with saturated aqueous sodium bicarbonate solution, water and saturated saline, and then evaporated under reduced pressrure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=5/1) to yield the compound 35-1a (170 mg, 79%). [0631]
  • [0632] 1H NMR(300 MHz, DMSO): δ 7.27(d, 2H, J=8.5 Hz), 7.10(m, 2H), 4.18(s, 2H), 3.29(s, 3H), 1.43(s, 9H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methylaminosulfonylaminobenzyl)thiourea (35-2a) [0633]
  • The compound 35-1a (170 mg) prepared in Step 1 was dissolved in anhydrous dichloromethane (4 ml), and to the solution was added excess trifluoroacetic acid while the temperature was contolled to 0° C., followed by stirring for 30 minutes. The resulting mixture was evaporated under reduced pressure to remove excess trifluoroacetic acid and the residue was dissolved in anhydrous dichloromethane (4 ml). To the solution were added triethylamine (98 μl) and 4-t-butylbenzylisothiocyanate (144 mg) and the mixture was stirred at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure, and the remained was diluted with ethyl acetate (70 ml), washed with water and saturated saline, and then concentrated under reduced pressure. The obtained residue was purified by column-chromatography (hexane/ethyl acetate=10/1) to yield the compound 35-2a (157 mg, 69%). [0634]
  • [0635] 1H NMR(300 MHz, MeOH-d5): δ7.33(d, 2H, J=8.5 Hz), 7.17(m, 2H), 4.65(s, 4H), 2.55(s, 31H), 1.25(s, 9H)
  • MS AB) m/e 421[M[0636] +1]
    • EXAMPLE 195
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-N,N-dimethylaminosulfonylaminobenzyl)thiourea (35-2b) [0637]
    Figure US20030153596A1-20030814-C00316
  • Step 1: Synthesis of N-t-butyloxycarbony1-4-N,N-dimethylaminosulfonylaminobenzylamine (35-1b) [0638]
  • Compound 35-1b (393 mg, 53%) was synthesized by adding dimethylsulfamoylchloride (266 ,uQ) and then by being allowed to warm up to 60° C. according the procedure as described in Example 194. [0639]
  • [0640] 1H NMR(300 MHz, CDCl3): δ7.18(m, 8H), 4.16(s, 4H), 2.77(s, 3H), 1.45(s, 9H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-N,N-dimethylaminosulfonylaminobenzyl)thiourea (35-2b) [0641]
  • Compound 35-2b (337 mg, 65%) was synthesized according to the similar procedure as described in Example 194. [0642]
  • [0643] 1H NMR(300 MHz, CDCl3): δ7.18(m, 8H), 4.56(s, 4H), 3.92(s, 3H), 1.27(s,
  • MS (FAB) m/e 435[M[0644] +1]
    • EXAMPLE 196
  • Synthesis of 1-(4-t-butylbenzyl)-3-(4-aminosulfonylanminobenzyl)thiourea (35-2c) [0645]
    Figure US20030153596A1-20030814-C00317
  • Step 1: Synthesis of N-t-butyloxycarbony1-4-N-(t-butyloxycarbonylaminosulfonyl)aminobenzylamine (35-1c) [0646]
  • Compound 35-1c (333 mg, 54%) was synthesized by adding N-(t-butyloxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl]azanide (464 mg) and then by being allowed to warm up to 60° C. according the procedure as described in Example 194. [0647]
  • [0648] 1H NMR(300 MHz, DMSO): δ7.12(m, 4H), 4.06(d, 2H, J=5.9 Hz), 1.37(s, 9H), 1.33(s, 9H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-aminosulfonylaminobenzyl)thiourea (35-2c) [0649]
  • Compound 35-2c (257 mg, 69%) was synthesized according to the similar procedure as described in Example 194. [0650]
  • [0651] 1H NMR(300 MHz, DMSO): δ7.18(m, 8H), 4.58(s, 4H1), 1.25(s, 9H) MS (FAB) m/e 407[M+1]
    • EXAMPLE 197: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-3-nitrobenzyl)thiourea (35-5)
  • [0652]
    Figure US20030153596A1-20030814-C00318
  • Step 1: Synthesis of 4-methanesulfonylamino-3-nitrobenzonitrile (35-4) [0653]
  • 3-nitro-4-aminobenzonitrile (150 mg) and sodium bistrimethylsilylamide (2 ml) were dissolved in anhydrous tetrahydrofiran (6 ml), and to the solution was added methanesulfonic anhydride (191 mg) at 0° C., followed by stirring for 3 hours. The reaction solution was evaporated under reduced pressure and the residue was diluted with ethyl acetate (70 ml), washed with diluted aqueous hydrochloric acid solution, saturated aqueous sodium bicarbonate solution, water and brine, and then evapoarated under reduced pressure. The obtained residue was purified by column-chromatogaphy (hexane/ethyl acetate=5/1) to yield the compound 35-4 (120 mg, 54%) [0654]
  • [0655] 1H NMR(300 MHz, Pyridine-d5): δ8.60(s, 1H), 8.17(d, 1H, J=8.76 Hz), 7.88(dd, 1H, J=1.95, 8.79 Hz), 3.48(s, 3H)
  • Step 2: Synthesis of 1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino-3-nitrobenzyl)thiourea (35-5) [0656]
  • The compound 35-4 (90 mg) prepared according to the same procedure as described in Step 1 was dissolved in ahydrous tetrahydrofuran and to the solution was added borane (1 M, 1.1 ml), followed by stirring for 6 hours. The resulting mixture was evaporated under reduced pressure, and the residue was diluted with ethyl acetate (50 ml), washed with water and brine, and then evaporated under reduced pressure to obtain anine. The obtained amine, which was not purified, was dissolved in dichloromethane (2 ml) and to the solution were added triethylamine (57 i) and 4-t-butylbenzylisothiocyanate (8.4 mg) at 0° C., followed by stirring at room temperature for 3 hours. The reaction solution was evaporated under reduced pressure. The residue was diluted with ethyl acetate (70 ml), and washed with water and brine. The solvent was evaporated under reduced pressure, and then the obtained residue was purified by column-chromatography (hexane/ethyl acetate=30/1) to yield the compound 35-5 (56 mg, 33%). [0657]
  • [0658] 1H NMR(300 MHz, CDCl3): δ8.60(s, 1H), 8.17(d, 1H, J=8.76 Hz), 7.88(dd, 1H, J=1.95, 8.79 Hz), 7.40(m, 4H), 4.80(d, 2H, J=5.13 Hz), 4.55(s, 2H), 3.10(s, 3H), 1.27(s, 9H)
  • MS (FAB) m/e 451 [[0659] +1]
    • EXAMPLE 198
  • Synthesis of 1-(4-t-butylbenzyl)-3-(1-(4-methanesulfonylphenyI)ethyl)thiourea (36-4) [0660]
    Figure US20030153596A1-20030814-C00319
  • Step 1: Synthesis of 4-methanesulfonylaminoacetophenone (36-1) [0661]
  • 4-aminoacetophenone (300 mg) was dissolved in dichloromethane, and to the solution were added methanesulfonic anhydride (2.44 mimol) and pyridine (53.85 μl) at 0° C., followed by stirring at room temperature for 3 hours. After confirng the completion of the reaction using TLC, the reaction was quenched with saturated sodium bicarbonate solution. The reaction mixture was diluted with dichloromethane, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a solid. The solid was recrystallized with ethyl acetate and hexane, to yield a pale yellow crystal (293.2 mg, 61.95%). [0662]
  • mp: 155.1-161.2° C.; [0663]
  • [0664] 1H NMR(400 MHz, CDCl3): δ 7.98(d, 2H, J=8.8 Hz), 7.27(d, 2H, J=8.8 Hz), 3.11(d, 3H, J=1.6 Hz),2.59(d, 3H, J=1.6 Hz)
  • IR(KBr pellet, cm[0665] −1): 3290.93, 3003.59, 2928.38, 1667.16, 1600.63, 1469.49, 1330.64, 1279.54, 1146.47
  • Step 2: Synthesis of 4-methanesulfonylaminoacetophenonoxime (36-2) [0666]
  • 4-methanesulfonylaminoacetophenone (36-1) (360.2 mg) was dissolved in ethanol and to the solution was added a solution of hydroxylamine hydrochloride (129.11 mg) and sodium acetate (249.40 mg) in minimal amount of water. To the mixture was added ethanol until the solution became clear and then the solution was refluxed for 20 hours, thereby to be changed from transparent yellow to transparent colorlessness. After confirming the completion of the reaction using TLC, the ethanol was removed therefrom, and the residue was extracted with ethyl acetate, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentratd under reduced pressure to obain a solid. The solid was recrystallized with ethyl acetate and hexane to yield a pale yellow crystal (289.6 mg, 75.11%) [0667]
  • mp: 181.5- 182.1° C.; [0668]
  • 1H NMR(400 MHz, CDCl[0669] 3): δ 7.60(d, 2H, J=7.2 Hz), 7.26(d, 2H, J=7.4 Hz), 2.96(s, 3H), 2.21(s, 3H).
  • IR(KBr pellet, cm[0670] −1): 3495.35, 3255.25, 3023.84, 2926.38, 1605.45, 1323.89, 1155.15;
  • Step 3: Synthesis of 1-(4-methanesulfonylaminophenyl)ethylamine (36-3) [0671]
  • 4-methanesulfonylaminoacetophenonoxime (36-2) (279 mg) was dissolved in methanol and to the solution was added palladium/carbon (55.8 mg), followed by stirring under hydrogen atmosphere. After confirming the completion of the reaction using TLC, palladium/carbon was filtered off and the filtrate was concentrated under reduced pressure to remove the methanol, thereby to yield a transparent yellow liquid (251.1 mg, 95.89%). [0672]
  • 1H NMR(400 MHz, CDCl[0673] 3): δ 7.28(d, 2H, J=8.8 Hz), 7.15(d, 2H, J=8.8 Hz), 4.09(q, 1H, J=6.6 Hz), 2.95 (s, 3H), 1.35(d, 3H, J=6.4 Hz)
  • IR(NaCl neat, cm[0674] −1): 3350.71, 3270.69, 3136.65, 3023.84, 2965.98, 1610.27, 1512.88, 1325.82, 1153.22;
  • Step 4: Synthesis of 1-(4-t-butylbenzyl)-3-(1-(4-methanesulfonylphenyl)ethyl)thiourea (36-4) [0675]
  • The compound 36-3 (56.3 mg) prepared in Step 3 was dissolved in dichloromethane and to the solution was added 4-t-butylbenzylisothiocyanate (64.7 mg), followed by stirring at room temperature for 12 hours. Affter confiming the completion of the reaction using TLC, dichloromethane was evaporated under reduced pressure and the residue was purified by column-chromatography (hexane/ethyl acetate=4/1) to yield a white solid (41.9 mg, 38.01%). [0676]
  • mp: 177.8-178.5° C. [0677]
  • [0678] 1H NMR(400 MHz, CDCl3): δ 9.33(s, 1H), 7.28(m, 8H), 5.51(s, 1H), 4.68(s, 2H), 4.08(q, 1H, J=4.8 Hz), 2.93(s, 3H), 1.48(d, 3H, J=4.8 Hz),1.31(s, 9H).
  • IR(KBr pellet, cm[0679] −1): 3356.50, 3262.97, 3057.58, 3025.76, 2964.05, 2868.59, 1544.70, 1512.88, 1325.82
    • EXAMPLE 199
  • Synthesis of 1-(1-(4-methanesulfonylphenyl)ethyl)-3-phenethylthiourea (36-5) [0680]
    Figure US20030153596A1-20030814-C00320
  • Solution of compound 36-3 (50 mg) in dichloromethane was mixed with phenethylisothiocyanate (65.7 mg) and the mixture was stirred at room temperature for 12 hours, followed by confiing the completion of the reaction using TLC. Dichloromnethane was evaporated and the residue was column-chromatographed (hexane/ethyl acetate=2/1) to yield a white solid (12.8 mg, 14.53%). mp: 190.8-192.1° C. [0681]
  • [0682] 1H NMR(400 MHz, DMSO-d6): δ 9.63(s, 11), 7.78(s, 1H), 7.19(m, 9H), 5.34(s, 1H), 3.56(s, 1H), 2.92(s, 2H), 2.74(t, 2H, J=6.6 Hz), 2.47(s, 3H), 1.33(d, 3H, J=6.6 Hz).IR(NaCl neat, cm−1): 3365.17, 3229.22, 3020.94, 1731.76, 1523.49, 1374.03;
    • EXAMPLE 200
  • Synthesis of 1-(4-t-butylbenzyl)-3-(1-(4-methanesulfonylphenyl)ethyl)-3-methylthiourea (36-6) [0683]
    Figure US20030153596A1-20030814-C00321
  • Compound 36-1 (200 mg) was dissolved in methanol and to the solution was added palladium/carbon (30.0 mg), followed by bringing the atmosphere of the reactor into an atrnsphere of hydrogen gas. To the solution was added methylamine solution (2 M) and the mixture was allowed to be reacted for 5 days. After confirming the completion of the reaction using TLC, palladiumn/carbon was filtered off and the filtrate was purified by column-chromatography eluting with hexanelethyl acetate (3/1) to remove neural material and subsequently eluting with dichloromethane/methanol (10/1) to obtain a yellow liquid (70 mg, 32.70%). The obtained compound (70 mg) was dissolved in dichloromethane and to the solution was added phenethylisothiocyanate (75.5 mg), followed by stirring at room temperature for 4 hours. After confi g the completion of the reaction using TLC, the resulting mixture was diluted with dichloromethane, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obain a solid. The solid was purified by colunm-chromatography (hexane/ethyl acetate=3/1) to yield a colorless liquid (42.6 mg, 32%). [0684] 1H NMR(400 MHz, CDCl3): δ 7.27(m, 811), 6.90(q, 1H, J=7.2 Hz), 5.53(s, 1H), 4.84(d, 2H, J=4.4 Hz), 2.98(s, 3H), 2.66(s, 3H), 1.58(s, 1H), 1.52(d, 3H, J=7.2 Hz), 1.29(s, 3).
  • IR(NaCl neat, cm[0685] −1): 3386.39, 3267.79, 2963.09, 1512.88, 1326.79;
    • EXPERIMENTAL EXAMPLE
  • Biological Potency Test [0686]
  • (1)45 Ca influx test [0687]
  • 1) Separation of spinal dorsal root ganglia (DRG) in newborn rats and primary culture thereof [0688]
  • Neonatal(2-day old or younger than 2-day old) SD rats were put in ice for 5 minutes to anesthetize and disinfected with 70% ethanol. DRG of all part of spinal cord were dissected (Wood et al., 1988, J. Neurosci. 8, pp3208-3220) and collected in DME/F12 medium to which 1.2 g/l sodium bicarbonate, 50 mg/l gentamycin were added. The DRG were incubated sequentially at 37° C. for 30 min in 200 U/mi collagenase and 2.5 mg/ml trypsin, separately. The ganglia were washed twice with DME/F12 medium supplemented with 10% horse serum, triturated through a fire-polished Pasteur pipette, filtered through Nitex 40 membrane to obtain single cell suspension. This was subjected to centrifugation, then re-suspended in cell culture medium at certain level of cell density. As the cell culture medium, DME/F12 medium supplemented with 10% horse serum, diluted 1:1 with identical medium conditioned by C6 glioma cells (2 days on a confluent monolayer) was used, and NGF(Nerve Growth Factor) was added to final concentration of 200 ng/ml. After the cells were grown 2 days in medium where cytosine arabinoside (Ara-C, 100 μM was added to kill dividing nonneuronal cells, medium was changed to one without Ara-C. The resuspended cells were plated at a density of 1500-1700 neurons/well onto Terasaki plates previously coated with 10 μg/ml poly-D-ornithine. [0689]
  • 2) 45 Ca influx experiments [0690]
  • DRG nerve cells from the primary culture of 2-3 days were equilibrated by washing 4 times with HEPES (lOmM, pH 7.4)-buffered Ca[0691] 2+, Mg2+-free HBSS (H-HBSS). The solution in each well was removed from the individual well. Medium containing the test compound plus capsaicin (final concentration 0.5 μM) and 45Ca (final concentration 10 μCi/ml) in H-HBSS was added to each well and incubated at room temperature for 10 min. Terasaki plates were washed six times with H-HBSS and dried in an oven. To each well, 0.3% SDS (10 μl) was added to elute 45Ca. After the addition of 2 ml of scintillation cocktail into each well, the amount of 45Ca influx into neuron was measured by counting radioactivity. Antagonistic activities of test compounds against vanilloid receptor were calculated as percent of the inhibition of maximal response of capsaicin at a concentration of 0.5 μM and results are given as IC50(Table 1a, 1b and 1c).
  • Agonistic activities of the test compounds for vanrilloid receptor were determined as a concentration of the test compound showing 50% of the [0692] 45Ca influx, compared to the maximal amount of 45Ca influx in case of using 3 μM capsaicin and results are given as EC50 (Table 1d).
  • (2) Channel activity assay [0693]
  • Antagonistic activities of test compounds were assayed based on electrical change of cation channel connected to vanilloid receptor and experiments were conducted according to reference method (Oh et al., 1996, J. Neuroscience 16, pp1659-1667) (Table 1a, 1b and 1c). [0694]
    TABLE 1a
    Results of Calcium Influx and Patchclamp Tests
    Calcium Uptake Patchelamp Test
    Examples Test(IC50) (antagonistic activities)
    5 1.1
    9 0.23
    13 0.037 ++
    15 1.2
    17 0.0084 ++
    18 0.72
    19 0.0058 ++
    30 1.5
    32 0.031 +
    33 0.11
    36 1.1
    44 0.11 +
    51 0.7
  • [0695]
    TABLE 1b
    Results of Calcium Influx and Patchclamp Tests
    Calcium Uptake Patchclamp Test
    Examples Test (IC50) (antagonistic activities)
    60 1.14 +
    61 0.25 +
    62 0.06 +
    64 0.35 +
    65 0.019 +
    66 0.25 +
    67 0.5 +
    68 0.063 +
    69 0.77 +
    70 0.58 +
    73 1.2
    83 1.1
    90 0.42
    96 0.59
  • [0696]
    TABLE 1c
    Results of Calcium Influx and Patchclamp Tests
    Calcium Uptake Patchclamp Test
    Examples Test (IC50) (antagonistic activities)
    134 0.81
    152 0.95 +
    153 0.38
    161 0.46
    178 0.11
    193 0.21
    194 0.31
    196 0.15
    Capsazepine 0.59 +
  • [0697]
    TABLE 1d
    Results of Calcium Influx Tests
    Calcium Uptake
    Examples Test (EC50)
    6 14.6
    24 8.2
    41 7.0
    46 2.6
    82 2.8
  • (3) Analgesic activity test: Mouse writhing test by inducing with phenyl-p-quinone [0698]
  • Male ICR mice (mean body weight 25 g) were maintained in a controlled lighting environment (12 h on/12 h off) for experiment. Animals received an intraperitoneal injection of 0.3 ml of the chemical irritant phenyl-p-quinone (dissolved in saline containing 5% ethanol to be a dose of 4.5mg/kg) and 6 min later, the number of abdominal constrictions was counted in the subsequent 6 min period. Animals (10 animals/group) received 0.2 ml of test compounds solution in vehicle of ethanoVTween 80/saline (10/10/80) intraperitoneally 30 min before the injection of phenyl-p-quinone. A reduction in the number of writhes responding to the test drag compound relative to the number responding in saline control group was considered to be indicative of an analgesic effect. Analgesic effect was calculated by % inhibition equation (% inhibition=(C-T)/C×100), wherein C and T represent the number of writhes in control and compound-treated group, respectively (Table 2). [0699]
  • The test results demonstrated that analgesic effect of the compounds used in this experiment is as potent as indomethacin which is a very potent antiinflmmato-ry and analgesic agent. In particular, it is significant to clarify that vanilloid receptor antagonist can exhibit such potent analgesic effect, and the results suggests that vanilloid receptor antagonist has potential as an analgesic agent. [0700]
    TABLE 2
    Test result of analgesic activity for writhing by phenyl-p-quinone
    Analgesic effect
    Examples Dose(mg/kg) (% Inhibition)
     5 10 53
     13 10 82
     17 10 98
     44 3 92
     52 10 94
     73 10 88
     83 10 85
     96 10 58
    104 10 95
    107 10 44
    153 1 57
    161 1 73
    Indomethacin 3 94
  • (4) Antiinflammatory activity test: TPA(12-O-tetradecanoylphorbol 13-acetate)-induced mouse ear edema test [0701]
  • Male JCR mice(body weight 25-30 g), 10 animals/group, were treated topically on th right ear with 30 μl of TPA (2.5 μg) solution in acetone and after 15 min, 30 μl of acetone or test compound solution in acetone was applied topically. After six hours, a identica treatment was applied again. After twenty four hours following the tratment of TPA, the animals were sacrificed and ear tissue was dissected using 6 mm-diameter punch. Ear tissue dissected were weighed to the nearest 0.1 mg on an electrobalance. The increased weight of the tissue compared to control group was considered as an index of inflammation. The percent inhibition is defined by the following equation: [0702]
  • % inhibition=(C−T)/C×100,
  • wherein C and T represent an increase of ear weight in TPA-treated and TPA+drug-treated group, respectively (Table 3). [0703]
  • The above experiment shows that vanilloid receptor antagonist exhibits anti-inflammatory effects of the same level with indomethacin which is very potent anti-inflammatory and analgesic agent. This phenomenon can be understood by connecting with the action of vanilloid receptor in neurogenic inflammation, and suggests potential applicability of vanilloid receptor antagonist in various inflammatory diseases, in particular, neurogenic inflammatory diseases. [0704]
    TABLE 3
    TPA-induced mice ear edema test
    Anti-inflammtory effect
    Examples Dose (mg/ear) (% Inhibition)
     13 1 74
     17 1 80
     33 1 66
     44 1 83
     73 1 77
    107 1 75
    Indomethacin 1 74
  • (5) Ulcer test: ethanol-induced anti-ulcer test [0705]
  • Male SD rats (body weight 180-200 g), 5 animals/group, were fasted for 24 hours, and their stomaches were damaged. The rats were administered with 10 ml/kg of test drug suspended in 1% methylcellulose orally and, after 1 hour, 1 rnl of 99% ethanol orally. After 1 hour without food and water, the rats were sacrificed by cervical dislocation and stomaches thereof were removed. The removed stomaches were incised along the greater curvature and opened. Then, the degree of gastric damage was scored based on the following ulcer index which is a criterion for evaluation and the percent inhibition of test drug against ulcer was calculated compared to control group (1% methylcellulose) (table 4). % inhibition -[(ulcer index of control group—ulcer index of drug-treated group)/( ulcer index of control group)]×100 [0706]
  • According to the present study using ethano1-induced ulcer model, the vanilloid receptor antagonist was found out to exhibit significant anti-ulcerous activities, contrary to ranitidine, which is a representative antiulcerant but did not show anti-ulcer activity in the present study. This study is the first to demonstrate the anti-ulcerous potential of vanilloid receptor antagonist. Based on the result, possibility that vanilloid receptor antagonist will be developed as an anti-ulcerant is suggested. [0707]
    Scoring Ulcer
    (grade) Index (UI)
    0 No lesion
    1 One hemorrhagic ulcer of length less
    than 5 mm & thin
    2 One hemorrhagic ulcer of length not less
    than 5 mm & thin
    3 More than one ulcer of grade 2
    4 One ulcer of length not less than
    5 mm & width not less than 2 mm
    5 Two or three ulcers of grade 4
    6 Four or five ulcers of grade 4
    7 More than six ulcers of grade 4
    8 Complete lesion of the mucosa
  • [0708]
    TABLE 4
    Ethanol-induced anti-ulcer test
    Anti-ulcerous effect
    Examples Dose(mg/kg) (% inhibition)
     13 30 30
     17 30 58
     33 30 31
     44 30 36
     73 30 22
    107 30 18
    Ranitidine 30 4
  • Industrial Applicability [0709]
  • The compounds according to the present invention are useful in the prevention or treatment of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma and chronic obstructive pulmonary diseases, irritation in slin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease, etc. [0710]

Claims (10)

1. A compound of the following formula (I):
Figure US20030153596A1-20030814-C00322
or a pharmaceutically acceptable salt thereof,
wherein:
X represents S, O or —NCN;
Y represents single bond, NR3, O or S;
R1 represents
Figure US20030153596A1-20030814-C00323
pyridinylmethyl, pyrrolylmethyl, oxazolyhuethyl, pyrazolylnethyl, imidazolylnethyl, anthracenylnethyl, naphthylmethyl, quinolinylmethyl, alkoxycarbonyl or alkylcarbonyloxy (wherein, m is 0, 1, 2, 3 or 4; R4 and R5 are independentyl hydrogen, lower alkyl having 1 to 5 carbon atoms, hydroxy, methanesulfanylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, alkoxycarbonyloxy, benzyloxy, acetoxymethyl, propinoyloxymethyl, butoxyalkyl, trimethylacetoxy, trimethylacetoxymethyl or halogen; and R6 and R7 are independently hydrogen, lower alkyl having 1 to 5 carbon atoms);
R2 represents R8—(CH2)n—
{wherein, n is 0, 1, 2, 3 or 4; R8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzimidazolyl, chromonyl or benzothiazolyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or
Figure US20030153596A1-20030814-C00324
(wherein, R9 is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, lower alkoxy having 1 to 5 carbon atoms, hydroxy, nitro, cyano, —NHSO2R2, —S(O)pR12, —NR13R14, carboxyl; R10 is hydrogen, nitro, NHSO2R12, S(O)pR12 or NR13R14; R11 is hydrogen or cyano; R12 is lower alkyl having 1 to 5 carbon atoms, methylphenyl, NR13R14, trifluoromethyl or alkenyl; R13 and R14 are independently hydrogen or lower alkyl having 1 to 5 carbon atoms; and p is 0 or 2.); or
Figure US20030153596A1-20030814-C00325
(wherein, Z is O, S, NH or —NCH3; R15 is hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, nitro, cyano, —NHSO2R12, —S(O)pR12, N,N-dimethylaminomethyl or alkoxycarbonylamino; and p and R12 have the same meanings as defined in R9);
Figure US20030153596A1-20030814-C00326
(wherein, W is O, S, NH, NR16, —N(SO2CH3)— or —CH2—; and R16 is pyridinyl or pyrimidinyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, methanesulfonylamino or halogen; or benzyl or phenethyl substituted or unsubstitued with lower alkyl having 1 to 5 carbon atoms, alkoxy, hydroxy, nitro, methanesulfonylamino or halogen);
or
Figure US20030153596A1-20030814-C00327
(wherein, R17, R18, R19, R20 and R21 are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, aminoalkoxy, alkoxycarbonylamno, —NHCH2CO2H, alkoxyalkylcarbonylamino, alkoxycarbonylalkylamino, nitro, formyl, acetyl, formnylarnino, acetoxyamino, cyano, —OSO2CH3, —NHSO2R12, —N(SO2R12)CH3, —N(SO2R12)2, —S(O)pR12, —NR13R14, thiocarbamnoyl, —C(═O)NHNH2, —C(═O)NHOH, —C(═O)NHOCH3, —PO(═O)(OCH3)2, carboxyl, NHBoc, —NHC(═O)SCH3 or guanidine; R22 and R23 are independently hydrogen, halogen, alkoxy or hydroxy; and p, R12, R13 and R14 have the same meanings as defined in R9);
or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and
R3 represents hydrogen, alkyl or cycloalkyl having 1 to 8 carbon atoms, lower alkylphenyl having 1 to 5 carbon atoms, pyridinylethyl, bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 5 carbon atoms, halogen or methanesulfonylamino.
2. A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein,
X represents S, O or —NCN;
Y represents N3 or O;
R1 represents
Figure US20030153596A1-20030814-C00328
(wherein, m is 0, 1 or 2; and R4 and R5 are independently hydrogen, lower alkyl having 1 to 4 carbon atoms, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxyalkoxy, methoxyalkoxyalkyl, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);
R2 represents R8—(CH2)n—
{wherein, n is 0, 1, 2 or 3; R8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl, oxazolyl, benzimidazolyl or chromonyl substituted or unsubstituted with lower alkyl having 1 to 5 carbon atoms, nitro, amino, cyano, methanesulfonylamino, formyl or halogen, or
Figure US20030153596A1-20030814-C00329
(wherein, R9 is hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, nitro, cyano, —NHSO2R12, —NR13R14 or carboxyl; R10 is hydrogen, nitro, NHSO2R12 or —NR13R14; R11 is hydrogen or cyano; R12 is lower alkyl having 1 to 4 carbon atoms, methylphenyl, —NR13R14 or trifluoromethyl; R13 and R14 are independently hydrogen or lower alkyl having 1 to 4 carbon atoms; and p is 0 or 2);
Figure US20030153596A1-20030814-C00330
(wherein, Z is O, S, NH or —NCH3; R1 is hydrogen, lower alkyl having 1 to 4 carbon atoms, nitro, cyano or NHSO2R12; and R12 has the same meanings as defined in R9); or
Figure US20030153596A1-20030814-C00331
(wherein, W is O, S, NH, NR16 or —CH2—; and R16 is pyridinyl or pyrirnidinyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, nitro or methanesulfonylamino; or benzyl or phenethyl substituted or unsubstituted with lower alkyl having 1 to 4 carbon atoms, alkoxy, hydroxy or methanesulfonylamino);
Figure US20030153596A1-20030814-C00332
(wherein, R17, R18, R19, R20 and R21 are independently hydrogen, halogen, lower alkyl having 1 to 5 carbon atoms, alkoxy, methylenedioxy, methanesulfonylaminomethyl, alkoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonylamino, —NHCH2CO2H, allcoxyalkylcarbonylamino, alkoxycarbonylalkylamino, nitro, formyl, acetyl, fonnylamino, acetoxyamino, cyano, —OSO2CH3, —NHSO2R12, —N(SO2R12)CH3, —N(SO2R12)2, —S(O)pR12, NR13R14, thiocarbamoyl, —C(═O)NHNH2, —C(═O)NHOH, —C(═O)NHOCH3, carboxyl, NHBoc, —NHC(═O)SCH3, guanidine; R22 and R23 are independently hydrogen, alkoxy or hydroxy; and p, R12, R13 and R14 have the same meanings as defined in R9);
or hydroxyphenylalkyl or (methanesulfonylaminophenyl)alkyl}; and
R3 represents hydrogen, alkyl having 1 to 4 carbon atoms, lower alkylphenyl having 1 to 3 carbon atoms, pyridinylethyl or bisphenylmethyl; or phenylalkyl substituted with lower alkyl having 1 to 4 carbon atoms, halogen or methanesulfonylamino.
3. A compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein,
X represents S, O or —NCN;
Y represents NR3 or O;
R1 represents
Figure US20030153596A1-20030814-C00333
(wherein, m is 1 or 2; and R4 and RW are independently hydrogen, t-butyl, hydroxy, methanesulfonylamino, lower alkoxy having 1 to 5 carbon atoms, methoxymethoxy, methoxyethoxy, benzyloxy, acetoxymethyl, trimethylacetoxymethyl or halogen);
R2 represents R8—(CH2)n—
{wherein, n is 1, 2 or 3; R8 is benzoyl, imidazolyl, indolyl, indazolyl, thiazolyl, pyrazolyl or benzimidazolyl substituted or unsubstituted with methyl, nitro or halogen;
or
Figure US20030153596A1-20030814-C00334
(wherein, R9 is hydrogen, halogen, methyl, nitro or methanesulfonylamino; R10 is hydrogen or nitro; alid R11 is hydrogen or cyano);
Figure US20030153596A1-20030814-C00335
(wherein, Z is O, S, NH or —NCH3; and R15 is hydrogen, methyl, nitro, cyano or methanesulfonylamino);
Figure US20030153596A1-20030814-C00336
(wherein, W is O, S, NH, NR16 or —CH2—; and R16 is pyridinyl, pyrirnidinyl; or benzyl or phenethyl substituted or unsubstituted with methyl, methoxy or hydroxy);
or
Figure US20030153596A1-20030814-C00337
(wherein, R17, R18, R19, R20 and R21 are independently hydrogen, halogen, lower alkyl having 1 to 4 carbon atoms, methoxy, methylenedioxy, methanesulfonylaminomethyl, methoxycarbonyl, hydroxy, sulfamoyl, alkoxycarbonylamino, —NHCH2CO2H, methoxymethylcarbonylamino, alkoxycarbonylalkylamino, nitro, acetyl, formylamino, acetoxyamino, cyano, —OSO2CH3, —NHSO2R12, —N(SO2R12)CH3, —N(SO2R12)2, —S(O)pR12, NR13R14, thiocarbamoyl, —C(═O)NHNH2, —C(═O)NHOH, —C(═O)NHOCH3, carboxyl, NHBoc, —NHC(═O)SCH3, guanidine; R22 and R23 are independently hydrogen, methoxy or hydroxy; and p, R12, R13 and R14 are the same meanings as defmed in R9);
or hydroxyphenylalkyl or (methanesulfonylarinophenyl)alkyl}; and
R3 represents hydrogen, methyl, isopropyl, isobutyl, cyclohexyl, benzyl, phenethyl or bisphenylmethyl; or phenylalkyl substituted with t-butyl, halogen or methanesulfonylamuno.
4. A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the fomula (I) represents
1-(4-t-butylbenzyl)-3-[2-(1-methyl 1H-pyrrol-2-yl)ethyl]thiourea;
1-(4-t-butylbenzyl)-3-(4-amino-2,5-difluorobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(4-sulfamoylbenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
1-phenethyl-3-(3-fluoro-4-methanesulfonylaninobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaniinobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-methoxycarboxy1-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-carboxy1-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-((3-N-hydroxyaminocarbony1-4-methanesulfonylamino)benzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-methoxycarboxylbenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-carboxylbenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(2,3,5 ,6-tetrafluoro-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(2,5-difluoro-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-[(3-methanesulfonylamino-6-pyridinyl)methyl]thiourea;
1-(4-t-butylbenzyl)-3-(2,6-dichloro-5-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminophenethyl)thiourea;
1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-[2,6-difluoro-3-(N-methanesulfonylanino)benzyl]thiourea;
1-(4-t-butylbenzyl)-3-[3-(N-methanesulfonylamino)benzyl]thiourea;
1-(4-t-butyl-2-methoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-ethoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-propoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-butoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-isopropoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfotiylaminobenzyl)thiourea;
1-(4-t-butyl-2-neopentoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-methoxymethoxybenzyl)-3-(4-methanesulfonylaninobenzyl)thiourea;
1-(4-t-butyl-2-methoxyethoxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butyl-2-benzyloxybenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(2-acetoxymethyl-4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-[2-(4-rnethylthiazol-5-yl)ethyl]thiourea;
1-(4-t-butylbenzyl)-3-((2-chloro-5-pyridinyl)methyl)thiourea;
1-(4-t-butylbenzyl)-3-(2-pyridin-2-ylethyl)thiourea;
1-(4-t-butylbenzyl)-3-(2,5-difluorobenzyl)tbiourea;
1-(4-t-butylbenzyl)-3-(3-fluorophenethyl)thiourea;
1-(4-t-butylbenzyl)-3-(4-sulfamoylphenethyl)thiourea;
1-(4-t-butylbenzyl)-3-(4-morpholinylethyl)thiourea;
1-(4-t-butylbenzyl)-3-[2-(1H-irnidazo1-4-yl)ethyl]thiourea;
1-(4-t-butylbenzyl)-3-[2-thiophen-2-ethyl]thiourea;
1-(4-t-butylbenzyl)-3-(4-methanesulfonylamino- 1-methyl- 1H-pyrrol-2-yl)tbiourea;
1-benzy1-1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea;
1-(3-(4-hydroxy-3-methoxyphenyl)propyl)- 1-phenethyl-3-phenethylthiourea;
1-bisphenylmethyl- 1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-3-phenethylthiourea; or
N″-cyano-N-(4-t-butylbenzyl)-N′-(4-methanesulfonylaminobenzyl)guanidine.
5. A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the fomula (1) represents
1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyt)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(3-methoxycarboxy1-4-methanesulfonylaminobenzyl)thiourea;
1-(4-t-butylbenzyl)-3-(4-methanesulfonylarninobenzyl)thiourea; or
1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylamnino)thiourea.
6. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient together with a pharmaceutically acceptable carrier.
7. A pharmaceutical composition according to claim 6, wherein the compound according to claim 1 or a -pharmaceutically acceptable salts thereof as an active ingredient together with an pharmaceutically acceptable carrier is present in an effective amount for preventing or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, stomach-duaodenal ulcer, inflammatory bowel disease or inflammatory diseases.
8. A method for preventing or treating pain, acute pain, chronic pain, nieuropathic pain, post-operative pain, migraine, arthralgia, neuropathfies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease) irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory bowel disease or inflammatory diseases, wherein the method comprises administering a therapeutically effective amount of the compound selected from the group consisting of compounds of formula I or a pharmaceutically acceptable salt thereof.
9. Use of a compound selected from the group consisting of compound of formula I or a pharmaceutically acceptable salt thereof as an antagonist of vanilloid receptor.
10. Use of a compound selected from the group consisting of compound of formula I or a pharmaceutically acceptable salt thereof as an agonist of vanilloid receptor.
US10/169,805 2000-08-21 2001-08-20 Novel thiourea derivatives and the pharmaceutical compositions containing the same Abandoned US20030153596A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/727,413 US8071650B2 (en) 2000-08-21 2007-03-26 Thiourea derivatives and the pharmaceutical compositions containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000048385 2000-08-21
KR2000/48385 2000-08-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/727,413 Continuation US8071650B2 (en) 2000-08-21 2007-03-26 Thiourea derivatives and the pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
US20030153596A1 true US20030153596A1 (en) 2003-08-14

Family

ID=36643340

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/362,079 Expired - Lifetime US7067553B2 (en) 2000-08-21 2001-08-20 Thiourea compounds and the pharmaceutical compositions containing the same
US10/169,805 Abandoned US20030153596A1 (en) 2000-08-21 2001-08-20 Novel thiourea derivatives and the pharmaceutical compositions containing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/362,079 Expired - Lifetime US7067553B2 (en) 2000-08-21 2001-08-20 Thiourea compounds and the pharmaceutical compositions containing the same

Country Status (9)

Country Link
US (2) US7067553B2 (en)
EP (1) EP1311478B1 (en)
JP (1) JP2004506714A (en)
KR (2) KR100453078B1 (en)
AT (1) ATE328868T1 (en)
AU (1) AU2001280230A1 (en)
DE (1) DE60120421T2 (en)
ES (1) ES2266227T3 (en)
WO (1) WO2002016319A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203944A1 (en) * 2000-08-21 2003-10-30 Suh Young Ger Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
US20030212140A1 (en) * 2000-08-21 2003-11-13 Suh Young Ger Novel thiourea compounds and the pharmaceutical compositions containing the same
US20040006091A1 (en) * 2002-03-01 2004-01-08 Kyle Donald J. Therapeutic agents useful for treating or preventing pain
US20040044003A1 (en) * 2002-02-01 2004-03-04 Kyle Donald J. Therapeutic agents useful for treating pain
US20040106625A1 (en) * 2002-06-28 2004-06-03 Kyle Donald J. Therapeutic agents useful for treating pain
US20040235853A1 (en) * 2002-07-26 2004-11-25 Kyle Donald J. Therapeutic agents useful for treating pain
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
US20060035882A1 (en) * 2004-07-15 2006-02-16 Japan Tobacco Inc. Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (vr1) activity
US20060040919A1 (en) * 2004-01-22 2006-02-23 Staffan Skogvall Bronchorelaxing compounds
US20060211741A1 (en) * 2005-03-17 2006-09-21 Pfizer, Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
WO2006101318A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US20060235022A1 (en) * 2003-09-22 2006-10-19 Qun Sun Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20070149517A1 (en) * 2005-12-28 2007-06-28 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity
WO2007142426A1 (en) * 2006-06-02 2007-12-13 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
US20090129856A1 (en) * 2007-11-21 2009-05-21 Michael Gomez Quick-release system
US9951086B2 (en) 2013-12-19 2018-04-24 Bayer Pharma Aktiengesellschaft Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
WO2018215070A1 (en) * 2017-05-24 2018-11-29 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
CN111548313A (en) * 2019-02-11 2020-08-18 绍兴从零医药科技有限公司 Guanidine Compounds for the Prevention and Treatment of Chronic Pain Drugs

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133743T2 (en) * 2000-08-21 2009-07-02 Pacific Corp. NEW THIOUREA DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TWI283665B (en) 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
RS63204A (en) 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
EP2033953A1 (en) 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
ATE533743T1 (en) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv UREA DERIVATIVES OF AMINOTETRALIN AS MODULATORS OF THE VANILLOID RECEPTOR VR1
WO2004007459A2 (en) 2002-07-12 2004-01-22 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
KR100556158B1 (en) * 2002-10-17 2006-03-06 (주) 디지탈바이오텍 Novel N-hydroxy thiourea, urea and amide compounds and pharmaceutical compositions containing them
JP4422034B2 (en) 2002-12-06 2010-02-24 バイエル・ヘルスケア・アクチェンゲゼルシャフト Tetrahydro-naphthalene derivatives
WO2004103954A1 (en) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. Amide derivative
KR100707123B1 (en) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 4-methylsulfonylaminophenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical composition containing the same
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1679296A4 (en) 2003-10-14 2007-12-26 Ajinomoto Kk Ether derivative
KR20050039573A (en) * 2003-10-23 2005-04-29 주식회사 태평양 Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability
ITMI20042042A1 (en) * 2004-10-26 2005-01-26 Pharmeste Srl ANTAGONIST SOLFONAMID DERIVATIVES OF THE VANILLOID RECEPTOR TRPV1
CN101087771A (en) 2004-11-10 2007-12-12 辉瑞大药厂 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds
ES2308562T3 (en) * 2004-11-10 2008-12-01 Pfizer, Inc. N-SULPHONYLAMINOBENCIL-2-PHENOXYACETAMIDE SUBSTITUTED COMPOUNDS.
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
ATE443056T1 (en) 2005-03-10 2009-10-15 Pfizer SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXYACETAMIDE COMPOUNDS
DE102005023943A1 (en) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorosulfanyl-substituted compound and its use for the preparation of medicaments
AP2008004432A0 (en) 2005-10-07 2008-04-30 Glenmark Pharmaceuticals Sa Substituted benzofused derivatives and their use as vanilloid receptor ligands
PE20070528A1 (en) * 2005-10-19 2007-07-20 Gruenenthal Chemie HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE VANYLOID RECEPTOR OF SUBTYPE 1
RU2427579C2 (en) 2005-12-28 2011-08-27 Джапан Тобакко Инк. 3,4-dihydrobenzoxazine compounds and vanilloid receptor subtype 1 (vr1) inhibitors
EP1857440A1 (en) * 2006-04-19 2007-11-21 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP5254228B2 (en) * 2006-07-27 2013-08-07 株式會社アモーレパシフィック Novel compounds, isomers or pharmaceutically acceptable salts thereof as vanilloid receptor antagonists; and pharmaceutical compositions containing the same
DE102007018150A1 (en) * 2007-04-16 2008-10-23 Grünenthal GmbH Treating pain, using dual action compound or combination of compounds with affinity for both mu-opioid and vanilloid VR1-receptors, also effective e.g. against coughs or asthma
US7801502B2 (en) * 2006-12-18 2010-09-21 Aai Corporation Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
DE102007018151A1 (en) * 2007-04-16 2008-10-23 Günenthal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
EP2238105B1 (en) 2008-01-28 2014-04-16 Amorepacific Corporation Novel compounds as vanilloid receptor antagonists
CN102137851B (en) 2008-07-02 2014-08-27 株式会社爱茉莉太平洋 Compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them
US8409628B2 (en) 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
US8900601B2 (en) 2010-03-31 2014-12-02 Jennifer Bartels Permeable mixtures, methods and compositions for the skin
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
WO2012136121A1 (en) * 2011-04-02 2012-10-11 中国人民解放军军事医学科学院毒物药物研究所 Amino phenylpropanoid compound and use thereof for preparing immunosuppressant
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117994A (en) * 1959-12-03 1964-01-14 Monsanto Canada Ltd Nu, nu', nu'-trisubstituted guanidines
US3546344A (en) * 1966-03-08 1970-12-08 Ciba Ltd Preparations containing urea or thiourea derivatives for use as molluscicides
US4460602A (en) * 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
US5403868A (en) * 1988-12-23 1995-04-04 Sandoz Ltd. Capsaicin derivatives
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6057451A (en) * 1995-12-29 2000-05-02 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-herpesvirus compounds and methods for identifying, making and using same
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
US20030203944A1 (en) * 2000-08-21 2003-10-30 Suh Young Ger Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
US20030212140A1 (en) * 2000-08-21 2003-11-13 Suh Young Ger Novel thiourea compounds and the pharmaceutical compositions containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2226313A (en) * 1938-08-29 1940-12-24 Harry C Little Floor furnace
GB1386076A (en) * 1971-06-03 1975-03-05 Wyeth John & Brother Ltd Isoquinoline derivatives
JPS5855417A (en) * 1981-09-27 1983-04-01 Nitto Electric Ind Co Ltd Medicinal composition
GB2168975A (en) 1984-12-20 1986-07-02 Procter & Gamble Amides and compositions thereof having anti-inflammatory and analgesic activity
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8715357D0 (en) 1987-06-30 1987-08-05 Sandoz Inst For Medical Resear Organic compounds
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
JPH0395153A (en) 1989-06-15 1991-04-19 Mitsubishi Kasei Corp Diphenyl urea derivative
HU210683B (en) * 1990-06-18 1995-06-28 Sandoz Ag Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same
HUT62558A (en) 1991-07-01 1993-05-28 Sandoz Ag Process for producing n-phenylthiourea derivaties and pharmaceutical compositions comprising same
GB9713484D0 (en) * 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
JPH1135545A (en) 1997-07-22 1999-02-09 Tanabe Seiyaku Co Ltd Urethane derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
AU2466799A (en) * 1998-01-22 1999-08-09 Regents Of The University Of California, The Nucleic acid sequences encoding capsaicin receptors
MXPA01008403A (en) 1999-02-22 2003-06-06 Pacific Corp Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof.
MXPA03000458A (en) 2000-07-20 2004-06-02 Neurogen Corp Capsaicin receptor ligands.
GB0105895D0 (en) 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
SK11952003A3 (en) 2001-03-26 2004-03-02 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
US20040259875A1 (en) 2001-07-31 2004-12-23 Takeshi Yura Amine derivatives

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117994A (en) * 1959-12-03 1964-01-14 Monsanto Canada Ltd Nu, nu', nu'-trisubstituted guanidines
US3546344A (en) * 1966-03-08 1970-12-08 Ciba Ltd Preparations containing urea or thiourea derivatives for use as molluscicides
US4460602A (en) * 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
US5403868A (en) * 1988-12-23 1995-04-04 Sandoz Ltd. Capsaicin derivatives
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6057451A (en) * 1995-12-29 2000-05-02 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-herpesvirus compounds and methods for identifying, making and using same
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
US20030203944A1 (en) * 2000-08-21 2003-10-30 Suh Young Ger Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
US20030212140A1 (en) * 2000-08-21 2003-11-13 Suh Young Ger Novel thiourea compounds and the pharmaceutical compositions containing the same

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067553B2 (en) 2000-08-21 2006-06-27 Pacific Corporation Thiourea compounds and the pharmaceutical compositions containing the same
US20030212140A1 (en) * 2000-08-21 2003-11-13 Suh Young Ger Novel thiourea compounds and the pharmaceutical compositions containing the same
US20060264480A1 (en) * 2000-08-21 2006-11-23 Suh Young G Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
US20030203944A1 (en) * 2000-08-21 2003-10-30 Suh Young Ger Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
US20040044003A1 (en) * 2002-02-01 2004-03-04 Kyle Donald J. Therapeutic agents useful for treating pain
US7256193B2 (en) 2002-02-01 2007-08-14 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7071335B2 (en) 2002-02-01 2006-07-04 Euro-Celtique S.A. 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
US20040006091A1 (en) * 2002-03-01 2004-01-08 Kyle Donald J. Therapeutic agents useful for treating or preventing pain
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US7342017B2 (en) 2002-03-01 2008-03-11 Euro-Celtique S.A. 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety
US20060074090A1 (en) * 2002-03-01 2006-04-06 Euro-Celtique S.A. 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety
US20040106625A1 (en) * 2002-06-28 2004-06-03 Kyle Donald J. Therapeutic agents useful for treating pain
US20080153835A1 (en) * 2002-06-28 2008-06-26 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7799786B2 (en) 2002-06-28 2010-09-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7696207B2 (en) 2002-07-26 2010-04-13 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20080200472A1 (en) * 2002-07-26 2008-08-21 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040235853A1 (en) * 2002-07-26 2004-11-25 Kyle Donald J. Therapeutic agents useful for treating pain
US7855210B2 (en) 2002-09-24 2010-12-21 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20110082152A1 (en) * 2002-09-24 2011-04-07 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7737148B2 (en) 2002-09-24 2010-06-15 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20090042902A1 (en) * 2002-09-24 2009-02-12 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20070142360A1 (en) * 2002-09-24 2007-06-21 Euro-Celtique S.A. Therapeutic agents useful for treating pain
EP2017276A1 (en) 2003-09-22 2009-01-21 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
US7799807B2 (en) 2003-09-22 2010-09-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7964606B2 (en) 2003-09-22 2011-06-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8129388B2 (en) 2003-09-22 2012-03-06 Purde Pharma L.P. Therapeutic agents useful for treating pain
US20060235022A1 (en) * 2003-09-22 2006-10-19 Qun Sun Therapeutic agents useful for treating pain
US20110009418A1 (en) * 2003-09-22 2011-01-13 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20060040919A1 (en) * 2004-01-22 2006-02-23 Staffan Skogvall Bronchorelaxing compounds
US20100022523A1 (en) * 2004-07-14 2010-01-28 Japan Tobacco Inc. 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
US8008292B2 (en) 2004-07-15 2011-08-30 Japan Tobacco Inc. Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
US20060035882A1 (en) * 2004-07-15 2006-02-16 Japan Tobacco Inc. Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (vr1) activity
US7622589B2 (en) 2005-03-17 2009-11-24 Pfizer Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
US20100035880A1 (en) * 2005-03-17 2010-02-11 Pfizer Inc Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists
US7915448B2 (en) 2005-03-17 2011-03-29 Pfizer Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
US20060211741A1 (en) * 2005-03-17 2006-09-21 Pfizer, Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
US20080234383A1 (en) * 2005-03-19 2008-09-25 Young-Ger Suh Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same
US7960584B2 (en) 2005-03-19 2011-06-14 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US7763657B2 (en) 2005-03-19 2010-07-27 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2006101321A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US20090105258A1 (en) * 2005-03-19 2009-04-23 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2006101318A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US20110212952A1 (en) * 2005-12-28 2011-09-01 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
US20070149517A1 (en) * 2005-12-28 2007-06-28 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity
WO2007142426A1 (en) * 2006-06-02 2007-12-13 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
US20090129856A1 (en) * 2007-11-21 2009-05-21 Michael Gomez Quick-release system
US9951086B2 (en) 2013-12-19 2018-04-24 Bayer Pharma Aktiengesellschaft Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
WO2018215070A1 (en) * 2017-05-24 2018-11-29 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
WO2018215610A1 (en) * 2017-05-24 2018-11-29 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
CN110891560A (en) * 2017-05-24 2020-03-17 法兰克福大学 Dual modulator of farnesoid X receptor and soluble epoxide hydrolase
JP2020524178A (en) * 2017-05-24 2020-08-13 ヨハン ヴォルフガング ゲーテ−ウニヴェルズィテート フランクフルト アム マイン Dual regulators of farnesoid X receptor and soluble epoxide hydrolase
CN111548313A (en) * 2019-02-11 2020-08-18 绍兴从零医药科技有限公司 Guanidine Compounds for the Prevention and Treatment of Chronic Pain Drugs

Also Published As

Publication number Publication date
EP1311478B1 (en) 2006-06-07
EP1311478A4 (en) 2004-08-04
EP1311478A1 (en) 2003-05-21
KR100468520B1 (en) 2005-01-28
US7067553B2 (en) 2006-06-27
ATE328868T1 (en) 2006-06-15
DE60120421T2 (en) 2006-12-28
KR20040048393A (en) 2004-06-09
ES2266227T3 (en) 2007-03-01
JP2004506714A (en) 2004-03-04
DE60120421D1 (en) 2006-07-20
AU2001280230A1 (en) 2002-03-04
KR100453078B1 (en) 2004-10-15
KR20020030009A (en) 2002-04-22
WO2002016319A1 (en) 2002-02-28
US20030212140A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
US20030153596A1 (en) Novel thiourea derivatives and the pharmaceutical compositions containing the same
US8071650B2 (en) Thiourea derivatives and the pharmaceutical compositions containing the same
AU2001280229A1 (en) Novel thiourea derivatives and the pharmaceutical compositions containing the same
DE69927050T2 (en) BIPHENYL COMPOUNDS AND BIPHENYL ANALOGS AS INTERGRIN ANTAGONISTS
AU2005278962C1 (en) Isoindolin-1-one derivatives
AU636239B2 (en) Sulfonamide derivatives
NL192454C (en) N, N'-disubstituted urea, thiourea, guanidine and diaminoethylene derivatives, process for their preparation and pharmaceutical preparations containing these derivatives.
JPH0220639B2 (en)
HUP0101793A2 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
CZ299664B6 (en) Novel N-(iminomethyl)amine derivatives, their use and pharmaceutical composition in which the derivatives are comprised
GB2216517A (en) 1-(3-aryl-prop-2-enyl)-4-tricyclyl-piperazines
WO2002016317A1 (en) Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
AU616014B2 (en) Butenoic or propenoic acid derivative
WO2012038904A1 (en) Nicotinamide derivatives, preparation thereof and therapeutic use thereof
KR920006823B1 (en) Butene acid derivatives
AU2006252047A1 (en) Inhibitors of histone deacetylase
WO2008062424A2 (en) Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
MXPA01003006A (en) Novel n-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
JPH04217646A (en) Phenoxy derivative

Legal Events

Date Code Title Description
AS Assignment

Owner name: PACIFIC CORPORATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUH, YOUNG GER;OH, UH TAEK;LEE, JEE WOO;AND OTHERS;REEL/FRAME:013250/0090

Effective date: 20020603

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION